Browse result page of CancerPDF Database
Please click on CancerPDF_ID for detailed information about peptide.
| CancerPDF_ID | Peptide seq | Protein Name | Fluid | Mass/Z | Profiling Technique | Cancer Type | Expression Regulation | PUBMED ID |
|---|---|---|---|---|---|---|---|---|
| CancerPDF_ID12 | SSSYSKQFTSSTSYNRGDSTFES | Fibrinogen alpha chain | Serum | 2553.01 | MALDI-TOF | Metastatic thyroid carcinomas | NA | 16896061 |
| CancerPDF_ID13 | SSSYSKQFTSSTSYNRGDSTFESKS | Fibrinogen alpha chain | Serum | 2768.3 | MALDI-TOF | Metastatic thyroid carcinomas | NA | 16896061 |
| CancerPDF_ID17 | SSYSKQFTSSTSYNRGDSTFE | Fibrinogen alpha chain | Serum | 2379.03 | MALDI-TOF | Metastatic thyroid carcinomas | NA | 16896061 |
| CancerPDF_ID21 | DEAGSEADHEGTHSTKRGHAKSRPV | Fibrinogen alpha chain | Serum | 2659.03 | MALDI-TOF | Metastatic thyroid carcinomas | NA | 16896061 |
| CancerPDF_ID40 | GLEEELQFSLGSKINVKVGGNS | Complement C4 precursor | Serum | 2305.2 | MALDI-TOF | Metastatic thyroid carcinomas | NA | 16896061 |
| CancerPDF_ID43 | TLEIPGNSDPNMIPDGDFNSYVR | Complement C4 precursor | Serum | 2551.06 | MALDI-TOF | Metastatic thyroid carcinomas | NA | 16896061 |
| CancerPDF_ID44 | TLEIPGNSDPNFIPDGDFNSYVR | Complement C4 precursor | Serum | 856.33 | MALDI-TOF | Metastatic thyroid carcinomas | NA | 16896061 |
| CancerPDF_ID51 | SRQLGLPGPPDVPDHAAYHPF | Inter-alpha-trypsin inhibitor heavy chain H9 | Serum | 2271.14 | MALDI-TOF | Metastatic thyroid carcinomas | NA | 16896061 |
| CancerPDF_ID52 | SSRQLGLPGPPDVPDHAAYHPF | Inter-alpha-trypsin inhibitor heavy chain H10 | Serum | 2358.09 | MALDI-TOF | Metastatic thyroid carcinomas | NA | 16896061 |
| CancerPDF_ID53 | GVLSSRQLGLPGPPDVPDHAAYHPF | Inter-alpha-trypsin inhibitor heavy chain H11 | Serum | 2627.48 | MALDI-TOF | Metastatic thyroid carcinomas | NA | 16896061 |
| CancerPDF_ID60 | NVHSGSTFFKYYLQGAKIPKPEA | Inter-alpha-trypsin inhibitor heavy chain H18 | Serum | 861.39 | MALDI-TOF | Metastatic thyroid carcinomas | NA | 16896061 |
| CancerPDF_ID62 | NVHSAGAAGSRMNFRPGVLSS | PRO1851(ITIH4 splice variant) | Serum | 2115.01 | MALDI-TOF | Metastatic thyroid carcinomas | NA | 16896061 |
| CancerPDF_ID63 | LMIDQNTKSPLFMGKVVNPTQK | Alpha-1-antitrypsin precursor | Serum | 830.51 | MALDI-TOF | Metastatic thyroid carcinomas | NA | 16896061 |
| CancerPDF_ID64 | LMIEQNTKSPLFMGKVVNPTQK | Alpha-1-antitrypsin precursor | Serum | 835.16 | MALDI-TOF | Metastatic thyroid carcinomas | NA | 16896061 |
| CancerPDF_ID65 | LMIEQNTKSPLFMGKVVNPTQ | Alpha-1-antitrypsin precursor | Serum | 792.46 | MALDI-TOF | Metastatic thyroid carcinomas | NA | 16896061 |
| CancerPDF_ID66 | MIEQNTKSPLFMGKVVNPTQK | Alpha-1-antitrypsin precursor | Serum | 797.34 | MALDI-TOF | Metastatic thyroid carcinomas | NA | 16896061 |
| CancerPDF_ID67 | MIDQNTKSPLFMGKVVNPTQK | Alpha-1-antitrypsin precursor | Serum | 792.68 | MALDI-TOF | Metastatic thyroid carcinomas | NA | 16896061 |
| CancerPDF_ID78 | ISASAEELRQRLAPLAEDVRGNL | Apolipoprotein A-IV | Serum | 2508.16 | MALDI-TOF | Metastatic thyroid carcinomas | NA | 16896061 |
| CancerPDF_ID81 | GNTEGLQKSLAELGGHLDQQVEEF | Apolipoprotein A-IV | Serum | 2599.18 | MALDI-TOF | Metastatic thyroid carcinomas | NA | 16896061 |
| CancerPDF_ID82 | GNTEGLQKSLAELGGHLDQQVEEFR | Apolipoprotein A-IV | Serum | 2755.2 | MALDI-TOF | Metastatic thyroid carcinomas | NA | 16896061 |
| CancerPDF_ID84 | DVSSALDKLKEFGNTLEDKARELIS | Apolipoprotein C-I | Serum | 2778.15 | MALDI-TOF | Metastatic thyroid carcinomas | NA | 16896061 |
| CancerPDF_ID85 | TVGSLAGQPLQERAQAWGERL | Apolipoprotein E | Serum | 2267.07 | MALDI-TOF | Metastatic thyroid carcinomas | NA | 16896061 |
| CancerPDF_ID86 | AATVGSLAGQPLQERAQAWGERL | Apolipoprotein E | Serum | 2409.13 | MALDI-TOF | Metastatic thyroid carcinomas | NA | 16896061 |
| CancerPDF_ID87 | AATVGSLAGQPLQERAQAWGERLR | Apolipoprotein E | Serum | 2565.45 | MALDI-TOF | Metastatic thyroid carcinomas | NA | 16896061 |
| CancerPDF_ID99 | AVPPNNSNAAEDDLPTVELQGVVPR | Factor XIIIa | Serum | 2602.15 | MALDI-TOF | Metastatic thyroid carcinomas | NA | 16896061 |
| CancerPDF_ID100 | ALGISPFHEHAEVVFTANDSGPR | Transthyretin precursor (‘prealbumin’) | Serum | 2451.11 | MALDI-TOF | Metastatic thyroid carcinomas | NA | 16896061 |
| CancerPDF_ID101 | PDAPRIKKIVQKKLAGDESAD | Platelet Basic Protein Precursor | Serum | 2279.18 | MALDI-TOF | Metastatic thyroid carcinomas | NA | 16896061 |
| CancerPDF_ID199 | HKSEVAHRFKDLGEENFKALVL | Serum albumin | Serum | 2567.3659 | MALDI-TOF | "Non-small cell lung cancer (NSCLC) patients, who were treated with first-line chemotherapy" | Peptide Ion Signature for differentiation between Short PFS(Progression Free survival) versus long PFS | 19728888 |
| CancerPDF_ID200 | AVPPNNSNAAEDDLPTVELQGVVPR | Coagulation factor XIIIA | Serum | 2602.3048 | MALDI-TOF | "Non-small cell lung cancer (NSCLC) patients, who were treated with first-line chemotherapy" | Peptide Ion Signature for differentiation between Short PFS(Progression Free survival) versus long PFS | 19728888 |
| CancerPDF_ID317 | LVEKVQAAVGTSAAPVPSDNH | Apolipoprotein E | Plasma | 697.3626667 | LC-MS | Ductal adenocarcinoma of the pancreas (DAP) | NA | 19795908 |
| CancerPDF_ID349 | GNTEGLQKSLAELGGHLDQQVEEFR | Apolipoprotein A-IV | Plasma | 919.12 | LC-MS | Ductal adenocarcinoma of the pancreas (DAP) | NA | 19795908 |
| CancerPDF_ID365 | SLPELEQQQEQQQEQQQEQVQ | Apolipoprotein A-IV | Plasma | 861.07 | LC-MS | Ductal adenocarcinoma of the pancreas (DAP) | NA | 19795908 |
| CancerPDF_ID401 | GSTGNRNPGSSGTGGTATWKPGSS | Fibrinogen alpha chain | Plasma | 741.01 | LC-MS | Ductal adenocarcinoma of the pancreas (DAP) | NA | 19795908 |
| CancerPDF_ID402 | GSTGNRNPGSSGTGGTATWKPGS | Fibrinogen alpha chain | Plasma | 712 | LC-MS | Ductal adenocarcinoma of the pancreas (DAP) | NA | 19795908 |
| CancerPDF_ID403 | STGNRNPGSSGTGGTATWKPGSSGP | Fibrinogen alpha chain | Plasma | "1159.54, 773.36" | LC-MS | Ductal adenocarcinoma of the pancreas (DAP) | NA | 19795908 |
| CancerPDF_ID404 | TGNRNPGSSGTGGTATWKPGSSGP | Fibrinogen alpha chain | Plasma | "1116.02, 744.35" | LC-MS | Ductal adenocarcinoma of the pancreas (DAP) | NA | 19795908 |
| CancerPDF_ID405 | TGNRNPGSSGTGGTATWKPGSS | Fibrinogen alpha chain | Plasma | 692.99 | LC-MS | Ductal adenocarcinoma of the pancreas (DAP) | NA | 19795908 |
| CancerPDF_ID406 | TGNRNPGSSGTGGTATWKPGS | Fibrinogen alpha chain | Plasma | 663.98 | LC-MS | Ductal adenocarcinoma of the pancreas (DAP) | NA | 19795908 |
| CancerPDF_ID409 | GNRNPGSSGTGGTATWKPGSSGP | Fibrinogen alpha chain | Plasma | "1065.5, 710.67" | LC-MS | Ductal adenocarcinoma of the pancreas (DAP) | NA | 19795908 |
| CancerPDF_ID412 | NRNPGSSGTGGTATWKPGSSGP | Fibrinogen alpha chain | Plasma | 691.66 | LC-MS | Ductal adenocarcinoma of the pancreas (DAP) | NA | 19795908 |
| CancerPDF_ID416 | RNPGSSGTGGTATWKPGSSGP | Fibrinogen alpha chain | Plasma | "979.97, 653.64" | LC-MS | Ductal adenocarcinoma of the pancreas (DAP) | NA | 19795908 |
| CancerPDF_ID424 | DEAAFFDTASTGKTFPGFFSPM | Fibrinogen alpha chain | Plasma | 1186.03 | LC-MS | Ductal adenocarcinoma of the pancreas (DAP) | NA | 19795908 |
| CancerPDF_ID427 | FDTASTGKTFPGFFSPMLGEFV | Fibrinogen alpha chain | Plasma | 1192.07 | LC-MS | Ductal adenocarcinoma of the pancreas (DAP) | NA | 19795908 |
| CancerPDF_ID428 | FDTASTGKTFPGFFSPMLGEF | Fibrinogen alpha chain | Plasma | 1142.53 | LC-MS | Ductal adenocarcinoma of the pancreas (DAP) | NA | 19795908 |
| CancerPDF_ID437 | DTASTGKTFPGFFSPMLGEFV | Fibrinogen alpha chain | Plasma | "1118.53, 746.02" | LC-MS | Ductal adenocarcinoma of the pancreas (DAP) | NA | 19795908 |
| CancerPDF_ID474 | LGEFVSETESRGSESGIFTNTKES | Fibrinogen alpha chain | Plasma | 864.4 | LC-MS | Ductal adenocarcinoma of the pancreas (DAP) | NA | 19795908 |
| CancerPDF_ID475 | LGEFVSETESRGSESGIFTNTK | Fibrinogen alpha chain | Plasma | 792.38 | LC-MS | Ductal adenocarcinoma of the pancreas (DAP) | NA | 19795908 |
| CancerPDF_ID476 | LGEFVSETESRGSESGIFTNT | Fibrinogen alpha chain | Plasma | 1124.02 | LC-MS | Ductal adenocarcinoma of the pancreas (DAP) | NA | 19795908 |
| CancerPDF_ID484 | GEFVSETESRGSESGIFTNTKES | Fibrinogen alpha chain | Plasma | 826.71 | LC-MS | Ductal adenocarcinoma of the pancreas (DAP) | NA | 19795908 |
| CancerPDF_ID485 | GEFVSETESRGSESGIFTNTKE | Fibrinogen alpha chain | Plasma | 797.7 | LC-MS | Ductal adenocarcinoma of the pancreas (DAP) | NA | 19795908 |
| CancerPDF_ID486 | GEFVSETESRGSESGIFTNTK | Fibrinogen alpha chain | Plasma | 754.68 | LC-MS | Ductal adenocarcinoma of the pancreas (DAP) | NA | 19795908 |
| CancerPDF_ID503 | TGSWNSGSSGTGSTGNQNPGSPRPG | Fibrinogen alpha chain | Plasma | 783.01 | LC-MS | Ductal adenocarcinoma of the pancreas (DAP) | NA | 19795908 |
| CancerPDF_ID506 | SWNSGSSGTGSTGNQNPGSPRPG | Fibrinogen alpha chain | Plasma | 730.32 | LC-MS | Ductal adenocarcinoma of the pancreas (DAP) | NA | 19795908 |
| CancerPDF_ID515 | TGSTGNQNPGSPRPGSTGTWN | Fibrinogen alpha chain | Plasma | 1036.97 | LC-MS | Ductal adenocarcinoma of the pancreas (DAP) | NA | 19795908 |
| CancerPDF_ID516 | PGSPRPGSTGTWNPGSSERGS | Fibrinogen alpha chain | Plasma | 690.99 | LC-MS | Ductal adenocarcinoma of the pancreas (DAP) | NA | 19795908 |
| CancerPDF_ID520 | SSSYSKQFTSSTSYNRGDSTFESK | Fibrinogen alpha chain | Plasma | 894.4 | LC-MS | Ductal adenocarcinoma of the pancreas (DAP) | NA | 19795908 |
| CancerPDF_ID521 | SSSYSKQFTSSTSYNRGDSTF | Fibrinogen alpha chain | Plasma | 1169.01 | LC-MS | Ductal adenocarcinoma of the pancreas (DAP) | NA | 19795908 |
| CancerPDF_ID528 | SYSKQFTSSTSYNRGDSTFESK | Fibrinogen alpha chain | Plasma | 836.38 | LC-MS | Ductal adenocarcinoma of the pancreas (DAP) | NA | 19795908 |
| CancerPDF_ID529 | SYSKQFTSSTSYNRGDSTFES | Fibrinogen alpha chain | Plasma | 793.68 | LC-MS | Ductal adenocarcinoma of the pancreas (DAP) | NA | 19795908 |
| CancerPDF_ID559 | SYKMADEAGSEADHEGTHSTKRGHA | Fibrinogen alpha chain | Plasma | 891.392 | LC-MS | Ductal adenocarcinoma of the pancreas (DAP) | NA | 19795908 |
| CancerPDF_ID560 | SYKMADEAGSEADHEGTHSTKR | Fibrinogen alpha chain | Plasma | 803.02 | LC-MS | Ductal adenocarcinoma of the pancreas (DAP) | NA | 19795908 |
| CancerPDF_ID561 | SYKMADEAGSEADHEGTHSTK | Fibrinogen alpha chain | Plasma | 750.99 | LC-MS | Ductal adenocarcinoma of the pancreas (DAP) | NA | 19795908 |
| CancerPDF_ID573 | GSESGIFTNTKESSSHHPGIAEFPS | Fibrinogen alpha chain | Plasma | 868.4 | LC-MS | Ductal adenocarcinoma of the pancreas (DAP) | NA | 19795908 |
| CancerPDF_ID574 | TNTKESSSHHPGIAEFPSRGK | Fibrinogen alpha chain | Plasma | 756.37 | LC-MS | Ductal adenocarcinoma of the pancreas (DAP) | NA | 19795908 |
| CancerPDF_ID593 | SVSGSTGQWHSESGSFRPDSPGSGNA | Fibrinogen alpha chain | Plasma | 860.04 | LC-MS | Ductal adenocarcinoma of the pancreas (DAP) | NA | 19795908 |
| CancerPDF_ID594 | SVSGSTGQWHSESGSFRPDSPGSGN | Fibrinogen alpha chain | Plasma | 836.36 | LC-MS | Ductal adenocarcinoma of the pancreas (DAP) | NA | 19795908 |
| CancerPDF_ID598 | SESGSFRPDSPGSGNARPNNPDWGTF | Fibrinogen alpha chain | Plasma | 912.73 | LC-MS | Ductal adenocarcinoma of the pancreas (DAP) | NA | 19795908 |
| CancerPDF_ID599 | SESGSFRPDSPGSGNARPNNPDWGT | Fibrinogen alpha chain | Plasma | 863.71 | LC-MS | Ductal adenocarcinoma of the pancreas (DAP) | NA | 19795908 |
| CancerPDF_ID600 | SESGSFRPDSPGSGNARPNNPDWG | Fibrinogen alpha chain | Plasma | 830.03 | LC-MS | Ductal adenocarcinoma of the pancreas (DAP) | NA | 19795908 |
| CancerPDF_ID607 | SGSFRPDSPGSGNARPNNPDWGTFE | Fibrinogen alpha chain | Plasma | 883.72 | LC-MS | Ductal adenocarcinoma of the pancreas (DAP) | NA | 19795908 |
| CancerPDF_ID610 | ARPNNPDWGTFEEVSGNVSPGTR | Fibrinogen alpha chain | Plasma | 829.72 | LC-MS | Ductal adenocarcinoma of the pancreas (DAP) | NA | 19795908 |
| CancerPDF_ID612 | PNNPDWGTFEEVSGNVSPGTR | Fibrinogen alpha chain | Plasma | 754.01 | LC-MS | Ductal adenocarcinoma of the pancreas (DAP) | NA | 19795908 |
| CancerPDF_ID647 | DLGTLSGIGTLDGFRHRHPDEAAF | Fibrinogen alpha chain | Plasma | 861.43 | LC-MS | Ductal adenocarcinoma of the pancreas (DAP) | NA | 19795908 |
| CancerPDF_ID648 | DLGTLSGIGTLDGFRHRHPDEA | Fibrinogen alpha chain | Plasma | 788.72 | LC-MS | Ductal adenocarcinoma of the pancreas (DAP) | NA | 19795908 |
| CancerPDF_ID659 | GTLSGIGTLDGFRHRHPDEAAF | Fibrinogen alpha chain | Plasma | 785.39 | LC-MS | Ductal adenocarcinoma of the pancreas (DAP) | NA | 19795908 |
| CancerPDF_ID678 | ALTDMPQMRMELERPGGNEITR | Fibrinogen alpha chain | Plasma | 849.07 | LC-MS | Ductal adenocarcinoma of the pancreas (DAP) | NA | 19795908 |
| CancerPDF_ID696 | GGSTSYGTGSETESPRNPSSAGSWN | Fibrinogen alpha chain | Plasma | 825.02 | LC-MS | Ductal adenocarcinoma of the pancreas (DAP) | NA | 19795908 |
| CancerPDF_ID697 | GGSTSYGTGSETESPRNPSSAG | Fibrinogen alpha chain | Plasma | 1043.44 | LC-MS | Ductal adenocarcinoma of the pancreas (DAP) | NA | 19795908 |
| CancerPDF_ID702 | GTGSETESPRNPSSAGSWNSGSSGP | Fibrinogen alpha chain | Plasma | "1197.01, 798.34" | LC-MS | Ductal adenocarcinoma of the pancreas (DAP) | NA | 19795908 |
| CancerPDF_ID704 | TGSETESPRNPSSAGSWNSGSSGP | Fibrinogen alpha chain | Plasma | 1168.5 | LC-MS | Ductal adenocarcinoma of the pancreas (DAP) | NA | 19795908 |
| CancerPDF_ID728 | SAVTALWGKVNVDEVGGEALGR | Hemoglobin subunit beta | Plasma | 743.39 | LC-MS | Ductal adenocarcinoma of the pancreas (DAP) | NA | 19795908 |
| CancerPDF_ID729 | SAVTALWGKVNVDEVGGEALG | Hemoglobin subunit beta | Plasma | 1036.53 | LC-MS | Ductal adenocarcinoma of the pancreas (DAP) | NA | 19795908 |
| CancerPDF_ID774 | PGVLSSRQLGLPGPPDVPDHA | Inter-alpha-trypsin inhibitor heavy chain H4 | Plasma | 703.7 | LC-MS | Ductal adenocarcinoma of the pancreas (DAP) | NA | 19795908 |
| CancerPDF_ID775 | SSRQLGLPGPPDVPDHAAYHPF | Inter-alpha-trypsin inhibitor heavy chain H4 | Plasma | 786.72 | LC-MS | Ductal adenocarcinoma of the pancreas (DAP) | NA | 19795908 |
| CancerPDF_ID827 | VNPFRPGDSEPPPAPGAQRAQ | Zyxin | Plasma | 730.03 | LC-MS | Ductal adenocarcinoma of the pancreas (DAP) | NA | 19795908 |
| CancerPDF_ID833 | VTEPISAESGEQVERVNEPSILEMS | Apolipoprotein L1 | Plasma | 910.77 | LC-MS | Ductal adenocarcinoma of the pancreas (DAP) | NA | 19795908 |
| CancerPDF_ID839 | SEEAERSDGDPVQPAVLQVHQTS | Serum deprivation-response protein | Plasma | 827.06 | LC-MS | Ductal adenocarcinoma of the pancreas (DAP) | NA | 19795908 |
| CancerPDF_ID843 | KREEAPSLRPAPPPISGGGYR | Fibrinogen beta chain | Plasma | 745.73 | LC-MS | Ductal adenocarcinoma of the pancreas (DAP) | NA | 19795908 |
| CancerPDF_ID873 | TLEIPGNSDPNMIPDGDFNSYVR | Complement C4-A | Plasma | "1276.08, 851.05" | LC-MS | Ductal adenocarcinoma of the pancreas (DAP) | NA | 19795908 |
| CancerPDF_ID874 | TLEIPGNSDPNMIPDGDFNSYV | Complement C4-B | Plasma | 1198.03 | LC-MS | Ductal adenocarcinoma of the pancreas (DAP) | NA | 19795908 |
| CancerPDF_ID884 | GLEEELQFSLGSKINVKVGGNS | Complement C4-B | Plasma | 769.07 | LC-MS | Ductal adenocarcinoma of the pancreas (DAP) | NA | 19795908 |
| CancerPDF_ID901 | DDPDAPLQPVTPLQLFEGRRN | Complement C4-B | Plasma | 793.4 | LC-MS | Ductal adenocarcinoma of the pancreas (DAP) | NA | 19795908 |
| CancerPDF_ID910 | KTETQEKNPLPSKETIEQEKQAGES | Thymosin beta-4 | Plasma | 943.8 | LC-MS | Ductal adenocarcinoma of the pancreas (DAP) | NA | 19795908 |
| CancerPDF_ID911 | TETQEKNPLPSKETIEQEKQAGES | Thymosin beta-4 | Plasma | 901.1 | LC-MS | Ductal adenocarcinoma of the pancreas (DAP) | NA | 19795908 |
| CancerPDF_ID918 | SWVPHTFESELSDPVELLVAES | Alpha-1B-glycoprotein | Plasma | 1236.09 | LC-MS | Ductal adenocarcinoma of the pancreas (DAP) | NA | 19795908 |
| CancerPDF_ID921 | KRDRRLDDFQGTAGRKTRQRPS | hypothetical LOC727950 | Plasma | 882.14 | LC-MS | Ductal adenocarcinoma of the pancreas (DAP) | NA | 19795908 |
| CancerPDF_ID950 | EGVQKEDIPPADLSDQVPDTESETR | Complement C3 | Plasma | 919.09 | LC-MS | Ductal adenocarcinoma of the pancreas (DAP) | NA | 19795908 |
| CancerPDF_ID1029 | SSSYSKQFTSSTSYNRGDSTFES | Fibrinogen alpha chain | Serum | 2553.01 | MALDI-TOF | "Advanced Prostate, Breast and Bladder cancer" | "Upregulated in cancer vs normal with Ratio of median intensity (patients/Controls) = 1.35, 1.31 and 1.5 in prostate, bladder and breast cancer respectively" | 16395409 |
| CancerPDF_ID1030 | SSSYSKQFTSSTSYNRGDSTFESKS | Fibrinogen alpha chain | Serum | 2768.3 | MALDI-TOF | "Advanced Prostate, Breast and Bladder cancer" | "Downregulated in cancer vs normal with Ratio of median intensity (patients/Controls) = 0.77, 0.03 and 0.98 in prostate, bladder and breast cancer respectively" | 16395409 |
| CancerPDF_ID1034 | SSYSKQFTSSTSYNRGDSTFE | Fibrinogen alpha chain | Serum | 2379.03 | MALDI-TOF | "Advanced Prostate, Breast and Bladder cancer" | "For bladder (Lower) and for breast (Higher) Differential ion intensity in cancer compare to normal with Ratio of median intensity (patients/Controls) = 1.57, 0.22 and 1.71 in prostate, bladder and breast cancer respectively" | 16395409 |
| CancerPDF_ID1037 | DEAGSEADHEGTHSTKRGHAKSRPV | Fibrinogen alpha chain | Serum | 2659.03 | MALDI-TOF | "Advanced Prostate, Breast and Bladder cancer" | "Upregulated in cancer vs normal with Ratio of median intensity (patients/Controls) = 1.37, 1.18 and 2.45 in prostate, bladder and breast cancer respectively" | 16395409 |
| CancerPDF_ID1055 | GLEEELQFSLGSKINVKVGGNS | Complement C4 precursor | Serum | 2305.2 | MALDI-TOF | "Advanced Prostate, Breast and Bladder cancer" | "Upregulated in cancer vs normal with Ratio of median intensity (patients/Controls) =3.75, 2.56 and 3.49 in prostate, bladder and breast cancer respectively" | 16395409 |
| CancerPDF_ID1058 | TLEIPGNSDPNMIPDGDFNSYVR | Complement C4 precursor | Serum | 2551.06 | MALDI-TOF | "Advanced Prostate, Breast and Bladder cancer" | NA | 16395409 |
| CancerPDF_ID1062 | SRQLGLPGPPDVPDHAAYHPF | Inter-alpha-trypsin inhibitor heavy chain H7 | Serum | 2271.14 | MALDI-TOF | "Advanced Prostate, Breast and Bladder cancer" | "Upregulated in cancer vs normal with Ratio of median intensity (patients/Controls) =4.58, 2.64 and 1.46 in prostate, bladder and breast cancer respectively" | 16395409 |
| CancerPDF_ID1063 | SSRQLGLPGPPDVPDHAAYHPF | Inter-alpha-trypsin inhibitor heavy chain H8 | Serum | 2358.09 | MALDI-TOF | "Advanced Prostate, Breast and Bladder cancer" | "Upregulated in cancer vs normal with Ratio of median intensity (patients/Controls) =100, 73 and 531 in prostate, bladder and breast cancer respectively" | 16395409 |
| CancerPDF_ID1064 | GVLSSRQLGLPGPPDVPDHAAYHPF | Inter-alpha-trypsin inhibitor heavy chain H9 | Serum | 2627.48 | MALDI-TOF | "Advanced Prostate, Breast and Bladder cancer" | "Downregulated in cancer vs normal with Ratio of median intensity (patients/Controls) =2.24, 0.26 and 1.07 in prostate, bladder and breast cancer respectively" | 16395409 |
| CancerPDF_ID1071 | NVHSAGAAGSRMNFRPGVLSS | PRO1851(ITIH4 splice variant) | Serum | 2115.01 | MALDI-TOF | "Advanced Prostate, Breast and Bladder cancer" | "Upregulated in cancer vs normal with Ratio of median intensity (patients/Controls) =3.22, 12.23 and 10.61 in prostate, bladder and breast cancer respectively" | 16395409 |
| CancerPDF_ID1077 | ISASAEELRQRLAPLAEDVRGNL | Apolipoprotein A-IV | Serum | 2508.16 | MALDI-TOF | "Advanced Prostate, Breast and Bladder cancer" | "Upregulated in cancer vs normal with Ratio of median intensity (patients/Controls) =1.38, 1.2 and 7.96 in prostate, bladder and breast cancer respectively" | 16395409 |
| CancerPDF_ID1079 | GNTEGLQKSLAELGGHLDQQVEEF | Apolipoprotein A-IV | Serum | 2599.18 | MALDI-TOF | "Advanced Prostate, Breast and Bladder cancer" | NA | 16395409 |
| CancerPDF_ID1080 | GNTEGLQKSLAELGGHLDQQVEEFR | Apolipoprotein A-IV | Serum | 2755.2 | MALDI-TOF | "Advanced Prostate, Breast and Bladder cancer" | "Upregulated in cancer vs normal with Ratio of median intensity (patients/Controls) =1.11, 12.37 and 1.22 in prostate, bladder and breast cancer respectively" | 16395409 |
| CancerPDF_ID1082 | DVSSALDKLKEFGNTLEDKARELIS | Apolipoprotein C-I | Serum | 2778.15 | MALDI-TOF | "Advanced Prostate, Breast and Bladder cancer" | NA | 16395409 |
| CancerPDF_ID1083 | TVGSLAGQPLQERAQAWGERL | Apolipoprotein E | Serum | 2267.07 | MALDI-TOF | "Advanced Prostate, Breast and Bladder cancer" | NA | 16395409 |
| CancerPDF_ID1084 | AATVGSLAGQPLQERAQAWGERL | Apolipoprotein E | Serum | 2409.13 | MALDI-TOF | "Advanced Prostate, Breast and Bladder cancer" | "Upregulated in cancer vs normal with Ratio of median intensity (patients/Controls) =97, 2124 and 109 in prostate, bladder and breast cancer respectively" | 16395409 |
| CancerPDF_ID1085 | AATVGSLAGQPLQERAQAWGERLR | Apolipoprotein E | Serum | 2565.45 | MALDI-TOF | "Advanced Prostate, Breast and Bladder cancer" | "Upregulated in cancer vs normal with Ratio of median intensity (patients/Controls) =1, 902 and 1 in prostate, bladder and breast cancer respectively" | 16395409 |
| CancerPDF_ID1095 | AVPPNNSNAAEDDLPTVELQGVVPR | Factor XIIIa | Serum | 2602.15 | MALDI-TOF | "Advanced Prostate, Breast and Bladder cancer" | "Upregulated in cancer vs normal with Ratio of median intensity (patients/Controls) =2.84, 2.3 and 4.73 in prostate, bladder and breast cancer respectively" | 16395409 |
| CancerPDF_ID1096 | ALGISPFHEHAEVVFTANDSGPR | Transtherin precursor (‘prealbumin’) | Serum | 2451.11 | MALDI-TOF | "Advanced Prostate, Breast and Bladder cancer" | "Upregulated in cancer vs normal with Ratio of median intensity (patients/Controls) =0.02, 1.17 and 3.07 in prostate, bladder and breast cancer respectively" | 16395409 |
| CancerPDF_ID1097 | PDAPRIKKIVQKKLAGDESAD | Platelet basic protein Precursor | Serum | 2279.18 | MALDI-TOF | "Advanced Prostate, Breast and Bladder cancer" | NA | 16395409 |
| CancerPDF_ID1250 | ADEAGSEADHEGTHSTKRGHA | Fibrinogen alpha | Serum | 2161.9373 | LC-MS | Colorectal cancer | NA | 21136997 |
| CancerPDF_ID1253 | SYKMADEAGSEADHEGTHSTK | Fibrinogen alpha | Serum | 2249.9495 | LC-MS | Colorectal cancer | NA | 21136997 |
| CancerPDF_ID1254 | MADEAGSEADHEGTHSTKRGHA | Fibrinogen alpha | Serum | 2292.97778 | LC-MS | Colorectal cancer | NA | 21136997 |
| CancerPDF_ID1255 | MADEAGSEADHEGTHSTKRGHA | Fibrinogen alpha | Serum | 2308.9727 | LC-MS | Colorectal cancer | NA | 21136997 |
| CancerPDF_ID1256 | SSSYSKQFTSSTSYNRGDSTF | Fibrinogen alpha | Serum | 2336.0193 | LC-MS | Colorectal cancer | NA | 21136997 |
| CancerPDF_ID1257 | TSSTSYNRGDSTFESKSYKMA | Fibrinogen alpha | Serum | 2346.0434 | LC-MS | Colorectal cancer | NA | 21136997 |
| CancerPDF_ID1258 | AGSEADHEGTHSTKRGHAKSRPV | Fibrinogen alpha | Serum | 2414.17993 | LC-MS | Colorectal cancer | NA | 21136997 |
| CancerPDF_ID1259 | DEAGSEADHEGTHSTKRGHAKSRPV | Fibrinogen alpha | Serum | 2658.24947 | LC-MS | Colorectal cancer | NA | 21136997 |
| CancerPDF_ID1260 | SYKMADEAGSEADHEGTHSTKRGHA | Fibrinogen alpha | Serum | 2671.1681 | LC-MS | Colorectal cancer | NA | 21136997 |
| CancerPDF_ID1261 | SSYSKQFTSSTSYNRGDSTFESKSY | Fibrinogen alpha | Serum | 2843.25221 | LC-MS | Colorectal cancer | Differentially expressed between cancer vs normal | 21136997 |
| CancerPDF_ID1262 | YSKQFTSSTSYNRGDSTFESKSYKM | Fibrinogen alpha | Serum | 2928.3236 | LC-MS | Colorectal cancer | NA | 21136997 |
| CancerPDF_ID1276 | SYSKQFTSSTSYNRGDSTFES | Fibrinogen alpha | Serum | 2378.02986 | LC-MS | Colorectal cancer | NA | 21136997 |
| CancerPDF_ID1277 | FTSSTSYNRGDSTFESKSYKM | Fibrinogen alpha | Serum | 2422.0747 | LC-MS | Colorectal cancer | NA | 21136997 |
| CancerPDF_ID1278 | SSYSKQFTSSTSYNRGDSTFES | Fibrinogen alpha | Serum | 2465.06189 | LC-MS | Colorectal cancer | NA | 21136997 |
| CancerPDF_ID1279 | FTSSTSYNRGDSTFESKSYKMA | Fibrinogen alpha | Serum | 2493.11182 | LC-MS | Colorectal cancer | NA | 21136997 |
| CancerPDF_ID1280 | KSYKMADEAGSEADHEGTHSTKR | Fibrinogen alpha | Serum | 2534.14558 | LC-MS | Colorectal cancer | NA | 21136997 |
| CancerPDF_ID1281 | SSSYSKQFTSSTSYNRGDSTFES | Fibrinogen alpha | Serum | 2552.09392 | LC-MS | Colorectal cancer | NA | 21136997 |
| CancerPDF_ID1282 | SSSYSKQFTSSTSYNRGDSTFESK | Fibrinogen alpha | Serum | 2680.18888 | LC-MS | Colorectal cancer | NA | 21136997 |
| CancerPDF_ID1283 | SSSYSKQFTSSTSYNRGDSTFESKS | Fibrinogen alpha | Serum | 2767.22091 | LC-MS | Colorectal cancer | NA | 21136997 |
| CancerPDF_ID1298 | SYKMADEAGSEADHEGTHSTKR | Fibrinogen alpha | Serum | 2406.05061 | LC-MS | Colorectal cancer | NA | 21136997 |
| CancerPDF_ID1305 | ALTDMPQMRMELERPGGNEIT | Fibrinogen alpha | Serum | 2388.12359 | LC-MS | Colorectal cancer | NA | 21136997 |
| CancerPDF_ID1306 | SYSKQFTSSTSYNRGDSTFESKSYK | Fibrinogen alpha | Serum | 2884.31515 | LC-MS | Colorectal cancer | NA | 21136997 |
| CancerPDF_ID1319 | YSKQFTSSTSYNRGDSTFESKS | Fibrinogen alpha | Serum | 2506.12483 | LC-MS | Colorectal cancer | NA | 21136997 |
| CancerPDF_ID1320 | SYKMADEAGSEADHEGTHSTKRGHA | Fibrinogen alpha | Serum | 2687.16302 | LC-MS | Colorectal cancer | NA | 21136997 |
| CancerPDF_ID1326 | GKSSSYSKQFTSSTSYNRGDSTFES | Fibrinogen alpha | Serum | 2737.21035 | LC-MS | Colorectal cancer | NA | 21136997 |
| CancerPDF_ID1342 | SYSKQFTSSTSYNRGDSTFESKSY | Fibrinogen alpha | Serum | 2756.22018 | LC-MS | Colorectal cancer | NA | 21136997 |
| CancerPDF_ID1347 | GSEADHEGTHSTKRGHAKSRPV | Fibrinogen alpha | Serum | 2343.14282 | LC-MS | Colorectal cancer | NA | 21136997 |
| CancerPDF_ID1386 | GRLTPYADEFKVKIDQTVEELR | Apolipoprotein A-IV | Serum | 2606.37042 | LC-MS | Colorectal cancer | NA | 21136997 |
| CancerPDF_ID1387 | GNTEGLQKSLAELGGHLDQQVEEFR | Apolipoprotein A-IV | Serum | 2754.35729 | LC-MS | Colorectal cancer | Differentially expressed between cancer vs normal | 21136997 |
| CancerPDF_ID1388 | RVEPYGENFNKALVQQMEQLRQK | Apolipoprotein A-IV | Serum | 2804.43918 | LC-MS | Colorectal cancer | NA | 21136997 |
| CancerPDF_ID1393 | SLAPYAQDTQEKLNHQLEGLTFQMK | Apolipoprotein A-IV | Serum | 2889.43309 | LC-MS | Colorectal cancer | NA | 21136997 |
| CancerPDF_ID1394 | SLAPYAQDTQEKLNHQLEGLTFQM | Apolipoprotein A-IV | Serum | 2777.33304 | LC-MS | Colorectal cancer | NA | 21136997 |
| CancerPDF_ID1400 | GNTEGLQKSLAELGGHLDQQVEEF | Apolipoprotein A-IV | Serum | 2598.25617 | LC-MS | Colorectal cancer | Differentially expressed between cancer vs normal | 21136997 |
| CancerPDF_ID1420 | AKIDQNVEELKGRLTPYADEFK | Apolipoprotein A-IV | Serum | 2563.32822 | LC-MS | Colorectal cancer | NA | 21136997 |
| CancerPDF_ID1424 | GRLTPYADEFKVKIDQTVEEL | Apolipoprotein A-IV | Serum | 2450.26931 | LC-MS | Colorectal cancer | NA | 21136997 |
| CancerPDF_ID1443 | AKIDQNVEELKGRLTPYADEF | Apolipoprotein A-IV | Serum | 2435.23325 | LC-MS | Colorectal cancer | NA | 21136997 |
| CancerPDF_ID1444 | SLAPYAQDTQEKLNHQLEGLTFQM | Apolipoprotein A-IV | Serum | 2761.33813 | LC-MS | Colorectal cancer | NA | 21136997 |
| CancerPDF_ID1448 | RVEPYGENFNKALVQQMEQLR | Apolipoprotein A-IV | Serum | 2548.28564 | LC-MS | Colorectal cancer | NA | 21136997 |
| CancerPDF_ID1449 | RVEPYGENFNKALVQQMEQLRQ | Apolipoprotein A-IV | Serum | 2676.34422 | LC-MS | Colorectal cancer | NA | 21136997 |
| CancerPDF_ID1472 | ILLQGTPVAQMTEDAVDAERLK | Complement C3 | Serum | 2397.25736 | LC-MS | Colorectal cancer | NA | 21136997 |
| CancerPDF_ID1488 | VPVAVQGEDTVQSLTQGDGVAK | Complement C3 | Serum | 2197.12264 | LC-MS | Colorectal cancer | NA | 21136997 |
| CancerPDF_ID1494 | VPVAVQGEDTVQSLTQGDGVA | Complement C3 | Serum | 2069.02768 | LC-MS | Colorectal cancer | NA | 21136997 |
| CancerPDF_ID1495 | ILLQGTPVAQMTEDAVDAERL | Complement C3 | Serum | 2269.1624 | LC-MS | Colorectal cancer | NA | 21136997 |
| CancerPDF_ID1496 | EGVQKEDIPPADLSDQVPDTESETR | Complement C3 | Serum | 2754.28318 | LC-MS | Colorectal cancer | NA | 21136997 |
| CancerPDF_ID1544 | SSLSVPYVIVPLKTGLQEVEVK | Complement C3 | Serum | 2384.35666 | LC-MS | Colorectal cancer | NA | 21136997 |
| CancerPDF_ID1546 | SEFPESWLWNVEDLKEPPKNGIST | Complement C3 | Serum | 2801.35483 | LC-MS | Colorectal cancer | NA | 21136997 |
| CancerPDF_ID1552 | QKPDGVFQEDAPVIHQEMIGGL | Complement C3 | Serum | 2407.1842 | LC-MS | Colorectal cancer | NA | 21136997 |
| CancerPDF_ID1553 | TMQALPYSTVGNSNNYLHLSVLR | Complement C3 | Serum | 2577.30096 | LC-MS | Colorectal cancer | NA | 21136997 |
| CancerPDF_ID1554 | YFKPGMPFDLMVFVTNPDGSPAY | Complement C3 | Serum | 2592.2069 | LC-MS | Colorectal cancer | NA | 21136997 |
| CancerPDF_ID1560 | DEPPQSPWDRVKDLATVYVDVLK | Apolipoprotein A-I | Serum | 2669.37008 | LC-MS | Colorectal cancer | NA | 21136997 |
| CancerPDF_ID1586 | QKLHELQEKLSPLGEEMRDRA | Apolipoprotein A-I | Serum | 2506.29621 | LC-MS | Colorectal cancer | NA | 21136997 |
| CancerPDF_ID1595 | DSGRDYVSQFEGSALGKQLNL | Apolipoprotein A-I | Serum | 2283.11314 | LC-MS | Colorectal cancer | NA | 21136997 |
| CancerPDF_ID1602 | DEPPQSPWDRVKDLATVYVDVL | Apolipoprotein A-I | Serum | 2541.27512 | LC-MS | Colorectal cancer | NA | 21136997 |
| CancerPDF_ID1639 | EDPQGDAAQKTDTSHHDQDHPTFN | Alpha-1 protease inhibitor | Serum | 2690.12293 | LC-MS | Colorectal cancer | NA | 21136997 |
| CancerPDF_ID1647 | TLNQPDSQLQLTTGNGLFLSEGLK | Alpha-1 protease inhibitor | Serum | 2573.3337 | LC-MS | Colorectal cancer | NA | 21136997 |
| CancerPDF_ID1653 | PQGDAAQKTDTSHHDQDHPTFN | Alpha-1 protease inhibitor | Serum | 2446.05339 | LC-MS | Colorectal cancer | NA | 21136997 |
| CancerPDF_ID1654 | EDPQGDAAQKTDTSHHDQDHPTFNK | Alpha-1 protease inhibitor | Serum | 2818.21789 | LC-MS | Colorectal cancer | NA | 21136997 |
| CancerPDF_ID1656 | VFSNGADLSGVTEEAPLKLSKAVH | Alpha-1 protease inhibitor | Serum | 2468.2911 | LC-MS | Colorectal cancer | NA | 21136997 |
| CancerPDF_ID1674 | HTFMGVVSLGSPSGEVSHPRKT | Alpha-2-HS-glycoprotein | Serum | 2309.15865 | LC-MS | Colorectal cancer | NA | 21136997 |
| CancerPDF_ID1675 | HTFMGVVSLGSPSGEVSHPRKT | Alpha-2-HS-glycoprotein | Serum | 2325.15356 | LC-MS | Colorectal cancer | NA | 21136997 |
| CancerPDF_ID1692 | AATVGSLAGQPLQERAQAWGERL | Apolipoprotein E | Serum | 2408.25606 | LC-MS | Colorectal cancer | NA | 21136997 |
| CancerPDF_ID1693 | AATVGSLAGQPLQERAQAWGERLR | Apolipoprotein E | Serum | 2564.35717 | LC-MS | Colorectal cancer | NA | 21136997 |
| CancerPDF_ID1695 | TVGSLAGQPLQERAQAWGERL | Apolipoprotein E | Serum | 2266.18183 | LC-MS | Colorectal cancer | NA | 21136997 |
| CancerPDF_ID1700 | AATVGSLAGQPLQERAQAWGER | Apolipoprotein E | Serum | 2295.17199 | LC-MS | Colorectal cancer | NA | 21136997 |
| CancerPDF_ID1709 | GRLVQYRGEVQAMLGQSTEELRV | Apolipoprotein E | Serum | 2618.35987 | LC-MS | Colorectal cancer | NA | 21136997 |
| CancerPDF_ID1717 | VSEADSSNADWVTKQLNEINYEDHKL | Complement factor B | Serum | 3004.40502 | LC-MS | Colorectal cancer | NA | 21136997 |
| CancerPDF_ID1748 | SEAEDASLLSFMQGYMKHATK | Apolipoprotein C-III precursor (Apo-CIII) | Serum | 2343.08752 | LC-MS | Colorectal cancer | NA | 21136997 |
| CancerPDF_ID1751 | SEAEDASLLSFMQGYMKHATKTAK | Apolipoprotein C-III precursor (Apo-CIII) | Serum | 2643.26727 | LC-MS | Colorectal cancer | NA | 21136997 |
| CancerPDF_ID1755 | SEAEDASLLSFMQGYMKHATKTA | Apolipoprotein C-III precursor (Apo-CIII) | Serum | 2515.17231 | LC-MS | Colorectal cancer | NA | 21136997 |
| CancerPDF_ID1759 | HATKTAKDALSSVQESQVAQQA | Apolipoprotein C-III precursor (Apo-CIII) | Serum | 2297.16115 | LC-MS | Colorectal cancer | NA | 21136997 |
| CancerPDF_ID1761 | HATKTAKDALSSVQESQVAQQAR | Apolipoprotein C-III precursor (Apo-CIII) | Serum | 2453.26226 | LC-MS | Colorectal cancer | NA | 21136997 |
| CancerPDF_ID1762 | SEAEDASLLSFMQGYMKHATKTA | Apolipoprotein C-III precursor (Apo-CIII) | Serum | 2531.16722 | LC-MS | Colorectal cancer | NA | 21136997 |
| CancerPDF_ID1787 | LSNENHGIAQRIYGNQDTSSQL | Inter-alpha-trypsin inhibitor heavy chain H2 | Serum | 2444.16803 | LC-MS | Colorectal cancer | NA | 21136997 |
| CancerPDF_ID1790 | LSNENHGIAQRIYGNQDTSSQLK | Inter-alpha-trypsin inhibitor heavy chain H2 | Serum | 2572.26299 | LC-MS | Colorectal cancer | NA | 21136997 |
| CancerPDF_ID1791 | IYGNQDTSSQLKKFYNQVSTPLL | Inter-alpha-trypsin inhibitor heavy chain H2 | Serum | 2643.35443 | LC-MS | Colorectal cancer | NA | 21136997 |
| CancerPDF_ID1793 | RLSNENHGIAQRIYGNQDTSSQL | Inter-alpha-trypsin inhibitor heavy chain H2 | Serum | 2600.26914 | LC-MS | Colorectal cancer | NA | 21136997 |
| CancerPDF_ID1811 | LTSEEAERSDGDPVQPAVLQVHQTS | Serum deprivation-response protein | Serum | 2692.29402 | LC-MS | Colorectal cancer | NA | 21136997 |
| CancerPDF_ID1813 | SEEAERSDGDPVQPAVLQVHQTS | Serum deprivation-response protein | Serum | 2478.16227 | LC-MS | Colorectal cancer | NA | 21136997 |
| CancerPDF_ID1826 | QYYEGSEIVVAGRIADNKQSSF | Inter-alpha-trypsin inhibitor heavy chain H1 | Serum | 2460.19212 | LC-MS | Colorectal cancer | NA | 21136997 |
| CancerPDF_ID1848 | IVEGSDAEIGMSPWQVMLFRK | Prothrombin | Serum | 2392.19192 | LC-MS | Colorectal cancer | NA | 21136997 |
| CancerPDF_ID1863 | QGPVNLLSDPEQGVEVTGQYEREK | Inter-alpha-trypsin inhibitor heavy chain H4 | Serum | 2671.30894 | LC-MS | Colorectal cancer | NA | 21136997 |
| CancerPDF_ID1875 | QGPVNLLSDPEQGVEVTGQYERE | Inter-alpha-trypsin inhibitor heavy chain H4 | Serum | 2543.21398 | LC-MS | Colorectal cancer | NA | 21136997 |
| CancerPDF_ID1902 | DDPDAPLQPVTPLQLFEGRRN | Complement C4-B | Serum | 2377.20262 | LC-MS | Colorectal cancer | NA | 21136997 |
| CancerPDF_ID1903 | TLEIPGNSDPNMIPDGDFNSYVR | Complement C4-B | Serum | 2550.16967 | LC-MS | Colorectal cancer | NA | 21136997 |
| CancerPDF_ID1904 | TLEIPGNSDPNMIPDGDFNSYV | Complement C4-B | Serum | 2394.06856 | LC-MS | Colorectal cancer | NA | 21136997 |
| CancerPDF_ID1909 | TLEIPGNSDPNMIPDGDFNSYVR | Complement C4-B | Serum | 2566.16458 | LC-MS | Colorectal cancer | NA | 21136997 |
| CancerPDF_ID1913 | GRTLEIPGNSDPNMIPDGDFNSYV | Complement C4-B | Serum | 2607.19113 | LC-MS | Colorectal cancer | NA | 21136997 |
| CancerPDF_ID1914 | GRTLEIPGNSDPNMIPDGDFNSYVR | Complement C4-B | Serum | 2763.29224 | LC-MS | Colorectal cancer | NA | 21136997 |
| CancerPDF_ID1927 | QEKNPLPSKETIEQEKQAGES | Thymosin beta-4 | Serum | 2369.17105 | LC-MS | Colorectal cancer | NA | 21136997 |
| CancerPDF_ID1928 | TETQEKNPLPSKETIEQEKQAGES | Thymosin beta-4 | Serum | 2700.309 | LC-MS | Colorectal cancer | NA | 21136997 |
| CancerPDF_ID1930 | TQEKNPLPSKETIEQEKQAGES | Thymosin beta-4 | Serum | 2470.21873 | LC-MS | Colorectal cancer | NA | 21136997 |
| CancerPDF_ID1933 | KTETQEKNPLPSKETIEQEKQAGES | Thymosin beta-4 | Serum | 2828.40396 | LC-MS | Colorectal cancer | NA | 21136997 |
| CancerPDF_ID1935 | AFLEVNEEGSEAAASTAVVIAGR | Antithrombin-III | Serum | 2290.1441 | LC-MS | Colorectal cancer | NA | 21136997 |
| CancerPDF_ID1937 | SPEKKATEDEGSEQKIPEATNR | Antithrombin-III | Serum | 2443.18267 | LC-MS | Colorectal cancer | NA | 21136997 |
| CancerPDF_ID1939 | SKLPGIVAEGRDDLYVSDAFH | Antithrombin-III | Serum | 2288.14371 | LC-MS | Colorectal cancer | NA | 21136997 |
| CancerPDF_ID1940 | SKLPGIVAEGRDDLYVSDAFHK | Antithrombin-III | Serum | 2416.23867 | LC-MS | Colorectal cancer | NA | 21136997 |
| CancerPDF_ID1973 | MEPLGRQLTSGPNQEQVSPLTLL | Alpha-2-antiplasmin | Serum | 2507.30537 | LC-MS | Colorectal cancer | NA | 21136997 |
| CancerPDF_ID1978 | MEPLGRQLTSGPNQEQVSPLTLLK | Alpha-2-antiplasmin | Serum | 2635.40034 | LC-MS | Colorectal cancer | NA | 21136997 |
| CancerPDF_ID1982 | LFGPDLKLVPPMEEDYPQFGSPK | Alpha-2-antiplasmin | Serum | 2603.29816 | LC-MS | Colorectal cancer | NA | 21136997 |
| CancerPDF_ID1988 | VTEPISAESGEQVERVNEPSILEMS | Apolipoprotein-L1 | Serum | 2729.30655 | LC-MS | Colorectal cancer | NA | 21136997 |
| CancerPDF_ID1990 | VTEPISAESGEQVERVNEPSILEMS | Apolipoprotein-L1 | Serum | 2745.30147 | LC-MS | Colorectal cancer | NA | 21136997 |
| CancerPDF_ID2000 | VNPFRPGDSEPPPAPGAQRAQ | Zyxin | Serum | 2187.08211 | LC-MS | Colorectal cancer | NA | 21136997 |
| CancerPDF_ID2002 | GPPASSPAPAPKFSPVTPKFTPVAS | Zyxin | Serum | 2434.28965 | LC-MS | Colorectal cancer | NA | 21136997 |
| CancerPDF_ID2023 | IADFELPTIIVPEQTIEIPSIK | Apolipoprotein B-100 | Serum | 2465.36689 | LC-MS | Colorectal cancer | NA | 21136997 |
| CancerPDF_ID2031 | SLDRNLPSDSQDLGQHGLEED | Secretory granule proteoglycan core protein | Serum | 2324.05166 | LC-MS | Colorectal cancer | NA | 21136997 |
| CancerPDF_ID2032 | SLDRNLPSDSQDLGQHGLEEDFM | Secretory granule proteoglycan core protein | Serum | 2602.16056 | LC-MS | Colorectal cancer | NA | 21136997 |
| CancerPDF_ID2033 | SLDRNLPSDSQDLGQHGLEEDF | Secretory granule proteoglycan core protein | Serum | 2471.12007 | LC-MS | Colorectal cancer | NA | 21136997 |
| CancerPDF_ID2035 | SLDRNLPSDSQDLGQHGLEEDFML | Secretory granule proteoglycan core protein | Serum | 2715.24462 | LC-MS | Colorectal cancer | NA | 21136997 |
| CancerPDF_ID2045 | AVPPNNSNAAEDDLPTVELQGVVPR | Coagulation factor XIII A chain | Serum | 2601.30346 | LC-MS | Colorectal cancer | NA | 21136997 |
| CancerPDF_ID2046 | RAVPPNNSNAAEDDLPTVELQGVVPR | Coagulation factor XIII A chain | Serum | 2757.40457 | LC-MS | Colorectal cancer | NA | 21136997 |
| CancerPDF_ID2049 | VPPNNSNAAEDDLPTVELQGVVPR | Coagulation factor XIII A chain | Serum | 2530.26635 | LC-MS | Colorectal cancer | NA | 21136997 |
| CancerPDF_ID2052 | AKAVLEEDEEVTEEAEMEPEDKGH | Tubulin beta-1 chain | Serum | 2713.19125 | LC-MS | Colorectal cancer | NA | 21136997 |
| CancerPDF_ID2055 | VLEEDEEVTEEAEMEPEDKGH | Tubulin beta-1 chain | Serum | 2443.02206 | LC-MS | Colorectal cancer | NA | 21136997 |
| CancerPDF_ID2104 | TLDLGENQLETLPPDLLRGPLQLER | Leucine-rich alpha-2-glycoprotein | Serum | 2829.52362 | LC-MS | Colorectal cancer | NA | 21136997 |
| CancerPDF_ID2107 | ALGISPFHEHAEVVFTANDSGPR | Transthyretin | Serum | 2450.19787 | LC-MS | Colorectal cancer | NA | 21136997 |
| CancerPDF_ID2108 | YTIAALLSPYSYSTTAVVTNPKE | Transthyretin | Serum | 2488.27372 | LC-MS | Colorectal cancer | NA | 21136997 |
| CancerPDF_ID2114 | SAKPTKPAASDLPVPAEGVRNIK | Caldesmon | Serum | 2345.30669 | LC-MS | Colorectal cancer | NA | 21136997 |
| CancerPDF_ID2138 | MFTTAPDQVDKEDEDFQESNK | Ceruloplasmin | Serum | 2473.05911 | LC-MS | Colorectal cancer | NA | 21136997 |
| CancerPDF_ID2139 | LISVDTEHSNIYLQNGPDRIGRLY | Ceruloplasmin | Serum | 2772.41949 | LC-MS | Colorectal cancer | NA | 21136997 |
| CancerPDF_ID2145 | SWVPHTFESELSDPVELLVAES | Alpha-1B-glycoprotein | Serum | 2470.19039 | LC-MS | Colorectal cancer | NA | 21136997 |
| CancerPDF_ID2151 | FGLEGDEESTMLEDSVSPKKSTVLQ | Talin-1 | Serum | 2725.30041 | LC-MS | Colorectal cancer | NA | 21136997 |
| CancerPDF_ID2155 | NRIPESGGDNSVFDIFELTGAAR | Thrombospondin-1 | Serum | 2464.19827 | LC-MS | Colorectal cancer | NA | 21136997 |
| CancerPDF_ID2156 | NRIPESGGDNSVFDIFELTGAA | Thrombospondin-1 | Serum | 2308.09715 | LC-MS | Colorectal cancer | NA | 21136997 |
| CancerPDF_ID2160 | SVVPSPKVSDTVVEPYNATLSVHQL | Tubulin beta chain | Serum | 2665.3963 | LC-MS | Colorectal cancer | NA | 21136997 |
| CancerPDF_ID2165 | LQSLFDSPDFSKITGKPIKLTQVEH | Pigment epithelium-derived factor | Serum | 2827.512 | LC-MS | Colorectal cancer | NA | 21136997 |
| CancerPDF_ID2176 | KGPGPGGPGGAGVARGGAGGGP | Neurogranin | Serum | 1686.85501 | LC-MS | Colorectal cancer | NA | 21136997 |
| CancerPDF_ID2184 | KVSKQEEASGGPTAPKAESGR | Vasodilator-stimulated phosphoprotein | Serum | 2113.07636 | LC-MS | Colorectal cancer | NA | 21136997 |
| CancerPDF_ID2185 | EKTPKDESANQEEPEARVPAQ | Vasodilator-stimulated phosphoprotein | Serum | 2352.11935 | LC-MS | Colorectal cancer | NA | 21136997 |
| CancerPDF_ID2197 | LPGDIQVVPIGVGPNANVQELER | von Willebrand factor | Serum | 2413.29652 | LC-MS | Colorectal cancer | NA | 21136997 |
| CancerPDF_ID2222 | KGHIYQGSEADSVFSGFLIFPSA | Complement C1q subcomponent subunit A | Serum | 2456.20123 | LC-MS | Colorectal cancer | NA | 21136997 |
| CancerPDF_ID2225 | VAEYMDWILEKTQSSDGKAQMQSPA | Plasma kallikrein | Serum | 2812.30478 | LC-MS | Colorectal cancer | NA | 21136997 |
| CancerPDF_ID2238 | IPPGASPVSSLSQASSQALAVA | Polyhomeotic-like protein 1 | Serum | 2037.07423 | LC-MS | Colorectal cancer | NA | 21136997 |
| CancerPDF_ID2247 | QVGSGVTTDQVQAEAKESGPTTYK | Ig mu chain C region | Serum | 2480.20308 | LC-MS | Colorectal cancer | NA | 21136997 |
| CancerPDF_ID2251 | ADSSPVKAGVETTTPSKQSNNK | Ig lambda chain C regions | Serum | 2245.11862 | LC-MS | Colorectal cancer | NA | 21136997 |
| CancerPDF_ID2262 | EGCGGGGGGGGGGGSGGSGGGG | Homeobox protein Hox-B3 | Serum | 1450.51275 | LC-MS | Colorectal cancer | NA | 21136997 |
| CancerPDF_ID2362 | NPSSAGSWNSGSSGPGSTGNR | Fibrinogen alpha | Plasma | 1962.8416 | LC-MS | Normal | NA | 21136997 |
| CancerPDF_ID2364 | GGSTSYGTGSETESPRNPSSA | Fibrinogen alpha | Plasma | 2027.8668 | LC-MS | Normal | NA | 21136997 |
| CancerPDF_ID2369 | GGSTSYGTGSETESPRNPSSAG | Fibrinogen alpha | Plasma | 2084.8883 | LC-MS | Normal | NA | 21136997 |
| CancerPDF_ID2375 | DEAGSEADHEGTHSTKRGHAK | Fibrinogen alpha | Plasma | 2218.9952 | LC-MS | Normal | NA | 21136997 |
| CancerPDF_ID2377 | SYKMADEAGSEADHEGTHSTK | Fibrinogen alpha | Plasma | 2249.9495 | LC-MS | Normal | NA | 21136997 |
| CancerPDF_ID2378 | DSGEGDFLAEGGGVRGPRVVER | Fibrinogen alpha | Plasma | 2258.104 | LC-MS | Normal | NA | 21136997 |
| CancerPDF_ID2379 | PNNPDWGTFEEVSGNVSPGTR | Fibrinogen alpha | Plasma | 2259.0192 | LC-MS | Normal | NA | 21136997 |
| CancerPDF_ID2381 | ADEAGSEADHEGTHSTKRGHAK | Fibrinogen alpha | Plasma | 2290.0323 | LC-MS | Normal | NA | 21136997 |
| CancerPDF_ID2384 | MADEAGSEADHEGTHSTKRGHA | Fibrinogen alpha | Plasma | 2292.9778 | LC-MS | Normal | NA | 21136997 |
| CancerPDF_ID2385 | ADSGEGDFLAEGGGVRGPRVVER | Fibrinogen alpha | Plasma | 2329.1411 | LC-MS | Normal | NA | 21136997 |
| CancerPDF_ID2388 | ALTDMPQMRMELERPGGNEIT | Fibrinogen alpha | Plasma | 2388.1236 | LC-MS | Normal | NA | 21136997 |
| CancerPDF_ID2389 | ALTDMPQMRMELERPGGNEIT | Fibrinogen alpha | Plasma | 2404.1185 | LC-MS | Normal | NA | 21136997 |
| CancerPDF_ID2390 | SYKMADEAGSEADHEGTHSTKR | Fibrinogen alpha | Plasma | 2406.0506 | LC-MS | Normal | NA | 21136997 |
| CancerPDF_ID2392 | QFTSSTSYNRGDSTFESKSYK | Fibrinogen alpha | Plasma | 2419.0928 | LC-MS | Normal | NA | 21136997 |
| CancerPDF_ID2393 | MADEAGSEADHEGTHSTKRGHAK | Fibrinogen alpha | Plasma | 2421.0728 | LC-MS | Normal | NA | 21136997 |
| CancerPDF_ID2394 | DSHSLTTNIMEILRGDFSSANN | Fibrinogen alpha | Plasma | 2421.123 | LC-MS | Normal | NA | 21136997 |
| CancerPDF_ID2395 | MADEAGSEADHEGTHSTKRGHAK | Fibrinogen alpha | Plasma | 2437.0677 | LC-MS | Normal | NA | 21136997 |
| CancerPDF_ID2396 | DSHSLTTNIMEILRGDFSSANN | Fibrinogen alpha | Plasma | 2437.118 | LC-MS | Normal | NA | 21136997 |
| CancerPDF_ID2397 | GGSTSYGTGSETESPRNPSSAGSWN | Fibrinogen alpha | Plasma | 2472.0426 | LC-MS | Normal | NA | 21136997 |
| CancerPDF_ID2398 | ALTDMPQMRMELERPGGNEITR | Fibrinogen alpha | Plasma | 2544.2247 | LC-MS | Normal | NA | 21136997 |
| CancerPDF_ID2399 | SSSYSKQFTSSTSYNRGDSTFES | Fibrinogen alpha | Plasma | 2552.0939 | LC-MS | Normal | NA | 21136997 |
| CancerPDF_ID2400 | DSHSLTTNIMEILRGDFSSANNR | Fibrinogen alpha | Plasma | 2577.2242 | LC-MS | Normal | NA | 21136997 |
| CancerPDF_ID2401 | DSHSLTTNIMEILRGDFSSANNR | Fibrinogen alpha | Plasma | 2593.2191 | LC-MS | Normal | NA | 21136997 |
| CancerPDF_ID2402 | GSESGIFTNTKESSSHHPGIAEFPS | Fibrinogen alpha | Plasma | 2602.1936 | LC-MS | Normal | NA | 21136997 |
| CancerPDF_ID2403 | SYKMADEAGSEADHEGTHSTKRGHA | Fibrinogen alpha | Plasma | 2671.1681 | LC-MS | Normal | NA | 21136997 |
| CancerPDF_ID2404 | SSSYSKQFTSSTSYNRGDSTFESK | Fibrinogen alpha | Plasma | 2680.1889 | LC-MS | Normal | NA | 21136997 |
| CancerPDF_ID2405 | TNIMEILRGDFSSANNRDNTYNR | Fibrinogen alpha | Plasma | 2700.2674 | LC-MS | Normal | NA | 21136997 |
| CancerPDF_ID2406 | ALAREVDLKDYEDQQKQLEQVIA | Fibrinogen alpha | Plasma | 2701.3923 | LC-MS | Normal | NA | 21136997 |
| CancerPDF_ID2408 | SSSYSKQFTSSTSYNRGDSTFESKS | Fibrinogen alpha | Plasma | 2767.2209 | LC-MS | Normal | NA | 21136997 |
| CancerPDF_ID2411 | ALAREVDLKDYEDQQKQLEQVIAK | Fibrinogen alpha | Plasma | 2829.4872 | LC-MS | Normal | NA | 21136997 |
| CancerPDF_ID2522 | LAARLEALKENGGARLAEYHA | Apolipoprotein A-I | Plasma | 2252.2026 | LC-MS | Normal | NA | 21136997 |
| CancerPDF_ID2524 | DSGRDYVSQFEGSALGKQLNL | Apolipoprotein A-I | Plasma | 2283.1131 | LC-MS | Normal | NA | 21136997 |
| CancerPDF_ID2528 | DSGRDYVSQFEGSALGKQLNLK | Apolipoprotein A-I | Plasma | 2411.2081 | LC-MS | Normal | NA | 21136997 |
| CancerPDF_ID2529 | THLAPYSDELRQRLAARLEAL | Apolipoprotein A-I | Plasma | 2422.3081 | LC-MS | Normal | NA | 21136997 |
| CancerPDF_ID2531 | QKLHELQEKLSPLGEEMRDRA | Apolipoprotein A-I | Plasma | 2506.2962 | LC-MS | Normal | NA | 21136997 |
| CancerPDF_ID2533 | ENGGARLAEYHAKATEHLSTLSEK | Apolipoprotein A-I | Plasma | 2611.299 | LC-MS | Normal | NA | 21136997 |
| CancerPDF_ID2535 | QKLHELQEKLSPLGEEMRDRAR | Apolipoprotein A-I | Plasma | 2662.3973 | LC-MS | Normal | NA | 21136997 |
| CancerPDF_ID2536 | VQPYLDDFQKKWQEEMELYRQ | Apolipoprotein A-I | Plasma | 2772.3218 | LC-MS | Normal | NA | 21136997 |
| CancerPDF_ID2537 | AKVQPYLDDFQKKWQEEMELYR | Apolipoprotein A-I | Plasma | 2843.3952 | LC-MS | Normal | NA | 21136997 |
| CancerPDF_ID2538 | AELQEGARQKLHELQEKLSPLGEEM | Apolipoprotein A-I | Plasma | 2862.4546 | LC-MS | Normal | NA | 21136997 |
| CancerPDF_ID2540 | LREQLGPVTQEFWDNLEKETEGLR | Apolipoprotein A-I | Plasma | 2886.4512 | LC-MS | Normal | NA | 21136997 |
| CancerPDF_ID2541 | AKVQPYLDDFQKKWQEEMELYRQ | Apolipoprotein A-I | Plasma | 2971.4538 | LC-MS | Normal | NA | 21136997 |
| CancerPDF_ID2625 | LGPHAGDVEGHLSFLEKDLRDK | Apolipoprotein A-IV | Plasma | 2432.2448 | LC-MS | Normal | NA | 21136997 |
| CancerPDF_ID2627 | GRLTPYADEFKVKIDQTVEEL | Apolipoprotein A-IV | Plasma | 2450.2693 | LC-MS | Normal | NA | 21136997 |
| CancerPDF_ID2628 | AKIDQNVEELKGRLTPYADEFK | Apolipoprotein A-IV | Plasma | 2563.3282 | LC-MS | Normal | NA | 21136997 |
| CancerPDF_ID2629 | GNTEGLQKSLAELGGHLDQQVEEF | Apolipoprotein A-IV | Plasma | 2598.2562 | LC-MS | Normal | NA | 21136997 |
| CancerPDF_ID2630 | GRLTPYADEFKVKIDQTVEELR | Apolipoprotein A-IV | Plasma | 2606.3704 | LC-MS | Normal | NA | 21136997 |
| CancerPDF_ID2631 | GNTEGLQKSLAELGGHLDQQVEEFR | Apolipoprotein A-IV | Plasma | 2754.3573 | LC-MS | Normal | Differentially expressed between cancer vs normal | 21136997 |
| CancerPDF_ID2632 | SLAPYAQDTQEKLNHQLEGLTFQM | Apolipoprotein A-IV | Plasma | 2761.3381 | LC-MS | Normal | NA | 21136997 |
| CancerPDF_ID2633 | RVEPYGENFNKALVQQMEQLRQK | Apolipoprotein A-IV | Plasma | 2804.4392 | LC-MS | Normal | NA | 21136997 |
| CancerPDF_ID2634 | SLAPYAQDTQEKLNHQLEGLTFQMK | Apolipoprotein A-IV | Plasma | 2889.4331 | LC-MS | Normal | NA | 21136997 |
| CancerPDF_ID2635 | SELTQQLNALFQDKLGEVNTYAGDLQ | Apolipoprotein A-IV | Plasma | 2894.4298 | LC-MS | Normal | NA | 21136997 |
| CancerPDF_ID2638 | SELTQQLNALFQDKLGEVNTYAGDLQK | Apolipoprotein A-IV | Plasma | 3022.5247 | LC-MS | Normal | NA | 21136997 |
| CancerPDF_ID2715 | VPVAVQGEDTVQSLTQGDGVA | Complement C3 | Plasma | 2069.0277 | LC-MS | Normal | NA | 21136997 |
| CancerPDF_ID2719 | VPVAVQGEDTVQSLTQGDGVAK | Complement C3 | Plasma | 2197.1226 | LC-MS | Normal | NA | 21136997 |
| CancerPDF_ID2721 | SSLSVPYVIVPLKTGLQEVEV | Complement C3 | Plasma | 2256.2617 | LC-MS | Normal | NA | 21136997 |
| CancerPDF_ID2722 | ILLQGTPVAQMTEDAVDAERL | Complement C3 | Plasma | 2269.1624 | LC-MS | Normal | NA | 21136997 |
| CancerPDF_ID2725 | SSLSVPYVIVPLKTGLQEVEVK | Complement C3 | Plasma | 2384.3567 | LC-MS | Normal | NA | 21136997 |
| CancerPDF_ID2726 | QKPDGVFQEDAPVIHQEMIGGL | Complement C3 | Plasma | 2407.1842 | LC-MS | Normal | NA | 21136997 |
| CancerPDF_ID2727 | TMQALPYSTVGNSNNYLHLSVL | Complement C3 | Plasma | 2421.1998 | LC-MS | Normal | NA | 21136997 |
| CancerPDF_ID2729 | EGVQKEDIPPADLSDQVPDTESETR | Complement C3 | Plasma | 2754.2832 | LC-MS | Normal | NA | 21136997 |
| CancerPDF_ID2730 | SEFPESWLWNVEDLKEPPKNGIST | Complement C3 | Plasma | 2801.3548 | LC-MS | Normal | NA | 21136997 |
| CancerPDF_ID2791 | KREEAPSLRPAPPPISGGGYR | Fibrinogen beta chain | Plasma | 2234.192 | LC-MS | Normal | NA | 21136997 |
| CancerPDF_ID2794 | AHYGGFTVQNEANKYQISVNK | Fibrinogen beta chain | Plasma | 2367.1608 | LC-MS | Normal | NA | 21136997 |
| CancerPDF_ID2795 | KGGETSEMYLIQPDSSVKPYR | Fibrinogen beta chain | Plasma | 2384.1682 | LC-MS | Normal | NA | 21136997 |
| CancerPDF_ID2796 | VKAHYGGFTVQNEANKYQISVN | Fibrinogen beta chain | Plasma | 2466.2292 | LC-MS | Normal | NA | 21136997 |
| CancerPDF_ID2797 | AHYGGFTVQNEANKYQISVNKY | Fibrinogen beta chain | Plasma | 2530.2241 | LC-MS | Normal | NA | 21136997 |
| CancerPDF_ID2798 | VKAHYGGFTVQNEANKYQISVNK | Fibrinogen beta chain | Plasma | 2594.3241 | LC-MS | Normal | NA | 21136997 |
| CancerPDF_ID2799 | VKAHYGGFTVQNEANKYQISVNKY | Fibrinogen beta chain | Plasma | 2757.3875 | LC-MS | Normal | NA | 21136997 |
| CancerPDF_ID2838 | TLNQPDSQLQLTTGNGLFLSEGLK | Alpha-1 protease inhibitor | Plasma | 2573.3337 | LC-MS | Normal | NA | 21136997 |
| CancerPDF_ID2839 | EDPQGDAAQKTDTSHHDQDHPTFN | Alpha-1 protease inhibitor | Plasma | 2690.1229 | LC-MS | Normal | NA | 21136997 |
| CancerPDF_ID2841 | LQHLENELTHDIITKFLENEDR | Alpha-1 protease inhibitor | Plasma | 2706.3613 | LC-MS | Normal | NA | 21136997 |
| CancerPDF_ID2842 | EDPQGDAAQKTDTSHHDQDHPTFNK | Alpha-1 protease inhibitor | Plasma | 2818.2179 | LC-MS | Normal | NA | 21136997 |
| CancerPDF_ID2844 | LQHLENELTHDIITKFLENEDRR | Alpha-1 protease inhibitor | Plasma | 2862.4624 | LC-MS | Normal | NA | 21136997 |
| CancerPDF_ID2846 | GKWERPFEVKDTEEEDFHVDQVTTV | Alpha-1 protease inhibitor | Plasma | 3019.42 | LC-MS | Normal | NA | 21136997 |
| CancerPDF_ID2885 | AIQLTYNPDESSKPNMIDAATL | Fibrinogen gamma | Plasma | 2391.1628 | LC-MS | Normal | NA | 21136997 |
| CancerPDF_ID2886 | AIQLTYNPDESSKPNMIDAATLK | Fibrinogen gamma | Plasma | 2519.2578 | LC-MS | Normal | NA | 21136997 |
| CancerPDF_ID2888 | TTMKIIPFNRLTIGEGQQHHLGGA | Fibrinogen gamma | Plasma | 2618.3751 | LC-MS | Normal | NA | 21136997 |
| CancerPDF_ID2889 | IHLISTQSAIPYALRVELEDWNG | Fibrinogen gamma | Plasma | 2624.3598 | LC-MS | Normal | NA | 21136997 |
| CancerPDF_ID2890 | IHLISTQSAIPYALRVELEDWNGR | Fibrinogen gamma | Plasma | 2780.461 | LC-MS | Normal | NA | 21136997 |
| CancerPDF_ID2918 | LSNENHGIAQRIYGNQDTSSQL | Inter-alpha-trypsin inhibitor heavy chain H2 | Plasma | 2444.168 | LC-MS | Normal | NA | 21136997 |
| CancerPDF_ID2919 | TILDDLRAEDHFSVIDFNQNI | Inter-alpha-trypsin inhibitor heavy chain H2 | Plasma | 2474.2078 | LC-MS | Normal | NA | 21136997 |
| CancerPDF_ID2920 | LSNENHGIAQRIYGNQDTSSQLK | Inter-alpha-trypsin inhibitor heavy chain H2 | Plasma | 2572.263 | LC-MS | Normal | NA | 21136997 |
| CancerPDF_ID2921 | IYGNQDTSSQLKKFYNQVSTPLL | Inter-alpha-trypsin inhibitor heavy chain H2 | Plasma | 2643.3544 | LC-MS | Normal | NA | 21136997 |
| CancerPDF_ID2922 | RLSNENHGIAQRIYGNQDTSSQLK | Inter-alpha-trypsin inhibitor heavy chain H2 | Plasma | 2728.3641 | LC-MS | Normal | NA | 21136997 |
| CancerPDF_ID2952 | VSEADSSNADWVTKQLNEINYEDHKL | Complement factor B | Plasma | 3004.405 | LC-MS | Normal | NA | 21136997 |
| CancerPDF_ID2974 | AATVGSLAGQPLQERAQAWGER | Apolipoprotein E | Plasma | 2295.172 | LC-MS | Normal | NA | 21136997 |
| CancerPDF_ID2975 | AATVGSLAGQPLQERAQAWGERL | Apolipoprotein E | Plasma | 2408.2561 | LC-MS | Normal | NA | 21136997 |
| CancerPDF_ID2976 | AATVGSLAGQPLQERAQAWGERLR | Apolipoprotein E | Plasma | 2564.3572 | LC-MS | Normal | NA | 21136997 |
| CancerPDF_ID2985 | HATKTAKDALSSVQESQVAQQA | Apolipoprotein C-III | Plasma | 2297.1612 | LC-MS | Normal | NA | 21136997 |
| CancerPDF_ID2986 | SEAEDASLLSFMQGYMKHATK | Apolipoprotein C-III | Plasma | 2343.0875 | LC-MS | Normal | NA | 21136997 |
| CancerPDF_ID2987 | HATKTAKDALSSVQESQVAQQAR | Apolipoprotein C-III | Plasma | 2453.2623 | LC-MS | Normal | NA | 21136997 |
| CancerPDF_ID2988 | SEAEDASLLSFMQGYMKHATKTA | Apolipoprotein C-III | Plasma | 2515.1723 | LC-MS | Normal | NA | 21136997 |
| CancerPDF_ID3003 | KAEEEHLGILGPQLHADVGDKV | Ceruloplasmin | Plasma | 2354.223 | LC-MS | Normal | NA | 21136997 |
| CancerPDF_ID3006 | TYSDHPEKVNKDDEEFIESNK | Ceruloplasmin | Plasma | 2523.1401 | LC-MS | Normal | NA | 21136997 |
| CancerPDF_ID3007 | AEEEHLGILGPQLHADVGDKVKIIF | Ceruloplasmin | Plasma | 2727.4596 | LC-MS | Normal | NA | 21136997 |
| CancerPDF_ID3008 | LISVDTEHSNIYLQNGPDRIGRLY | Ceruloplasmin | Plasma | 2772.4195 | LC-MS | Normal | NA | 21136997 |
| CancerPDF_ID3009 | KEKHYYIGIIETTWDYASDHGEK | Ceruloplasmin | Plasma | 2782.3239 | LC-MS | Normal | NA | 21136997 |
| CancerPDF_ID3011 | KLISVDTEHSNIYLQNGPDRIGRLY | Ceruloplasmin | Plasma | 2900.5144 | LC-MS | Normal | NA | 21136997 |
| CancerPDF_ID3012 | HRGVYSSDVFDIFPGTYQTLEMFPR | Ceruloplasmin | Plasma | 2961.412 | LC-MS | Normal | NA | 21136997 |
| CancerPDF_ID3033 | QGPVNLLSDPEQGVEVTGQYEREK | Inter-alpha-trypsin inhibitor heavy chain H4 | Plasma | 2671.3089 | LC-MS | Normal | NA | 21136997 |
| CancerPDF_ID3071 | PPTSAHGNVAEGETKPDPDVTER | Hemopexin | Plasma | 2403.1302 | LC-MS | Normal | NA | 21136997 |
| CancerPDF_ID3072 | QGHNSVFLIKGDKVWVYPPEK | Hemopexin | Plasma | 2440.2903 | LC-MS | Normal | NA | 21136997 |
| CancerPDF_ID3081 | SKLPGIVAEGRDDLYVSDAFH | Antithrombin-III | Plasma | 2288.1437 | LC-MS | Normal | NA | 21136997 |
| CancerPDF_ID3082 | AFLEVNEEGSEAAASTAVVIAGR | Antithrombin-III | Plasma | 2290.1441 | LC-MS | Normal | NA | 21136997 |
| CancerPDF_ID3083 | SKLPGIVAEGRDDLYVSDAFHK | Antithrombin-III | Plasma | 2416.2387 | LC-MS | Normal | NA | 21136997 |
| CancerPDF_ID3084 | SPEKKATEDEGSEQKIPEATNR | Antithrombin-III | Plasma | 2443.1827 | LC-MS | Normal | NA | 21136997 |
| CancerPDF_ID3103 | VREYYFAEAQIADFSDPAFISK | Heparin cofactor 2 | Plasma | 2566.238 | LC-MS | Normal | NA | 21136997 |
| CancerPDF_ID3104 | LPKFKLEKNYNLVESLKLMGIRMLF | Heparin cofactor 2 | Plasma | 3023.7068 | LC-MS | Normal | NA | 21136997 |
| CancerPDF_ID3124 | AQPVQVAEGSEPDGFWEALGGK | Gelsolin | Plasma | 2271.0808 | LC-MS | Normal | NA | 21136997 |
| CancerPDF_ID3125 | MDYPKQTQVSVLPEGGETPLF | Gelsolin | Plasma | 2335.1406 | LC-MS | Normal | NA | 21136997 |
| CancerPDF_ID3126 | NWRDPDQTDGLGLSYLSSHIANVER | Gelsolin | Plasma | 2842.3634 | LC-MS | Normal | NA | 21136997 |
| CancerPDF_ID3140 | MEPLGRQLTSGPNQEQVSPLTLL | Alpha-2-antiplasmin | Plasma | 2507.3054 | LC-MS | Normal | NA | 21136997 |
| CancerPDF_ID3141 | MEPLGRQLTSGPNQEQVSPLTLLK | Alpha-2-antiplasmin | Plasma | 2635.4003 | LC-MS | Normal | NA | 21136997 |
| CancerPDF_ID3152 | TMYGEILSPNYPQAYPSEVEK | Complement C1s subcomponent | Plasma | 2415.1304 | LC-MS | Normal | NA | 21136997 |
| CancerPDF_ID3153 | EPTMYGEILSPNYPQAYPSEVEK | Complement C1s subcomponent | Plasma | 2641.2258 | LC-MS | Normal | NA | 21136997 |
| CancerPDF_ID3154 | SSNNPHSPIVEEFQVPYNKLQVIF | Complement C1s subcomponent | Plasma | 2785.4075 | LC-MS | Normal | NA | 21136997 |
| CancerPDF_ID3155 | SSNNPHSPIVEEFQVPYNKLQVIFK | Complement C1s subcomponent | Plasma | 2913.5025 | LC-MS | Normal | NA | 21136997 |
| CancerPDF_ID3167 | LDHRGRTLEIPGNSDPNMIPDG | Complement C4-A | Plasma | 2403.1601 | LC-MS | Normal | NA | 21136997 |
| CancerPDF_ID3168 | TLEIPGNSDPNMIPDGDFNSYVR | Complement C4-A | Plasma | 2550.1697 | LC-MS | Normal | NA | 21136997 |
| CancerPDF_ID3169 | GRTLEIPGNSDPNMIPDGDFNSYV | Complement C4-A | Plasma | 2607.1911 | LC-MS | Normal | NA | 21136997 |
| CancerPDF_ID3170 | GRTLEIPGNSDPNMIPDGDFNSYVR | Complement C4-A | Plasma | 2763.2922 | LC-MS | Normal | NA | 21136997 |
| CancerPDF_ID3171 | VLQIEKEGAIHREELVYELNPLDHR | Complement C4-A | Plasma | 2999.5829 | LC-MS | Normal | NA | 21136997 |
| CancerPDF_ID3185 | DQTVSDNELQEMSNQGSKYVNK | Clusterin | Plasma | 2513.134 | LC-MS | Normal | NA | 21136997 |
| CancerPDF_ID3186 | ASSIIDELFQDRFFTREPQDT | Clusterin | Plasma | 2514.2027 | LC-MS | Normal | NA | 21136997 |
| CancerPDF_ID3199 | TPDVSSALDKLKEFGNTLEDK | Apolipoprotein C-I | Plasma | 2306.1642 | LC-MS | Normal | NA | 21136997 |
| CancerPDF_ID3204 | ALGISPFHEHAEVVFTANDSGPR | Transthyretin | Plasma | 2450.1979 | LC-MS | Normal | NA | 21136997 |
| CancerPDF_ID3205 | TSESGELHGLTTEEEFVEGIYK | Transthyretin | Plasma | 2454.1438 | LC-MS | Normal | NA | 21136997 |
| CancerPDF_ID3206 | YTIAALLSPYSYSTTAVVTNPKE | Transthyretin | Plasma | 2488.2737 | LC-MS | Normal | NA | 21136997 |
| CancerPDF_ID3211 | HTFMGVVSLGSPSGEVSHPRKT | Alpha-2-HS-glycoprotein | Plasma | 2309.1586 | LC-MS | Normal | NA | 21136997 |
| CancerPDF_ID3212 | HTFMGVVSLGSPSGEVSHPRKT | Alpha-2-HS-glycoprotein | Plasma | 2325.1536 | LC-MS | Normal | NA | 21136997 |
| CancerPDF_ID3220 | TSPVDEKALQDQLVLVAAKLDTEDK | Angiotensinogen | Plasma | 2725.4386 | LC-MS | Normal | NA | 21136997 |
| CancerPDF_ID3236 | FKLDDDLEHQGGHVLDHGHKH | Kininogen-1 | Plasma | 2433.1574 | LC-MS | Normal | NA | 21136997 |
| CancerPDF_ID3237 | FKLDDDLEHQGGHVLDHGHKHK | Kininogen-1 | Plasma | 2561.2524 | LC-MS | Normal | NA | 21136997 |
| CancerPDF_ID3243 | VTEPISAESGEQVERVNEPSILEMS | Apolipoprotein-L1 | Plasma | 2729.3065 | LC-MS | Normal | NA | 21136997 |
| CancerPDF_ID3245 | VAQELEEKLNILNNNYKILQADQEL | Apolipoprotein-L1 | Plasma | 2941.5397 | LC-MS | Normal | NA | 21136997 |
| CancerPDF_ID3404 | WGLLLALLPPGAASTQAVWTWMTR | Receptor tyrosine-protein kinase erbB-2 | Plasma | NA | Linear ion-trap mass spectrometer (LTQ) coupled with a Surveyor HPLC-MS | Breast cancer | Differentially expressed between normal and patients | 24565027 |
| CancerPDF_ID3405 | LSWNHVARALTLTQSLVSSVTSGK | NT-3 growth factor receptor | Plasma | NA | Linear ion-trap mass spectrometer (LTQ) coupled with a Surveyor HPLC-MS | Breast cancer | Differentially expressed between normal and patients | 24565027 |
| CancerPDF_ID3408 | DHLACWDYDLCITCYNTKNHDHK | Histone acetyltransferase p300 | Plasma | NA | Linear ion-trap mass spectrometer (LTQ) coupled with a Surveyor HPLC-MS | Breast cancer | Differentially expressed between normal and patients | 24565027 |
| CancerPDF_ID3414 | AGPPGEAGKK PGEQGVPGDL | Collagen type a1 | Urine | NA | LC-MS | CRLM( Colorectal liver metastses) | Upregulated in cancer vs normal | 27186406 |
| CancerPDF_ID3470 | NpGPPGpSGSpGKDGPpGPAG | Collagen alpha-1(III) chain | Urine | NA | "CE-MS, Micro-TOF-MS" | Bladder cancer | Differentially expressed between primary UBC and normal individual | 27026199 |
| CancerPDF_ID3472 | pPGPTGPGGDKGDTGPpGPQG | "Collagen alpha-1(III) chain, COL3A1" | Urine | NA | "CE-MS, Micro-TOF-MS" | Bladder cancer | Differentially expressed between primary UBC and normal individual | 27026199 |
| CancerPDF_ID3474 | ADLADGVSGGEGKGGSDGGGSH | "CD99 antigen, CD99" | Urine | NA | "CE-MS, Micro-TOF-MS" | Bladder cancer | Differentially expressed between primary UBC and normal individual | 27026199 |
| CancerPDF_ID3475 | GApGApGGKGDAGAPGERGppG | Collagen alpha-1(III) chain | Urine | NA | "CE-MS, Micro-TOF-MS" | Bladder cancer | Differentially expressed between primary UBC and normal individual | 27026199 |
| CancerPDF_ID3480 | GppGESGREGApGAEGSPGRDG | Collagen alpha-1(I) chain | Urine | NA | "CE-MS, Micro-TOF-MS" | Bladder cancer | Differentially expressed between primary UBC and normal individual | 27026199 |
| CancerPDF_ID3481 | KPGDGDSFYSDIPPGVSTNSA | Disintegrin and metalloproteinase domain-containing protein 22 | Urine | NA | "CE-MS, Micro-TOF-MS" | Bladder cancer | Differentially expressed between primary UBC and normal individual | 27026199 |
| CancerPDF_ID3483 | GpTGpIGPpGpAGQPGDKGEGGAP | Collagen alpha-1(III) chain | Urine | NA | "CE-MS, Micro-TOF-MS" | Bladder cancer | Differentially expressed between primary UBC and normal individual | 27026199 |
| CancerPDF_ID3484 | EAEDLQVGQVELGGGPGAGSLQP | Insulin | Urine | NA | "CE-MS, Micro-TOF-MS" | Bladder cancer | Differentially expressed between primary UBC and normal individual | 27026199 |
| CancerPDF_ID3485 | AAAAQGTAPPQDGEQPAESPEPP | Diacylglycerol kinase kappa | Urine | NA | "CE-MS, Micro-TOF-MS" | Bladder cancer | Differentially expressed between primary UBC and normal individual | 27026199 |
| CancerPDF_ID3486 | NGDDGEAGKPGRpGERGPpGPQG | Collagen alpha-1(I) chain | Urine | NA | "CE-MS, Micro-TOF-MS" | Bladder cancer | Differentially expressed between primary UBC and normal individual | 27026199 |
| CancerPDF_ID3487 | NGDDGEAGKPGRPGERGppGpQG | Collagen alpha-1(I) chain | Urine | NA | "CE-MS, Micro-TOF-MS" | Bladder cancer | Differentially expressed between primary UBC and normal individual | 27026199 |
| CancerPDF_ID3489 | QNGEpGGKGERGApGEKGEGGppG | "Collagen alpha-1(III) chain, COL3A1" | Urine | NA | "CE-MS, Micro-TOF-MS" | Bladder cancer | Differentially expressed between primary UBC and normal individual | 27026199 |
| CancerPDF_ID3490 | EHGPPPPPDERDHSHGPPLPQ | Histidine-rich glycoprotein | Urine | NA | "CE-MS, Micro-TOF-MS" | Bladder cancer | Differentially expressed between primary UBC and normal individual | 27026199 |
| CancerPDF_ID3491 | GDSMDRIEKDRLqGMAPAAGAD | "Collagen alpha-1(XVII) chain, COL17A1" | Urine | NA | "CE-MS, Micro-TOF-MS" | Bladder cancer | Differentially expressed between primary UBC and normal individual | 27026199 |
| CancerPDF_ID3495 | ELDCWDGKGEDQEPIITHGKAMC | "1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase beta-4, PLCB4" | Urine | NA | "CE-MS, Micro-TOF-MS" | Bladder cancer | Differentially expressed between primary UBC and normal individual | 27026199 |
| CancerPDF_ID3639 | PGPAGARGnDGATGAAGPpGP | Collagen alpha-1(I) chain | Urine | NA | "CE-MS, Micro-TOF-MS" | Bladder cancer | Differentially expressed between recurrence of UBC vs recurrence control | 27026199 |
| CancerPDF_ID3651 | NDGAKGDAGApGApGSQGApG | Collagen alpha-1(I) chain | Urine | NA | "CE-MS, Micro-TOF-MS" | Bladder cancer | Differentially expressed between recurrence of UBC vs recurrence control | 27026199 |
| CancerPDF_ID3665 | NpGPPGpSGSpGKDGPpGPAG | Collagen alpha-1(III) chain | Urine | NA | "CE-MS, Micro-TOF-MS" | Bladder cancer | Differentially expressed between recurrence of UBC vs recurrence control | 27026199 |
| CancerPDF_ID3669 | pPGPTGPGGDKGDTGPpGPQG | Collagen alpha-1(III) chain | Urine | NA | "CE-MS, Micro-TOF-MS" | Bladder cancer | Differentially expressed between recurrence of UBC vs recurrence control | 27026199 |
| CancerPDF_ID3672 | ADLADGVSGGEGKGGSDGGGSH | "CD99 antigen, CD99" | Urine | NA | "CE-MS, Micro-TOF-MS" | Bladder cancer | Differentially expressed between recurrence of UBC vs recurrence control | 27026199 |
| CancerPDF_ID3673 | PGppGpRGPSGAPGADGpQGP | Collagen alpha-1(V) chain | Urine | NA | "CE-MS, Micro-TOF-MS" | Bladder cancer | Differentially expressed between recurrence of UBC vs recurrence control | 27026199 |
| CancerPDF_ID3675 | GApGApGGKGDAGAPGERGppG | Collagen alpha-1(III) chain | Urine | NA | "CE-MS, Micro-TOF-MS" | Bladder cancer | Differentially expressed between recurrence of UBC vs recurrence control | 27026199 |
| CancerPDF_ID3677 | SGEpGApGSKGDTGAKGEpGP | "Collagen alpha-1(I) chain, Collagen alpha- 1(I) chain (Alpha-1 type I collagen)" | Urine | NA | "CE-MS, Micro-TOF-MS" | Bladder cancer | Differentially expressed between recurrence of UBC vs recurrence control | 27026199 |
| CancerPDF_ID3678 | RGEPGPpGPAGAAGPAGnpGAD | Collagen alpha-1(I) chain | Urine | NA | "CE-MS, Micro-TOF-MS" | Bladder cancer | Differentially expressed between recurrence of UBC vs recurrence control | 27026199 |
| CancerPDF_ID3679 | NGApGNDGAKGDAGApGApGSQ | Collagen alpha-1(I) chain | Urine | NA | "CE-MS, Micro-TOF-MS" | Bladder cancer | Differentially expressed between recurrence of UBC vs recurrence control | 27026199 |
| CancerPDF_ID3685 | pGAAGNpGAPGHVGApGPSGPpG | Collagen alpha-1(XXII) chain | Urine | NA | "CE-MS, Micro-TOF-MS" | Bladder cancer | Differentially expressed between recurrence of UBC vs recurrence control | 27026199 |
| CancerPDF_ID3687 | GEKGpSGEAGTAGPpGTpGPQG | Collagen alpha-2(I) chain | Urine | NA | "CE-MS, Micro-TOF-MS" | Bladder cancer | Differentially expressed between recurrence of UBC vs recurrence control | 27026199 |
| CancerPDF_ID3688 | SGIDGSPGEKGDPGDVGGPGpP | Collagen alpha-3(V) chain | Urine | NA | "CE-MS, Micro-TOF-MS" | Bladder cancer | Differentially expressed between recurrence of UBC vs recurrence control | 27026199 |
| CancerPDF_ID3692 | pGPpGEKGENGDVGPMGPpGP | Collagen alpha-1(XI) chain | Urine | NA | "CE-MS, Micro-TOF-MS" | Bladder cancer | Differentially expressed between recurrence of UBC vs recurrence control | 27026199 |
| CancerPDF_ID3693 | GEKGpSGEAGTAGPpGTpGPQG | Collagen alpha-2(I) chain | Urine | NA | "CE-MS, Micro-TOF-MS" | Bladder cancer | Differentially expressed between recurrence of UBC vs recurrence control | 27026199 |
| CancerPDF_ID3697 | PDGGLVVLSGGGTSGRMAFLm | Glucokinase regulatory protein | Urine | NA | "CE-MS, Micro-TOF-MS" | Bladder cancer | Differentially expressed between recurrence of UBC vs recurrence control | 27026199 |
| CancerPDF_ID3698 | GppGESGREGApGAEGSPGRDG | Collagen alpha-1(I) chain | Urine | NA | "CE-MS, Micro-TOF-MS" | Bladder cancer | Differentially expressed between recurrence of UBC vs recurrence control | 27026199 |
| CancerPDF_ID3701 | GSNGNpGpPGPSGSpGKDGPpGP | Collagen alpha-1(III) chain | Urine | NA | "CE-MS, Micro-TOF-MS" | Bladder cancer | Differentially expressed between recurrence of UBC vs recurrence control | 27026199 |
| CancerPDF_ID3702 | NGDDGEAGKpGRpGERGPPGP | "Collagen alpha-1(I) chain, Collagen alpha- 1(I) chain (Alpha-1 type I collagen)" | Urine | NA | "CE-MS, Micro-TOF-MS" | Bladder cancer | Differentially expressed between recurrence of UBC vs recurrence control | 27026199 |
| CancerPDF_ID3703 | NGDDGEAGKpGRPGERGpPGp | Collagen alpha-1(I) chain | Urine | NA | "CE-MS, Micro-TOF-MS" | Bladder cancer | Differentially expressed between recurrence of UBC vs recurrence control | 27026199 |
| CancerPDF_ID3704 | PGSSGTGGTATWKPGSSGPGSTGS | Fibrinogen alpha chain | Urine | NA | "CE-MS, Micro-TOF-MS" | Bladder cancer | Differentially expressed between recurrence of UBC vs recurrence control | 27026199 |
| CancerPDF_ID3706 | GPGMRGMPGSPGGpGSDGKpGpP | Collagen alpha-1(III) chain | Urine | NA | "CE-MS, Micro-TOF-MS" | Bladder cancer | Differentially expressed between recurrence of UBC vs recurrence control | 27026199 |
| CancerPDF_ID3707 | GpPGEAGKpGEQGVpGDLGAPGp | Collagen alpha-1(I) chain | Urine | NA | "CE-MS, Micro-TOF-MS" | Bladder cancer | Differentially expressed between recurrence of UBC vs recurrence control | 27026199 |
| CancerPDF_ID3710 | PGPpGPKGVDGLPGDMGppGTpG | Collagen alpha-1(IV) chain | Urine | NA | "CE-MS, Micro-TOF-MS" | Bladder cancer | Differentially expressed between recurrence of UBC vs recurrence control | 27026199 |
| CancerPDF_ID3712 | GDAGApGAPGGKGDAGApGERGpPG | Collagen alpha-1(III) chain | Urine | NA | "CE-MS, Micro-TOF-MS" | Bladder cancer | Differentially expressed between recurrence of UBC vs recurrence control | 27026199 |
| CancerPDF_ID3713 | GpTGpIGPpGpAGQPGDKGEGGAP | Collagen alpha-1(III) chain | Urine | NA | "CE-MS, Micro-TOF-MS" | Bladder cancer | Differentially expressed between recurrence of UBC vs recurrence control | 27026199 |
| CancerPDF_ID3714 | pLGpQGEKGVMGYPGPPGVpGp | Collagen alpha-1(XXIV) chain | Urine | NA | "CE-MS, Micro-TOF-MS" | Bladder cancer | Differentially expressed between recurrence of UBC vs recurrence control | 27026199 |
| CancerPDF_ID3715 | NSGEKGDQGFQGQPGFPGPPGP | Collagen alpha-1(XVI) chain | Urine | NA | "CE-MS, Micro-TOF-MS" | Urinary bladder Cancer (UBC) | Differential expression between recurrence of UBC and recurrence control | 27026199 |
| CancerPDF_ID3717 | ADGQPGAKGEPGDAGAKGDAGPpGP | Collagen alpha-1(I) chain | Urine | NA | "CE-MS, Micro-TOF-MS" | Bladder cancer | Differentially expressed between recurrence of UBC vs recurrence control | 27026199 |
| CancerPDF_ID3718 | NDGPpGRDGQpGHKGERGYpG | Collagen alpha-2(I) chain | Urine | NA | "CE-MS, Micro-TOF-MS" | Bladder cancer | Differentially expressed between recurrence of UBC vs recurrence control | 27026199 |
| CancerPDF_ID3720 | AAAAQGTAPPQDGEQPAESPEPP | Diacylglycerol kinase kappa | Urine | NA | "CE-MS, Micro-TOF-MS" | Bladder cancer | Differentially expressed between recurrence of UBC vs recurrence control | 27026199 |
| CancerPDF_ID3721 | ADGQpGAKGEpGDAGAKGDAGPPGp | Collagen alpha-1(I) chain | Urine | NA | "CE-MS, Micro-TOF-MS" | Bladder cancer | Differentially expressed between recurrence of UBC vs recurrence control | 27026199 |
| CancerPDF_ID3722 | GNSGEKGDQGFQGQPGFPGPpGP | Collagen alpha-1(XVI) chain | Urine | NA | "CE-MS, Micro-TOF-MS" | Bladder cancer | Differentially expressed between recurrence of UBC vs recurrence control | 27026199 |
| CancerPDF_ID3723 | ADGQpGAKGEpGDAGAKGDAGppGP | Collagen alpha-1(I) chain | Urine | NA | "CE-MS, Micro-TOF-MS" | Bladder cancer | Differentially expressed between recurrence of UBC vs recurrence control | 27026199 |
| CancerPDF_ID3727 | GLpGpAGpPGEAGKPGEQGVpGDLG | Collagen alpha-1(I) chain | Urine | NA | "CE-MS, Micro-TOF-MS" | Bladder cancer | Differentially expressed between recurrence of UBC vs recurrence control | 27026199 |
| CancerPDF_ID3728 | EGGKGPRGETGpAGRpGEVGppGP | Collagen alpha-1(I) chain | Urine | NA | "CE-MS, Micro-TOF-MS" | Bladder cancer | Differentially expressed between recurrence of UBC vs recurrence control | 27026199 |
| CancerPDF_ID3729 | QNGEpGGKGERGApGEKGEGGppG | "Collagen alpha-1(III) chain, COL3A1" | Urine | NA | "CE-MS, Micro-TOF-MS" | Bladder cancer | Differentially expressed between recurrence of UBC vs recurrence control | 27026199 |
| CancerPDF_ID3731 | PpGppGPpGVPGSDGIDGDNGPPGK | Collagen alpha-2(IX) chain | Urine | NA | "CE-MS, Micro-TOF-MS" | Bladder cancer | Differentially expressed between recurrence of UBC vs recurrence control | 27026199 |
| CancerPDF_ID3738 | SEAEDASLLSFMQGYMKHATK | Apolipoprotein C-III | Urine | NA | "CE-MS, Micro-TOF-MS" | Bladder cancer | Differentially expressed between recurrence of UBC vs recurrence control | 27026199 |
| CancerPDF_ID3740 | EEVEVAQVQVPTPARDSAGVPAP | TRMT1-like protein | Urine | NA | "CE-MS, Micro-TOF-MS" | Bladder cancer | Differentially expressed between recurrence of UBC vs recurrence control | 27026199 |
| CancerPDF_ID3741 | EEVEVAQVQVPTPARDSAGVPAP | TRMT1-like protein | Urine | NA | "CE-MS, Micro-TOF-MS" | Bladder cancer | Differentially expressed between recurrence of UBC vs recurrence control | 27026199 |
| CancerPDF_ID3743 | KNGDDGEAGKpGRPGERGpPGPQG | Collagen alpha-1(I) chain | Urine | NA | "CE-MS, Micro-TOF-MS" | Bladder cancer | Differentially expressed between recurrence of UBC vs recurrence control | 27026199 |
| CancerPDF_ID3746 | SGNAGPpGPPGPAGKEGGKGpRGETGP | Collagen alpha-1(I) chain | Urine | NA | "CE-MS, Micro-TOF-MS" | Bladder cancer | Differentially expressed between recurrence of UBC vs recurrence control | 27026199 |
| CancerPDF_ID3749 | TQQPQQDEMPSPTFLTQVKES | Apolipoprotein C-IV | Urine | NA | "CE-MS, Micro-TOF-MS" | Bladder cancer | Differentially expressed between recurrence of UBC vs recurrence control | 27026199 |
| CancerPDF_ID3751 | LMIEQNTKSPLFMGKVVNPTQK | Alpha-1-antitrypsin | Urine | NA | "CE-MS, Micro-TOF-MS" | Bladder cancer | Differentially expressed between recurrence of UBC vs recurrence control | 27026199 |
| CancerPDF_ID3755 | DEAGSEADHEGTHSTKRGHAKSRP | "Fibrinogen alpha chain, Fibrinogen alpha chain" | Urine | NA | "CE-MS, Micro-TOF-MS" | Bladder cancer | Differentially expressed between recurrence of UBC vs recurrence control | 27026199 |
| CancerPDF_ID3764 | DEAGSEADHEGTHSTKRGHAKSRPV | Fibrinogen alpha chain | Urine | NA | "CE-MS, Micro-TOF-MS" | Bladder cancer | Differentially expressed between recurrence of UBC vs recurrence control | 27026199 |
| CancerPDF_ID3854 | RFGYGYGPYQPVPEQPLYPQPYQPQ | Statherin | Saliva | NA | LC-MS and iTRAQ | Normal | NA | 22809520 |
| CancerPDF_ID3924 | GPPPPPQGGRPHRPPQGQPPQ | Basic PRP3 (Basic salivary proline-rich protein 3) | Saliva | NA | LC-MS and iTRAQ | Normal | NA | 22809520 |
| CancerPDF_ID3925 | QSLNEDVSQEESPSVISGKPEGR | Basic PRP3 (Basic salivary proline-rich protein 3) | Saliva | NA | LC-MS and iTRAQ | Normal | NA | 22809520 |
| CancerPDF_ID3933 | QSLNEDVSQEESPSVISGKPEGR | Basic PRP3 (Basic salivary proline-rich protein 3) | Saliva | NA | LC-MS and iTRAQ | Normal | NA | 22809520 |
| CancerPDF_ID3934 | QSLNEDVSQEESPSVISGKPEGR | Basic PRP3 (Basic salivary proline-rich protein 3) | Saliva | NA | LC-MS and iTRAQ | Normal | NA | 22809520 |
| CancerPDF_ID3936 | GPPPPPQGGRPPRPAQGQQPPQ | Basic PRP4 (Basic salivary proline-rich protein 4) | Saliva | NA | LC-MS and iTRAQ | Normal | NA | 22809520 |
| CancerPDF_ID3943 | APPQPFGPGFVPPPPPPPYGPGR | Submaxillary gland androgen-regulated protein 3B | Saliva | NA | LC-MS and iTRAQ | Normal | NA | 22809520 |
| CancerPDF_ID3958 | APPQPFGPGFVPPPPPPPYGPGR | Submaxillary gland androgen-regulated protein 3B | Saliva | NA | LC-MS and iTRAQ | Normal | NA | 22809520 |
| CancerPDF_ID3961 | LAPPQPFGPGFVPPPPPPPYGPGR | Submaxillary gland androgen-regulated protein 3B | Saliva | NA | LC-MS and iTRAQ | Normal | NA | 22809520 |
| CancerPDF_ID3982 | GRPQGPPQQGGHQQGPPPPPPGKPQ | aPRP (phosphorylated acidic proline-rich proteins ) | Saliva | NA | LC-MS and iTRAQ | Normal | NA | 22809520 |
| CancerPDF_ID4004 | VLPIPQQVVPYPQRAVPVQALL | Beta-casein | Human milk | NA | MALDI-TOF | Normal and pre-term Milk individual | Downregulated 3 fold in Pre-term case as compare to normal | 23891694 |
| CancerPDF_ID4006 | VLPIPQQVVPYPQRAVPVQALLLNQ | Beta-casein | Human milk | NA | MALDI-TOF | Normal | Downregulated 3 fold in Pre-term case as compare to normal | 23891694 |
| CancerPDF_ID4007 | VLPIPQQVVPYPQRAVPVQALLL | Beta-casein | Human milk | NA | MALDI-TOF | Normal | Downregulated 3 fold in Pre-term case as compare to normal | 23891694 |
| CancerPDF_ID4008 | HLPLPLLQPLMQQVPQPIPQT | Beta-casein | Human milk | NA | MALDI-TOF | Normal | Downregulated 3 fold in Pre-term case as compare to normal | 23891694 |
| CancerPDF_ID4009 | LKSPTIPFFDPQIPKLTDLEN | Beta-casein | Human milk | NA | MALDI-TOF | Normal | Downregulated 3 fold in Pre-term case as compare to normal | 23891694 |
| CancerPDF_ID4016 | LLLNQELLLNPTHQIYPVTQPLAP | Beta-casein | Human milk | NA | MALDI-TOF | Normal | Downregulated 3 fold in Pre-term case as compare to normal | 23891694 |
| CancerPDF_ID4024 | DDPDAPLQPVTPLQLFEGRRN | C4A(Complement C4-A) variant protein | Human milk | NA | MALDI-TOF | Normal | Downregulated 3 fold in Pre-term case as compare to normal | 23891694 |
| CancerPDF_ID4025 | GRVMPVLKSPTIPFFDPQIPK | Beta-casein | Human milk | NA | MALDI-TOF | Normal | Downregulated 3 fold in Pre-term case as compare to normal | 23891694 |
| CancerPDF_ID4026 | LLQPLMQQVPQPIPQTLALPPQP | Beta-casein | Human milk | NA | MALDI-TOF | Normal | Downregulated 3 fold in Pre-term case as compare to normal | 23891694 |
| CancerPDF_ID4029 | ASQLMGENRTMTIHNGMFFST | Fibrinogen beta chain | Human milk | NA | MALDI-TOF | Normal | Downregulated 3 fold in Pre-term case as compare to normal | 23891694 |
| CancerPDF_ID4033 | AVVLPVPQPEIMEVPKAKDTVYT | Beta-casein | Human milk | NA | MALDI-TOF | Normal | Downregulated 3 fold in Pre-term case as compare to normal | 23891694 |
| CancerPDF_ID4034 | WRKMCRKLLDMTFSSKTNTLVVR | vWF-cleaving protease | Human milk | NA | MALDI-TOF | Normal | Downregulated 3 fold in Pre-term case as compare to normal | 23891694 |
| CancerPDF_ID4035 | QPLMQQVPQPIPQTLALPPQP | Beta-casein | Human milk | NA | MALDI-TOF | Normal | Downregulated 3 fold in Pre-term case as compare to normal | 23891694 |
| CancerPDF_ID4049 | AAGQQQPPREPPAAPGAWRQQI | Protein-lysine 6-oxidase | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID4050 | AAGQQQPPREPPAAPGAWRQQIQ | Protein-lysine 6-oxidase | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID4055 | AAKVGTGEPCCDWVGDEGAGHFV | "6-phosphogluconate dehydrogenase, decarboxylating" | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID4062 | AAPEAQVSVQPNFQQDKFLGRWF | Prostaglandin-H2 D-isomerase | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID4063 | AAPEAQVSVQPNFQQDKFLGRWFSA | Prostaglandin D2 synthase 21kDa | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID4064 | AAPEAQVSVQPNFQQDKFLGRWFSA | Prostaglandin-H2 D-isomerase | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID4067 | AAPSVFIFPPSDEQLKSGTASV | 26 kDa protein | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID4068 | AAPSVFIFPPSDEQLKSGTASV | 26 kDa protein | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID4069 | AAPSVFIFPPSDEQLKSGTASV | Anti-RhD monoclonal T125 kappa light chain | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID4070 | AAPSVFIFPPSDEQLKSGTASV | Ig kappa chain C region | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID4071 | AAPSVFIFPPSDEQLKSGTASV | Ig kappa chain C region | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID4072 | AAPSVFIFPPSDEQLKSGTASV | IGKat protein | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID4073 | AAPSVFIFPPSDEQLKSGTASV | IGKat protein | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID4074 | AAPSVFIFPPSDEQLKSGTASV | Putative uncharacterized protein | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID4075 | AAPSVFIFPPSDEQLKSGTASVV | 26 kDa protein | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID4076 | AAPSVFIFPPSDEQLKSGTASVV | 26 kDa protein | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID4077 | AAPSVFIFPPSDEQLKSGTASVV | Anti-RhD monoclonal T125 kappa light chain | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID4078 | AAPSVFIFPPSDEQLKSGTASVV | Ig kappa chain C region | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID4079 | AAPSVFIFPPSDEQLKSGTASVV | Ig kappa chain C region | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID4080 | AAPSVFIFPPSDEQLKSGTASVV | IGKat protein | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID4081 | AAPSVFIFPPSDEQLKSGTASVV | IGKat protein | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID4082 | AAPSVFIFPPSDEQLKSGTASVV | Putative uncharacterized protein | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID4090 | AAVLEYLTAEILELAGNAARDNKKT | Histone H2A type 1 | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID4091 | AAVLEYLTAEILELAGNAARDNKKT | Histone H2A type 1-C | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID4092 | AAVLEYLTAEILELAGNAARDNKKT | Histone H2A type 2-A | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID4093 | AAVLEYLTAEILELAGNAARDNKKT | Histone H2A type 2-B | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID4094 | AAVPDEIPPLEGDEDASRMEEVD | Heat shock protein HSP 90-beta | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID4095 | AAVPGKTFVNITPAEVGVLVGKDRS | Profilin-1 | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID4099 | ACAEGCQAIVDTGTSLLTGPTSPI | Pepsin A | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID4117 | ADRGECVPGEQEPEPILIPRV | Protein AMBP | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID4128 | AEDYLSVVLNQLCVLHEKTPV | Isoform 1 of Serum albumin | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID4131 | AEKDSLDPSFTHAMQLLTAEIEKI | "Isoform 1 of KH domain-containing, RNA-binding, signal transduction-associated protein 1" | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID4143 | AFAQYLQQCPFEDHVKLVNEV | Isoform 1 of Serum albumin | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID4158 | AFFDTASTGKTFPGFFSPMLGE | Isoform 1 of Fibrinogen alpha chain | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID4159 | AFFDTASTGKTFPGFFSPMLGEFV | Isoform 1 of Fibrinogen alpha chain | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID4165 | AGAFQGLRQLDMLDLSNNSLA | Leucine-rich alpha-2-glycoprotein | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID4168 | AGAPGAPGGKGDAGAPGERGPPG | Isoform 1 of Collagen alpha-1(III) chain | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID4173 | AGGARMPCAELVREPGCGCCSV | "Insulin-like growth factor binding protein 2, 36kDa precursor" | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID4181 | AGPPGATGFPGAAGRVGPPGP | Collagen alpha-1(I) chain | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID4186 | AGQPGEKGSPGAQGPPGAPGPLG | Isoform 1 of Collagen alpha-1(III) chain | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID4188 | AGQQQPPREPPAAPGAWRQQI | Protein-lysine 6-oxidase | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID4189 | AGQQQPPREPPAAPGAWRQQIQ | Protein-lysine 6-oxidase | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID4193 | AGTAGEPGRDGNPGSDGLPGRD | Isoform 1 of Collagen alpha-1(III) chain | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID4227 | AIVGYKDSPSVWAAVPGKTFV | Profilin-1 | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID4228 | AKGSVYIGGAPDVATLTGGRF | Basement membrane-specific heparan sulfate proteoglycan core protein | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID4235 | AKPALEDLRQGLLPVLESFKV | Apolipoprotein A-I | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID4261 | ALLYSQGSKGPGEDFRMATLY | Prostaglandin D2 synthase 21kDa | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID4262 | ALLYSQGSKGPGEDFRMATLY | Prostaglandin-H2 D-isomerase | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID4272 | ALQPMVSALNIRVGGTGMFTV | Isoform 1 of Uromodulin | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID4275 | ALRNTGMETPTGVCAALAAAGVQPH | Monocyte differentiation antigen CD14 | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID4279 | ALVLEALPQIAAKIAAPLTKVDEI | Flotillin-2 | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID4280 | ALVLIAFAQYLQQCPFEDHVK | Isoform 1 of Serum albumin | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID4281 | ALWGKVNVDEVGGEALGRLLV | Hemoglobin subunit beta | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID4287 | AMGIMNSFVNDIFERIAGEAS | Histone H2B type 1-C/E/F/G/I | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID4288 | AMGIMNSFVNDIFERIAGEAS | Histone H2B type 1-K | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID4290 | ANFFSGSCAPCADGTDFPQLC | Serotransferrin | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID4304 | APEAQVSVQPNFQQDKFLGRWF | Prostaglandin D2 synthase 21kDa | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID4305 | APEAQVSVQPNFQQDKFLGRWFSA | Prostaglandin D2 synthase 21kDa | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID4306 | APEAQVSVQPNFQQDKFLGRWFSA | Prostaglandin-H2 D-isomerase | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID4308 | APGAPGGKGDAGAPGERGPPG | Isoform 1 of Collagen alpha-1(III) chain | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID4313 | APGLPGPRGIPGPVGAAGATGARG | Collagen alpha-2(I) chain | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID4343 | AQVSVQPNFQQDKFLGRWFSA | Prostaglandin D2 synthase 21kDa | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID4344 | AQVSVQPNFQQDKFLGRWFSA | Prostaglandin-H2 D-isomerase | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID4345 | AQVSVQPNFQQDKFLGRWFSAG | Prostaglandin D2 synthase 21kDa | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID4346 | AQVSVQPNFQQDKFLGRWFSAG | Prostaglandin-H2 D-isomerase | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID4347 | AQVSVQPNFQQDKFLGRWFSAGL | Prostaglandin D2 synthase 21kDa | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID4348 | AQVSVQPNFQQDKFLGRWFSAGL | Prostaglandin-H2 D-isomerase | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID4355 | ARDIVPGDIVEVAVGDKVPADLRLI | Isoform SERCA3B of Sarcoplasmic/endoplasmic reticulum calcium ATPase 3 | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID4362 | ASFLQKGNDDHWIVDTDYDTY | Retinol-binding protein 4 | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID4363 | ASFLQKGNDDHWIVDTDYDTYAV | Retinol-binding protein 4 | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID4389 | ATSGVLPGGGFVASAAAVAGP | Isoform 1 of EGF-containing fibulin-like extracellular matrix protein 1 | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID4398 | AVFGTLASLYLGALDHTADRLQAI | Angiotensinogen | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID4402 | AVGSPGVNGAPGEAGRDGNPGND | Collagen alpha-2(I) chain | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID4403 | AVHPSGVALQDRVPLASQGLGPGST | Interferon-induced 17 kDa protein | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID4420 | AVSQVVHKAVLDVFEEGTEASAATA | "cDNA FLJ35730 fis, clone TESTI2003131, highly similar to ALPHA-1-ANTICHYMOTRYPSIN" | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID4422 | AVYDQSATALHFLGRVANPLSTA | Angiotensinogen | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID4448 | CATSGDGLYEGLDWLSNQLRNQK | ADP-ribosylation factor 1 | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID4454 | CEVTHQGLSSPVTKSFNRGEC | Ig kappa chain C region | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID4455 | CEVTHQGLSSPVTKSFNRGEC | IGKat protein | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID4456 | CEVTHQGLSSPVTKSFNRGEC | IGKat protein | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID4457 | CEVTHQGLSSPVTKSFNRGEC | Putative uncharacterized protein IGKC | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID4519 | CLPSKDYAEVGRVGYVSGWGRNA | Haptoglobin isoform 2 preproprotein | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID4540 | CWFLDEAAARLLTVPFEKHSTL | 6-phosphogluconolactonase | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID4546 | DALGLNIYEQNDRLTPKIGFPWSEI | Moesin | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID4550 | DAPGQYGAYFHDDGFLAFPGHV | Basement membrane-specific heparan sulfate proteoglycan core protein | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID4551 | DAPGQYGAYFHDDGFLAFPGHVF | Basement membrane-specific heparan sulfate proteoglycan core protein | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID4552 | DAPGQYGAYFHDDGFLAFPGHVFS | Basement membrane-specific heparan sulfate proteoglycan core protein | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID4555 | DASTAIDAPSNLRFLATTPNSLLV | Isoform 1 of Fibronectin | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID4559 | DEELGGTPVQSRVVQGKEPAHL | Isoform 1 of Gelsolin | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID4560 | DEKLPGLLGNFPGPFEEEMKGI | "N-acylsphingosine amidohydrolase (Acid ceramidase) 1, isoform CRA_c" | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID4561 | DEPPQSPWDRVKDLATVYVDV | Apolipoprotein A-I | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID4569 | DFGLDLQPCIDLIEKPAGPPGILAL | Isoform 1 of Myosin-9 | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID4577 | DGALCMEKSLGPNSCSANGPGLYLI | Hemopexin | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID4579 | DGGGSPKGDVDPFYYDYETVRNGGL | Isoform 1 of Sodium/potassium-transporting ATPase subunit gamma | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID4580 | DGNASGTTLLEALDCILPPTRPTDKPL | Elongation factor 1-alpha | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID4591 | DIQMTQSPSSLSASVGDRVTI | Ig kappa chain C region | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID4592 | DIQMTQSPSSLSASVGDRVTI | Ig kappa chain V-I region AU | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID4594 | DIQMTQSPSTLSASVGDRVTI | Rheumatoid factor C6 light chain (Fragment) | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID4602 | DIVMTQSPLSLPVTPGEPASI | Putative uncharacterized protein ENSP00000419353 | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID4603 | DIVMTQSPLSLPVTPGEPASI | Putative uncharacterized protein IGKC | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID4605 | DKFVGIKDEDQLEAFLKKLIG | "cDNA FLJ55158, highly similar to Thioredoxin, mitochondrial" | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID4621 | DLGENQLETLPPDLLRGPLQL | Leucine-rich alpha-2-glycoprotein | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID4622 | DLGENQLETLPPDLLRGPLQLE | Leucine-rich alpha-2-glycoprotein | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID4623 | DLGENQLETLPPDLLRGPLQLERL | Leucine-rich alpha-2-glycoprotein | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID4635 | DLMVFVTNPDGSPAYRVPVAV | Complement C3f | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID4636 | DLPAVSEKDIQDLKFGVEQDVDM | Isoform M2 of Pyruvate kinase isozymes M1/M2 | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID4637 | DLPAVSEKDIQDLKFGVEQDVDMVF | Isoform M2 of Pyruvate kinase isozymes M1/M2 | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID4653 | DLTRNALTGLPPGLFQASATLDT | Leucine-rich alpha-2-glycoprotein | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID4654 | DLTRNALTGLPPGLFQASATLDTL | Leucine-rich alpha-2-glycoprotein | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID4666 | DNWDSVTSTFSKLREQLGPVTQ | Apolipoprotein A-I | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID4667 | DNWDSVTSTFSKLREQLGPVTQEF | Apolipoprotein A-I | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID4672 | DQQLDLELRPDSSFLAPGFTLQNV | A disintegrin and metalloproteinase with thrombospondin motifs 1 | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID4687 | DVCADMVGTFTDTEDPAKFKMK | Retinol-binding protein 4 | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID4688 | DVCADMVGTFTDTEDPAKFKMKY | Retinol-binding protein 4 | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID4692 | DVNPFQDPSVTQLTNAPQGGLAEFNPF | Secretory carrier-associated membrane protein 2 | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID4693 | DVPTLTGAFGILAAHVPTLQV | "ATP synthase subunit delta, mitochondrial" | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID4694 | DVSNLSLQALPGDLSGLFPRLR | Vasorin | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID4704 | DYDQYALLYSQGSKGPGEDFRMA | Prostaglandin D2 synthase 21kDa | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID4705 | DYDQYALLYSQGSKGPGEDFRMA | Prostaglandin-H2 D-isomerase | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID4706 | DYDQYALLYSQGSKGPGEDFRMAT | Prostaglandin D2 synthase 21kDa | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID4707 | DYDQYALLYSQGSKGPGEDFRMAT | Prostaglandin-H2 D-isomerase | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID4713 | EAEPLVDIRVTGPVPGALGAAL | Multimerin-2 | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID4724 | EDVPAFQALGSLNDLQFFRYNS | Zinc-alpha-2-glycoprotein | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID4732 | EGSNKVPVDPATYGQFYGGDSYII | Isoform 1 of Gelsolin | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID4739 | EICPSFQRVIETLLMDTPSSYEA | Uteroglobin | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID4743 | EIPSIKFSVPAGIVIPSFQALTA | Apolipoprotein B-100 | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID4750 | EIVLTQSPGTLSLSPGERATL | Ig kappa chain V-III region HAH | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID4751 | EIVLTQSPGTLSLSPGERATLSC | Ig kappa chain V-III region HAH | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID4768 | ELTETGVEAAAASAISVARTL | Plasma protease C1 inhibitor | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID4769 | ELTETGVEAAAASAISVARTLL | Plasma protease C1 inhibitor | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID4777 | ERLHLEGNKLQVLGKDLLLPQPDLR | Leucine-rich alpha-2-glycoprotein | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID4782 | ESGVPSRFSGSGSGTDFTLTI | Ig kappa chain C region | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID4785 | ETDYDQYALLYSQGSKGPGEDFRMA | Prostaglandin D2 synthase 21kDa | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID4791 | FAGEKGPSGEAGTAGPPGTPGP | Collagen alpha-2(I) chain | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID4792 | FAIGNKGADQAELEEIAFDSSL | Isoform 1 of Collagen alpha-3(VI) chain | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID4814 | FDTASTGKTFPGFFSPMLGEFV | Isoform 1 of Fibrinogen alpha chain | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID4832 | FFLPDEGKLQHLENELTHDIITK | Isoform 1 of Alpha-1-antitrypsin | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID4842 | FGDTEEAKKQINDYVEKGTQGKIVD | Isoform 1 of Alpha-1-antitrypsin | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID4845 | FGEHLLESDLFPTSTSLSPFYLRPP | Alpha-crystallin B chain | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID4921 | FIFPPSDEQLKSGTASVVCLL | 26 kDa protein | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID4922 | FIFPPSDEQLKSGTASVVCLL | 26 kDa protein | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID4923 | FIFPPSDEQLKSGTASVVCLL | Ig kappa chain C region | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID4924 | FIFPPSDEQLKSGTASVVCLL | Ig kappa chain C region | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID4925 | FIFPPSDEQLKSGTASVVCLL | IGKat protein | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID4926 | FIFPPSDEQLKSGTASVVCLL | IGKat protein | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID4927 | FIFPPSDEQLKSGTASVVCLL | IGKat protein | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID4928 | FIFPPSDEQLKSGTASVVCLL | Putative uncharacterized protein IGKC | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID4929 | FIFPPSDEQLKSGTASVVCLLNNF | 26 kDa protein | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID4930 | FIFPPSDEQLKSGTASVVCLLNNF | 26 kDa protein | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID4931 | FIFPPSDEQLKSGTASVVCLLNNF | Ig kappa chain C region | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID4932 | FIFPPSDEQLKSGTASVVCLLNNF | Ig kappa chain C region | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID4933 | FIFPPSDEQLKSGTASVVCLLNNF | IGKat protein | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID4934 | FIFPPSDEQLKSGTASVVCLLNNF | IGKat protein | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID4935 | FIFPPSDEQLKSGTASVVCLLNNF | IGKat protein | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID4936 | FIFPPSDEQLKSGTASVVCLLNNF | Putative uncharacterized protein IGKC | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID4952 | FLEAIPMSIPPEVKFNKPFVF | Isoform 1 of Alpha-1-antitrypsin | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID4954 | FLGLTAPPGSKEAEVQAKQQA | SH3 domain-binding glutamic acid-rich-like protein | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID4959 | FLGWDDDYWSVDPLDRAMAEL | Isoform 1 of Gelsolin | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID4969 | FLNGNKLARVAAGAFQGLRQLDM | Leucine-rich alpha-2-glycoprotein | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID4987 | FNEVAPGYFSRDGWQLQVQGGVAQ | Secreted and transmembrane protein 1 | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID4988 | FNEVAPGYFSRDGWQLQVQGGVAQL | Secreted and transmembrane protein 1 | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID4992 | FPGAAGRVGPPGPSGNAGPPGPPGP | Collagen alpha-1(I) chain | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID5027 | FSGLQGPPGPPGSPGEQGPSG | Collagen alpha-1(I) chain | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID5034 | FSNGADLSGVTEEAPLKLSKA | Isoform 1 of Alpha-1-antitrypsin | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID5035 | FSNGADLSGVTEEAPLKLSKAV | Isoform 1 of Alpha-1-antitrypsin | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID5082 | GAALDILCPSGPIKSLYPLTFI | Isoform 1 of Beta-galactosidase | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID5091 | GAPGAPGGKGDAGAPGERGPPG | Isoform 1 of Collagen alpha-1(III) chain | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID5092 | GAPGLPGPRGIPGPVGAAGATGARG | Collagen alpha-2(I) chain | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID5108 | GDIGNVNMWDFVLSPDEINTI | Isoform 1 of C-reactive protein | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID5121 | GEPGEPGASGPMGPRGPPGPPG | Collagen alpha-1(I) chain | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID5127 | GFPGAAGRVGPPGPSGNAGPPGPPGP | Collagen alpha-1(I) chain | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID5129 | GFSRVPPRIDSGLYLGSGYFT | "cDNA FLJ58679, highly similar to Lactotransferrin" | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID5131 | GGDAGDAFDGFDFGDDPSDKFFT | Isoform Gamma-B of Fibrinogen gamma chain | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID5135 | GGGEEASGSGGGYGGGSGKSSHS | "Keratin, type I cytoskeletal 9" | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID5138 | GGIGTVPVGRVETGVLKPGMVV | Elongation factor 1-alpha | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID5155 | GIEEAFTSKADLSGITGARNL | "cDNA FLJ35730 fis, clone TESTI2003131, highly similar to ALPHA-1-ANTICHYMOTRYPSIN" | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID5185 | GKPQGPPPQGGNQPQGPPPPPGKPQ | Basic salivary proline-rich protein 2 | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID5188 | GKSNFLNCYVSGFHPSDIEVD | Beta-2-microglobulin | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID5194 | GLAGTAGEPGRDGNPGSDGLPGRD | Isoform 1 of Collagen alpha-1(III) chain | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID5201 | GLGDALSEGVGKAIGKEAGGAAG | Isoform 1 of Dermokine | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID5209 | GLNIYEQNDRLTPKIGFPWSEI | Moesin | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID5216 | GLQDGHLVFRYQLGSGEARLV | Basement membrane-specific heparan sulfate proteoglycan core protein | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID5217 | GLQLLELPPEESLPLGPLLGDTAVI | "N(G),N(G)-dimethylarginine dimethylaminohydrolase 2" | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID5219 | GLSETEPGSFLYYAPFDGILGL | Pepsin A | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID5221 | GLSKHVEDVPAFQALGSLNDLQF | Zinc-alpha-2-glycoprotein | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID5222 | GLSKHVEDVPAFQALGSLNDLQFF | Zinc-alpha-2-glycoprotein | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID5248 | GPPGPPGPPGPPGPPSAGFDF | Collagen alpha-1(I) chain | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID5249 | GPPGPPGPPGPPGPPSAGFDFS | Collagen alpha-1(I) chain | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID5250 | GPPGPPGPPGPPGVSGGGYDFG | Collagen alpha-2(I) chain | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID5256 | GPPGSNGNPGPPGPSGSPGKD | Isoform 1 of Collagen alpha-1(III) chain | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID5257 | GPTGPPGPPGPPGPPGLGGNFA | Collagen alpha-2(I) chain | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID5282 | GQQQPPREPPAAPGAWRQQIQ | Protein-lysine 6-oxidase | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID5283 | GRFVIEEVPGELMQEDLATDDVML | Isoform 1 of Gelsolin | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID5285 | GSAGPPGATGFPGAAGRVGPPGP | Collagen alpha-1(I) chain | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID5295 | GSNRASGVPDRFSGSGSGTDFT | Putative uncharacterized protein IGKC | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID5311 | GTAGEPGRDGNPGSDGLPGRD | Isoform 1 of Collagen alpha-1(III) chain | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID5321 | GVFTAPGLHLKQPFVQGLALYTPV | Angiotensinogen | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID5327 | GVGVGGIPTYGVGAGGFPGFGVGV | Elastin isoform c precursor | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID5352 | HCIAEVENDEMPADLPSLAADFV | Isoform 1 of Serum albumin | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID5375 | HLEGNKLQVLGKDLLLPQPDLR | Leucine-rich alpha-2-glycoprotein | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID5376 | HLEGNKLQVLGKDLLLPQPDLRY | Leucine-rich alpha-2-glycoprotein | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID5377 | HLEGNKLQVLGKDLLLPQPDLRYL | Leucine-rich alpha-2-glycoprotein | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID5387 | HLSSNGLESLSPEFLRPVPQL | Leucine-rich alpha-2-glycoprotein | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID5419 | IARMAPYTGPDSVPGALDYMSF | Alpha-actinin-1 | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID5443 | IFPPSDEQLKSGTASVVCLLNNF | 26 kDa protein | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID5444 | IFPPSDEQLKSGTASVVCLLNNF | 26 kDa protein | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID5445 | IFPPSDEQLKSGTASVVCLLNNF | Ig kappa chain C region | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID5446 | IFPPSDEQLKSGTASVVCLLNNF | Ig kappa chain C region | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID5447 | IFPPSDEQLKSGTASVVCLLNNF | IGKat protein | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID5448 | IFPPSDEQLKSGTASVVCLLNNF | IGKat protein | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID5449 | IFPPSDEQLKSGTASVVCLLNNF | IGKat protein | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID5450 | IFPPSDEQLKSGTASVVCLLNNF | Putative uncharacterized protein IGKC | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID5459 | IFTMADRGECVPGEQEPEPILIPR | Protein AMBP | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID5462 | IGGAPDVATLTGGRFSSGITGCVK | Basement membrane-specific heparan sulfate proteoglycan core protein | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID5464 | IGGIGTVPVGRVETGVLKPGM | Elongation factor 1-alpha | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID5465 | IGGIGTVPVGRVETGVLKPGMVV | Elongation factor 1-alpha | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID5472 | IHEAQQAMDIHFHSPAFQHPPTE | Isoform 1 of Clusterin | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID5475 | IHSSDPDFQILEDGSVYTTNTIL | Isoform 2A of Desmocollin-2 | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID5476 | IIERETGWLKVTEPLDRERIATYTL | Cadherin-1 | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID5477 | IISCHPVGTDEEPLQFRVPGTSTS | Isoform 1 of Fibronectin | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID5487 | ILEYLTAEVLELAGNASKDLKVK | Histone H2A.V | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID5490 | ILGLPGSRGERGLPGVAGAVGEPGP | Collagen alpha-2(I) chain | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID5525 | ISRDWHGVPGQVDAAMAGRIY | Vitronectin | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID5529 | ISRTPEVTCVVVDVSHEDPEVKF | IGHat protein | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID5530 | ISRTPEVTCVVVDVSHEDPEVKF | Putative uncharacterized protein DKFZp686C11235 | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID5531 | ISRTPEVTCVVVDVSHEDPEVKF | Putative uncharacterized protein DKFZp686G11190 | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID5532 | ISRTPEVTCVVVDVSHEDPEVKF | Putative uncharacterized protein DKFZp686O01196 | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID5533 | ISRTPEVTCVVVDVSHEDPEVKF | Putative uncharacterized protein DKFZp686P15220 | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID5558 | IYEETRGVLKVFLENVIRDAV | Histone H4 | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID5565 | IYTGLSKHVEDVPAFQALGSLNDL | Zinc-alpha-2-glycoprotein | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID5566 | IYTGLSKHVEDVPAFQALGSLNDLQ | Zinc-alpha-2-glycoprotein | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID5568 | IYYPGGSYDPRNNSPYEIENG | Isoform 1 of Fibrinogen alpha chain | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID5587 | KEQLGEFYEALDCLRIPKSDV | Alpha-1-acid glycoprotein 1 | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID5609 | KLSNNALSGLPQGVFGKLGSLQE | Carboxypeptidase N subunit 2 | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID5616 | KQDSLSSQNQLGVLPLSWDIPELV | Complement C3f | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID5627 | KVEPPQGIPGDDTALNGIRLH | Vitelline membrane outer layer protein 1 homolog | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID5629 | KVLGAFSDGLAHLDNLKGTFA | Hemoglobin subunit beta | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID5667 | KVWPQQPSGELFEIEIDTLET | Alpha-2-HS-glycoprotein | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID5676 | LAENYKSQQSSDPDPNCVDRPV | "cDNA FLJ58679, highly similar to Lactotransferrin" | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID5680 | LAFPGHVFSRSLPEVPETIEL | Basement membrane-specific heparan sulfate proteoglycan core protein | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID5685 | LAIVDGHLQLSYNLGSQPVVL | Agrin | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID5687 | LALEPGILDTANVEALRLAGLGL | Vasorin | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID5692 | LAPLAKVIHDNFGIVEGLMTTV | Glyceraldehyde-3-phosphate dehydrogenase | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID5699 | LARELPAAVAPAGPASLARWT | 6-phosphogluconolactonase | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID5701 | LAVSQVVHKAVLDVFEEGTEASAA | "cDNA FLJ35730 fis, clone TESTI2003131, highly similar to ALPHA-1-ANTICHYMOTRYPSIN" | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID5716 | LDAGSFAGLPGLQLLDLSQNQIA | Vasorin | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID5727 | LDLGENQLETLPPDLLRGPLQLERL | Leucine-rich alpha-2-glycoprotein | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID5731 | LDLTRNALTGLPPGLFQASATLDT | Leucine-rich alpha-2-glycoprotein | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID5735 | LDNWDSVTSTFSKLREQLGPVTQEF | Apolipoprotein A-I | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID5742 | LDVAPLSLGLETAGGVMTALI | Heat shock 70 kDa protein 1A/1B | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID5750 | LELPPEESLPLGPLLGDTAVI | "N(G),N(G)-dimethylarginine dimethylaminohydrolase 2" | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID5757 | LETGVPSRFSGSGSGTDFTFTI | Ig kappa chain V-I region AU | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID5822 | LGPTPTTPPQPPDPSQPPPGP | Protein phosphatase 1 regulatory subunit 11 | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID5826 | LGQPKAAPSVTLFPPSSEELQANKA | hypothetical protein XP_002348153 | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID5827 | LGQPKAAPSVTLFPPSSEELQANKA | IGLat protein | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID5828 | LGQPKAAPSVTLFPPSSEELQANKA | IGLat protein | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID5829 | LGQPKAAPSVTLFPPSSEELQANKA | IGLat protein | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID5830 | LGQPKAAPSVTLFPPSSEELQANKA | IGLat protein | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID5831 | LGQPKAAPSVTLFPPSSEELQANKA | IGLat protein | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID5832 | LGQPKAAPSVTLFPPSSEELQANKA | Lambda-chain | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID5850 | LGWDDDYWSVDPLDRAMAELAA | Isoform 1 of Gelsolin | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID5857 | LIAFAQYLQQCPFEDHVKLVNEV | Isoform 1 of Serum albumin | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID5863 | LILRDTKTYMLAFDVNDEKNWGLSV | Alpha-1-acid glycoprotein 1 | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID5880 | LIYDASNRATGIPARFSGSGSGTDF | Rheumatoid factor D5 light chain (Fragment) | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID5883 | LIYGASSRATGIPDRFSGSGSGTDF | IGKat protein | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID5894 | LKLSNNALSGLPQGVFGKLGSLQEL | Carboxypeptidase N subunit 2 | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID5895 | LKNGERIEKVEHSDLSFSKDWS | Beta-2-microglobulin | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID5916 | LLKNGERIEKVEHSDLSFSKDWS | Beta-2-microglobulin | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID5928 | LLQDFRVVAQGVGIPEDSIFT | Protein AMBP | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID5929 | LLQDFRVVAQGVGIPEDSIFTM | Protein AMBP | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID5985 | LPGVAGAPGLPGPRGIPGPVG | Collagen alpha-2(I) chain | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID5989 | LQANKATLVCLISDFYPGAVT | 25 kDa protein | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID5990 | LQANKATLVCLISDFYPGAVT | 25 kDa protein | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID5991 | LQANKATLVCLISDFYPGAVT | hypothetical protein XP_002348153 | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID5992 | LQANKATLVCLISDFYPGAVT | IGLat protein | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID5993 | LQANKATLVCLISDFYPGAVT | IGLat protein | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID5994 | LQANKATLVCLISDFYPGAVT | IGLat protein | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID5995 | LQANKATLVCLISDFYPGAVTV | 25 kDa protein | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID5996 | LQANKATLVCLISDFYPGAVTV | 25 kDa protein | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID5997 | LQANKATLVCLISDFYPGAVTV | hypothetical protein XP_002348153 | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID5998 | LQANKATLVCLISDFYPGAVTV | IGLat protein | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID5999 | LQANKATLVCLISDFYPGAVTV | IGLat protein | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID6000 | LQANKATLVCLISDFYPGAVTV | IGLat protein | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID6009 | LQDFRVVAQGVGIPEDSIFTM | Protein AMBP | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID6013 | LQGSYDLQDLLAQAELPAILHT | Angiotensinogen | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID6023 | LQPAGSLGSYSYRSPHWGSTY | Prostaglandin-H2 D-isomerase | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID6030 | LRGVDIYTRLLPALASVPALPSDS | "cDNA FLJ60317, highly similar to Aminoacylase-1" | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID6036 | LRTLDLGENQLETLPPDLLRGP | Leucine-rich alpha-2-glycoprotein | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID6037 | LRTLDLGENQLETLPPDLLRGPL | Leucine-rich alpha-2-glycoprotein | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID6038 | LRTLDLGENQLETLPPDLLRGPLQ | Leucine-rich alpha-2-glycoprotein | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID6039 | LRTLDLGENQLETLPPDLLRGPLQL | Leucine-rich alpha-2-glycoprotein | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID6050 | LSDPDKVTIGLLFWDGRGEGLRL | Isoform 2 of Inter-alpha-trypsin inhibitor heavy chain H4 | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID6053 | LSDPEQGVEVTGQYEREKAGF | Isoform 2 of Inter-alpha-trypsin inhibitor heavy chain H4 | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID6054 | LSDPEQGVEVTGQYEREKAGFSW | Isoform 2 of Inter-alpha-trypsin inhibitor heavy chain H4 | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID6056 | LSEADVRALGGLACDLPGRFV | Isoform 2 of Mesothelin | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID6061 | LSEGLKLVDKFLEDVKKLYHSEA | Isoform 1 of Alpha-1-antitrypsin | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID6080 | LSSHIANVERVPFDAATLHTSTA | Isoform 1 of Gelsolin | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID6081 | LSSLTETIEGVDAEDGHGPGEQQ | "cDNA FLJ55673, highly similar to Complement factor B" | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID6119 | LVESGGGLVQPGGSLRLSCAA | Putative uncharacterized protein DKFZp686C11235 | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID6120 | LVFEDAPNGVEAALAAGMQVV | Haloacid dehalogenase-like hydrolase domain-containing protein 1A | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID6135 | LVLKAPDKNVIFSPLSISTAL | "cDNA FLJ35730 fis, clone TESTI2003131, highly similar to ALPHA-1-ANTICHYMOTRYPSIN" | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID6136 | LVLKAPDKNVIFSPLSISTALAF | "cDNA FLJ35730 fis, clone TESTI2003131, highly similar to ALPHA-1-ANTICHYMOTRYPSIN" | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID6141 | LVVDNGSGMCKAGFAGDDAPRA | "Actin, cytoplasmic 1" | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID6147 | LWVGTGASEAEKTGAQELLRV | Isoform 1 of Gelsolin | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID6160 | MADGTCQDAAIVGYKDSPSVW | Profilin-1 | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID6162 | MADRGECVPGEQEPEPILIPR | Protein AMBP | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID6181 | MFLEAIPMSIPPEVKFNKPFVF | Isoform 1 of Alpha-1-antitrypsin | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID6202 | MLTELEKALNSIIDVYHKYSL | Protein S100-A8 | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID6203 | MLTELEKALNSIIDVYHKYSLI | Protein S100-A8 | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID6227 | MTDGLHNMGGDPITVIDEIRDLL | "cDNA FLJ55673, highly similar to Complement factor B" | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID6232 | MVEHTPDEESIDWTKIEPSVN | Vesicular integral-membrane protein VIP36 | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID6246 | NCLAPLAKVIHDNFGIVEGLMT | Glyceraldehyde-3-phosphate dehydrogenase | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID6253 | NDDIIVNWVNETLREAEKSSSI | Plastin-2 | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID6264 | NEVAPGYFSRDGWQLQVQGGVAQ | Secreted and transmembrane protein 1 | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID6265 | NEVAPGYFSRDGWQLQVQGGVAQL | Secreted and transmembrane protein 1 | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID6284 | NGVQYPVPPSAYILQSEGSCI | Pepsin A | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID6287 | NIKLPGSSKIFSVYCDQETSLGGWL | Isoform 1 of Fibrinogen alpha chain | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID6289 | NIQDGPDFQDRVVNSETPVVV | "cDNA FLJ55158, highly similar to Thioredoxin, mitochondrial" | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID6314 | NLPLDSMAAPWETGDTFPDVV | Isoform 1 of N-acetylmuramoyl-L-alanine amidase | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID6329 | NRVPIPWVSGTSASTPVFGGIL | "cDNA FLJ56402, highly similar to Tripeptidyl-peptidase 1" | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID6339 | NTVGGTGGIGGVGGTGGVGNRAP | Isoform 1 of Multimerin-1 | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID6387 | PAAGQQQPPREPPAAPGAWRQ | Protein-lysine 6-oxidase | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID6388 | PAAGQQQPPREPPAAPGAWRQQI | Protein-lysine 6-oxidase | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID6389 | PAAGQQQPPREPPAAPGAWRQQIQ | Protein-lysine 6-oxidase | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID6390 | PAGPPGEAGKPGEQGVPGDLGAPGP | Collagen alpha-1(I) chain | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID6392 | PDEGKLQHLENELTHDIITKF | Isoform 1 of Alpha-1-antitrypsin | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID6428 | PPGPPGPPGPPGPPSAGFDFS | Collagen alpha-1(I) chain | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID6465 | QAAPEAQVSVQPNFQQDKFLGRWF | Prostaglandin-H2 D-isomerase | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID6466 | QAFHLGKCPNPPVQENFDVNKY | Apolipoprotein D | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID6480 | QANKATLVCLISDFYPGAVTV | 25 kDa protein | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID6481 | QANKATLVCLISDFYPGAVTV | 25 kDa protein | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID6482 | QANKATLVCLISDFYPGAVTV | hypothetical protein XP_002348153 | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID6483 | QANKATLVCLISDFYPGAVTV | IGLat protein | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID6484 | QANKATLVCLISDFYPGAVTV | IGLat protein | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID6485 | QANKATLVCLISDFYPGAVTV | IGLat protein | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID6498 | QDGEFSMDLRTKSTGGAPTFNV | Profilin-1 | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID6508 | QELHLSSNGLESLSPEFLRPVPQL | Leucine-rich alpha-2-glycoprotein | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID6514 | QENQDGRYSLTYIYTGLSKHV | Zinc-alpha-2-glycoprotein | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID6516 | QESQSEEIDCNDKDLFKAVDA | Isoform LMW of Kininogen-1 | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID6519 | QFDADELRAAMKGLGTDEDTL | Annexin A1 | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID6528 | QGLPGLAGTAGEPGRDGNPGSD | Isoform 1 of Collagen alpha-1(III) chain | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID6539 | QITPAEGPVVTAQYDCLGCVHPI | Isoform LMW of Kininogen-1 | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID6557 | QLVENFCRNPDGDEEGVWCYV | Prothrombin (Fragment) | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID6565 | QPKANPTVTLFPPSSEELQANKA | 25 kDa protein | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID6566 | QPKANPTVTLFPPSSEELQANKA | 25 kDa protein | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID6576 | QRQDDLDTLGLGLQGGIPNGY | Isoform 2 of Mesothelin | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID6584 | QSISGVPSRFSGSGSGTDFTLTI | Putative uncharacterized protein ENSP00000413304 | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID6592 | QVAEGSEPDGFWEALGGKAAY | Isoform 1 of Gelsolin | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID6600 | QVSVQPNFQQDKFLGRWFSAG | Prostaglandin D2 synthase 21kDa | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID6601 | QVSVQPNFQQDKFLGRWFSAG | Prostaglandin-H2 D-isomerase | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID6602 | QVSVQPNFQQDKFLGRWFSAGL | Prostaglandin D2 synthase 21kDa | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID6603 | QVSVQPNFQQDKFLGRWFSAGL | Prostaglandin-H2 D-isomerase | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID6613 | QWKVDNALQSGNSQESVTEQDSKDS | 26 kDa protein | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID6614 | QWKVDNALQSGNSQESVTEQDSKDS | 26 kDa protein | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID6615 | QWKVDNALQSGNSQESVTEQDSKDS | Anti-RhD monoclonal T125 kappa light chain | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID6616 | QWKVDNALQSGNSQESVTEQDSKDS | Ig kappa chain C region | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID6617 | QWKVDNALQSGNSQESVTEQDSKDS | Ig kappa chain C region | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID6618 | QWKVDNALQSGNSQESVTEQDSKDS | IGKat protein | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID6619 | QWKVDNALQSGNSQESVTEQDSKDS | IGKat protein | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID6620 | QWKVDNALQSGNSQESVTEQDSKDS | Putative uncharacterized protein | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID6621 | QWKVDNALQSGNSQESVTEQDSKDS | Putative uncharacterized protein IGKC | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID6622 | QWKVDNALQSGNSQESVTEQDSKDSTY | 26 kDa protein | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID6623 | QWKVDNALQSGNSQESVTEQDSKDSTY | 26 kDa protein | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID6624 | QWKVDNALQSGNSQESVTEQDSKDSTY | Anti-RhD monoclonal T125 kappa light chain | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID6625 | QWKVDNALQSGNSQESVTEQDSKDSTY | Ig kappa chain C region | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID6626 | QWKVDNALQSGNSQESVTEQDSKDSTY | Ig kappa chain C region | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID6627 | QWKVDNALQSGNSQESVTEQDSKDSTY | IGKat protein | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID6628 | QWKVDNALQSGNSQESVTEQDSKDSTY | IGKat protein | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID6629 | QWKVDNALQSGNSQESVTEQDSKDSTY | Putative uncharacterized protein | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID6630 | QWKVDNALQSGNSQESVTEQDSKDSTY | Putative uncharacterized protein IGKC | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID6633 | QYGGCMGNGNNFVTEKECLQTCRTV | Protein AMBP | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID6648 | REPGQDLVVLPLSITTDFIPSFRLV | Complement C3f | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID6651 | RETLLQDFRVVAQGVGIPEDSIFT | Protein AMBP | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID6668 | RGENGSPGAPGAPGHPGPPGP | Isoform 1 of Collagen alpha-1(III) chain | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID6674 | RHHGPTITAKLYGRAPQLRET | Protein AMBP | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID6677 | RLFPETAPGAPGSIPAPPAPG | polydom | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID6691 | RLLLPGELAKHAVSEGTKAVT | Histone H2B type 1-C/E/F/G/I | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID6692 | RLLLPGELAKHAVSEGTKAVT | Histone H2B type 1-K | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID6693 | RLLLPGELAKHAVSEGTKAVT | Histone H2B type 1-L | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID6694 | RLLLPGELAKHAVSEGTKAVTKY | Histone H2B type 1-C/E/F/G/I | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID6695 | RLLLPGELAKHAVSEGTKAVTKY | Histone H2B type 1-L | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID6696 | RLLLPGELAKHAVSEGTKAVTKYTS | Histone H2B type 1-C/E/F/G/I | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID6697 | RLLLPGELAKHAVSEGTKAVTKYTS | Histone H2B type 1-K | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID6698 | RLLLPGELAKHAVSEGTKAVTKYTS | Histone H2B type 1-L | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID6708 | RLPTGYYFGASAGTGDLSDNHDII | Vesicular integral-membrane protein VIP36 | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID6717 | RNDEELNKLLGKVTIAQGGVLPNIQ | Histone H2A type 1 | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID6718 | RNDEELNKLLGKVTIAQGGVLPNIQ | Histone H2A type 2-A | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID6721 | RNTGMETPTGVCAALAAAGVQPH | Monocyte differentiation antigen CD14 | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID6724 | RVLDLTRNALTGLPPGLFQASATLDT | Leucine-rich alpha-2-glycoprotein | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID6726 | RVPIPWVSGTSASTPVFGGIL | "cDNA FLJ56402, highly similar to Tripeptidyl-peptidase 1" | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID6737 | SAAILEYLTAEVLELAGNASKDLKVK | Histone H2A.V | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID6739 | SADIETIGEILKKIIPTLEEG | Isoform 1 of Heterogeneous nuclear ribonucleoprotein K | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID6747 | SAGDVDTLAFDGRTFVEYLNAVT | Agrin | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID6748 | SAGPPGATGFPGAAGRVGPPGP | Collagen alpha-1(I) chain | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID6795 | SEGLKLVDKFLEDVKKLYHSEA | Isoform 1 of Alpha-1-antitrypsin | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID6797 | SEKAKPALEDLRQGLLPVLESFKV | Apolipoprotein A-I | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID6801 | SELQLSVSAGSPHPAIARLTV | Complement C4-B | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID6802 | SELQLSVSAGSPHPAIARLTV | Complement component C4B | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID6803 | SELQLSVSAGSPHPAIARLTV | Putative uncharacterized protein C4A | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID6810 | SFIPDFAVAIPTFRQLGTVQQV | Isoform 1 of Collagen alpha-3(VI) chain | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID6845 | SGGTAALGCLVKDYFPEPVTV | IGHat protein | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID6846 | SGGTAALGCLVKDYFPEPVTV | Putative uncharacterized protein DKFZp686G11190 | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID6847 | SGGTAALGCLVKDYFPEPVTV | Putative uncharacterized protein DKFZp686O01196 | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID6848 | SGGTAALGCLVKDYFPEPVTV | Putative uncharacterized protein DKFZp686P15220 | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID6860 | SGLLLWQGVEVGEAGQGKDFI | Basement membrane-specific heparan sulfate proteoglycan core protein | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID6880 | SGRSPGPNVAVNAKGSVYIGGAPDVA | Basement membrane-specific heparan sulfate proteoglycan core protein | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID6885 | SGSTGQWHSESGSFRPDSPGSGN | Isoform 1 of Fibrinogen alpha chain | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID6912 | SGVHTFPAVLQSSGLYSLSSVV | IGHat protein | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID6913 | SGVHTFPAVLQSSGLYSLSSVV | Putative uncharacterized protein DKFZp686C11235 | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID6914 | SGVHTFPAVLQSSGLYSLSSVV | Putative uncharacterized protein DKFZp686G11190 | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID6915 | SGVHTFPAVLQSSGLYSLSSVV | Putative uncharacterized protein DKFZp686I04196 (Fragment) | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID6916 | SGVHTFPAVLQSSGLYSLSSVV | Putative uncharacterized protein DKFZp686O01196 | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID6917 | SGVHTFPAVLQSSGLYSLSSVV | Putative uncharacterized protein DKFZp686P15220 | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID6934 | SIFQDDFVIPDISEPGTWKISA | Complement C4-B | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID6935 | SIFQDDFVIPDISEPGTWKISA | Complement component C4B | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID6936 | SIFQDDFVIPDISEPGTWKISA | Putative uncharacterized protein C4A | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID6950 | SITGTYDLKSVLGQLGITKVFSNG | Isoform 1 of Alpha-1-antitrypsin | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID6953 | SLAALKKALAAAGYDVEKNNSRI | Histone H1.4 | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID6954 | SLAALKKALAAAGYDVEKNNSRIKL | Histone H1.4 | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID6974 | SLGLQDGHLVFRYQLGSGEARLV | Basement membrane-specific heparan sulfate proteoglycan core protein | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID6992 | SLPTGISANEEDLKALVEGVDQLF | Complement C5 | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID6993 | SLQELDTSSGVLLPFFDPDTNIV | Coronin-1A | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID6998 | SLQSGVPSRFSGSGSGTDFTLTI | 26 kDa protein | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID7003 | SLSTFQQMWISKQEYDESGPSIV | "Actin, cytoplasmic 1" | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID7005 | SLTHNQLETVAEGTFAHLSNL | Carboxypeptidase N subunit 2 | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID7009 | SMGVISDGNSYGVPDDLLYSFPV | Malate dehydrogenase | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID7021 | SNGADLSGVTEEAPLKLSKAVHKA | Isoform 1 of Alpha-1-antitrypsin | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID7028 | SNLETGVPSRFSGSGSGTDFTFTI | Ig kappa chain V-I region AU | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID7044 | SPGTLSLSPGERATLSCRASQSVSS | Ig kappa chain V-III region HAH | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID7047 | SPYPTFNPSSDVAALHKAIMV | Annexin A1 | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID7050 | SQFLQAAERYGINTTDIFQTV | Transgelin-2 | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID7057 | SQSISGVPSRFSGSGSGTDFTL | Putative uncharacterized protein ENSP00000413304 | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID7058 | SQSISGVPSRFSGSGSGTDFTLTI | Putative uncharacterized protein ENSP00000413304 | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID7065 | SRHHGPTITAKLYGRAPQLRETLL | Protein AMBP | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID7073 | SRTPEVTCVVVDVSHEDPEVKF | IGHat protein | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID7074 | SRTPEVTCVVVDVSHEDPEVKF | Putative uncharacterized protein DKFZp686C11235 | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID7075 | SRTPEVTCVVVDVSHEDPEVKF | Putative uncharacterized protein DKFZp686G11190 | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID7076 | SRTPEVTCVVVDVSHEDPEVKF | Putative uncharacterized protein DKFZp686O01196 | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID7077 | SRTPEVTCVVVDVSHEDPEVKF | Putative uncharacterized protein DKFZp686P15220 | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID7087 | SSDFNSDTHSSTFDAGAGIAL | Glyceraldehyde-3-phosphate dehydrogenase | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID7093 | SSHIANVERVPFDAATLHTSTA | Isoform 1 of Gelsolin | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID7102 | SSLESGVPSRFSGSGSGTEFTLTI | Rheumatoid factor C6 light chain (Fragment) | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID7115 | SSLQSGVPSRFSGSGSGTDFTLTI | 26 kDa protein | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID7119 | SSNQTLVDTEAIMATLTIGSLQI | Potassium channel subfamily U member 1 | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID7123 | SSQEPYFSYSGAFKCLRDGAGDV | "cDNA FLJ58679, highly similar to Lactotransferrin" | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID7125 | SSRATGIPDRFSGSGSGTDFTLTI | Ig kappa chain V-III region HAH | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID7126 | SSRATGIPDRFSGSGSGTDFTLTI | IGKat protein | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID7127 | SSRATGIPDRFSGSGSGTDFTLTI | IGKat protein | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID7135 | SSVPGVRLLQDSVDFSLADAI | Vimentin | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID7138 | SSVQESQVAQQARGWVTDGFSSLKD | Apolipoprotein C-III | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID7146 | STLQSGVPSRFSGSGSGTDFTLTI | Anti-RhD monoclonal T125 kappa light chain | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID7148 | STLQSGVPSRFSGSGSGTEFTLTI | 26 kDa protein | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID7151 | STRASGVPSRFSGSGSGTEFTLTI | Ig kappa chain C region | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID7152 | STSGGTAALGCLVKDYFPEPV | IGHat protein | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID7153 | STSGGTAALGCLVKDYFPEPV | Putative uncharacterized protein DKFZp686G11190 | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID7154 | STSGGTAALGCLVKDYFPEPV | Putative uncharacterized protein DKFZp686O01196 | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID7155 | STSGGTAALGCLVKDYFPEPV | Putative uncharacterized protein DKFZp686P15220 | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID7174 | SVSALTLATETVRSILKIDDVVNTR | T-complex protein 1 subunit delta | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID7204 | SVYVYKVLKQVHPDTGISSKAMGI | Histone H2B type 1-C/E/F/G/I | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID7205 | SVYVYKVLKQVHPDTGISSKAMGI | Histone H2B type 1-K | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID7206 | SVYVYKVLKQVHPDTGISSKAMGI | Histone H2B type 1-L | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID7243 | SWNSGALTSGVHTFPAVLQSS | IGHat protein | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID7244 | SWNSGALTSGVHTFPAVLQSS | Putative uncharacterized protein DKFZp686C11235 | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID7245 | SWNSGALTSGVHTFPAVLQSS | Putative uncharacterized protein DKFZp686G11190 | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID7246 | SWNSGALTSGVHTFPAVLQSS | Putative uncharacterized protein DKFZp686I04196 (Fragment) | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID7247 | SWNSGALTSGVHTFPAVLQSS | Putative uncharacterized protein DKFZp686O01196 | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID7248 | SWNSGALTSGVHTFPAVLQSS | Putative uncharacterized protein DKFZp686P15220 | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID7249 | SWNSGALTSGVHTFPAVLQSSGL | Putative uncharacterized protein DKFZp686P15220 | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID7250 | SWNSGALTSGVHTFPAVLQSSGLY | IGHat protein | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID7251 | SWNSGALTSGVHTFPAVLQSSGLY | Putative uncharacterized protein DKFZp686C11235 | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID7252 | SWNSGALTSGVHTFPAVLQSSGLY | Putative uncharacterized protein DKFZp686G11190 | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID7253 | SWNSGALTSGVHTFPAVLQSSGLY | Putative uncharacterized protein DKFZp686I04196 (Fragment) | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID7254 | SWNSGALTSGVHTFPAVLQSSGLY | Putative uncharacterized protein DKFZp686O01196 | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID7255 | SWNSGALTSGVHTFPAVLQSSGLY | Putative uncharacterized protein DKFZp686P15220 | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID7256 | SWNSGALTSGVHTFPAVLQSSGLYS | IGHat protein | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID7257 | SWNSGALTSGVHTFPAVLQSSGLYS | Putative uncharacterized protein DKFZp686C11235 | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID7258 | SWNSGALTSGVHTFPAVLQSSGLYS | Putative uncharacterized protein DKFZp686G11190 | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID7259 | SWNSGALTSGVHTFPAVLQSSGLYS | Putative uncharacterized protein DKFZp686I04196 (Fragment) | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID7260 | SWNSGALTSGVHTFPAVLQSSGLYS | Putative uncharacterized protein DKFZp686O01196 | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID7261 | SWNSGALTSGVHTFPAVLQSSGLYS | Putative uncharacterized protein DKFZp686P15220 | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID7313 | SYELTQPPSVSVSPGQTARITC | Ig lambda chain V-IV region Hil | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID7314 | SYELTQPPSVSVSPGQTARITC | IGLat protein | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID7315 | SYELTQPPSVSVSPGQTARITC | V2-17 protein | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID7316 | SYELTQPPSVSVSPGQTARITC | V2-7 protein | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID7333 | TAAVGGSAGEQEGAMVAATQG | Isoform 1 of Heterogeneous nuclear ribonucleoprotein D0 | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID7347 | TALWGKVNVDEVGGEALGRLLV | Hemoglobin subunit beta | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID7350 | TASDPLDTLGSEGALSPGGVASLL | Complement C4-B | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID7351 | TASDPLDTLGSEGALSPGGVASLL | Complement component C4B | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID7352 | TASDPLDTLGSEGALSPGGVASLL | Putative uncharacterized protein C4A | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID7356 | TAVQEISHLIEPLANAARAEASQLGH | Talin-1 | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID7360 | TDLEDKNEWKNCIDITGVRLPTG | Vesicular integral-membrane protein VIP36 | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID7362 | TDYDQYALLYSQGSKGPGEDFRM | Prostaglandin D2 synthase 21kDa | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID7363 | TDYDQYALLYSQGSKGPGEDFRM | Prostaglandin-H2 D-isomerase | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID7364 | TDYDQYALLYSQGSKGPGEDFRMA | Prostaglandin D2 synthase 21kDa | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID7365 | TDYDQYALLYSQGSKGPGEDFRMA | Prostaglandin-H2 D-isomerase | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID7404 | TGLSKHVEDVPAFQALGSLNDLQF | Zinc-alpha-2-glycoprotein | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID7408 | TGNGLFLSEGLKLVDKFLEDV | Isoform 1 of Alpha-1-antitrypsin | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID7425 | TGTYDLKSVLGQLGITKVFSNGA | Isoform 1 of Alpha-1-antitrypsin | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID7426 | TGTYDLKSVLGQLGITKVFSNGADL | Isoform 1 of Alpha-1-antitrypsin | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID7438 | TIFQERDPSKIKWGDAGAEYV | Glyceraldehyde-3-phosphate dehydrogenase | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID7439 | TIGNERFRCPEALFQPSFLGMESC | "Actin, cytoplasmic 1" | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID7454 | TLAAHLPAEFTPAVHASLDKFLASV | Hemoglobin subunit alpha | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID7458 | TLDAGLVYDAYLAPNNLKPVVAEF | Serotransferrin | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID7462 | TLDLGENQLETLPPDLLRGPL | Leucine-rich alpha-2-glycoprotein | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID7468 | TLEIPGNSDPNMIPDGDFNSYVRV | Complement C4-B | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID7469 | TLEIPGNSDPNMIPDGDFNSYVRV | Complement component C4B | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID7470 | TLEIPGNSDPNMIPDGDFNSYVRV | Putative uncharacterized protein C4A | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID7493 | TLGQPPAAEIHGVGDWGSTYS | Prostaglandin D2 synthase 21kDa | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID7499 | TLKMSVQPTVSLGGFEITPPVVL | Isoform 2 of Nucleophosmin | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID7500 | TLLQDFRVVAQGVGIPEDSIFT | Protein AMBP | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID7510 | TLPDFRLPEIAIPEFIIPTLN | Apolipoprotein B-100 | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID7523 | TLVCESAPGPITMDLTGDLEALK | Rho GDP-dissociation inhibitor 2 | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID7543 | TMADRGECVPGEQEPEPILIPR | Protein AMBP | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID7544 | TMDDFRWALSQSNPSALRETV | Transitional endoplasmic reticulum ATPase | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID7548 | TMLDAGSFAGLPGLQLLDLSQNQIA | Vasorin | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID7551 | TNCLAPLAKVIHDNFGIVEGLMT | Glyceraldehyde-3-phosphate dehydrogenase | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID7553 | TNVGDEGGFAPNILENKEGLELL | Isoform alpha-enolase of Alpha-enolase | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID7574 | TSKGLFRAAVPSGASTGIYEALEL | Isoform alpha-enolase of Alpha-enolase | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID7576 | TSTCPNLILSPLSVALALSHL | 55 kDa protein | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID7592 | TVNQSLLSPLVLEVDPNIQAV | "Keratin, type II cytoskeletal 8" | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID7603 | TVRVPETVADARQSIDVGKTS | "Adrenodoxin, mitochondrial" | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID7626 | TVSWNSGALTSGVHTFPAVLQ | IGHat protein | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID7627 | TVSWNSGALTSGVHTFPAVLQ | Putative uncharacterized protein DKFZp686C11235 | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID7628 | TVSWNSGALTSGVHTFPAVLQ | Putative uncharacterized protein DKFZp686G11190 | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID7629 | TVSWNSGALTSGVHTFPAVLQ | Putative uncharacterized protein DKFZp686I04196 (Fragment) | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID7630 | TVSWNSGALTSGVHTFPAVLQ | Putative uncharacterized protein DKFZp686O01196 | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID7631 | TVSWNSGALTSGVHTFPAVLQ | Putative uncharacterized protein DKFZp686P15220 | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID7632 | TVSWNSGALTSGVHTFPAVLQS | IGHat protein | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID7633 | TVSWNSGALTSGVHTFPAVLQS | Putative uncharacterized protein DKFZp686C11235 | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID7634 | TVSWNSGALTSGVHTFPAVLQS | Putative uncharacterized protein DKFZp686G11190 | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID7635 | TVSWNSGALTSGVHTFPAVLQS | Putative uncharacterized protein DKFZp686I04196 (Fragment) | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID7636 | TVSWNSGALTSGVHTFPAVLQS | Putative uncharacterized protein DKFZp686O01196 | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID7637 | TVSWNSGALTSGVHTFPAVLQS | Putative uncharacterized protein DKFZp686P15220 | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID7638 | TVSWNSGALTSGVHTFPAVLQSSGL | Putative uncharacterized protein DKFZp686P15220 | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID7687 | TYIYTGLSKHVEDVPAFQALGSLND | Zinc-alpha-2-glycoprotein | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID7696 | VADESAENCDKSLHTLFGDKLCTV | Isoform 1 of Serum albumin | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID7697 | VADESAENCDKSLHTLFGDKLCTVA | Isoform 1 of Serum albumin | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID7709 | VAPGYFSRDGWQLQVQGGVAQ | Secreted and transmembrane protein 1 | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID7710 | VAPGYFSRDGWQLQVQGGVAQL | Secreted and transmembrane protein 1 | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID7763 | VDNGSGMCKAGFAGDDAPRAV | "Actin, cytoplasmic 1" | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID7764 | VDSGNDVTDIADDGCPKPPEIA | Haptoglobin isoform 2 preproprotein | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID7791 | VETDYDQYALLYSQGSKGPGEDFRM | Prostaglandin D2 synthase 21kDa | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID7792 | VETDYDQYALLYSQGSKGPGEDFRM | Prostaglandin-H2 D-isomerase | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID7843 | VGPPGPPGPPGPPGPPSAGFD | Collagen alpha-1(I) chain | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID7844 | VGPPGPPGPPGPPGPPSAGFDFSFL | Collagen alpha-1(I) chain | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID7850 | VGVFTAPGLHLKQPFVQGLALYTPV | Angiotensinogen | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID7863 | VLAGALLEEAEQLLDRGIHPI | T-complex protein 1 subunit epsilon | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID7889 | VLEYLTAEILELAGNAARDNKKT | Histone H2A type 1 | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID7890 | VLEYLTAEILELAGNAARDNKKT | Histone H2A type 1-C | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID7891 | VLEYLTAEILELAGNAARDNKKT | Histone H2A type 2-A | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID7892 | VLEYLTAEILELAGNAARDNKKT | Histone H2A type 2-B | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID7903 | VLKAPDKNVIFSPLSISTALAFL | "cDNA FLJ35730 fis, clone TESTI2003131, highly similar to ALPHA-1-ANTICHYMOTRYPSIN" | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID7912 | VLQGSYDLQDLLAQAELPAIL | Angiotensinogen | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID7953 | VLSGGTTMYPGIADRMQKEIT | "Actin, cytoplasmic 1" | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID7954 | VLSGGTTMYPGIADRMQKEIT | "Actin, gamma-enteric smooth muscle" | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID7960 | VMDSGDGVTHTVPIYEGYALPHAI | "Actin, cytoplasmic 1" | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID7972 | VPGKTFVNITPAEVGVLVGKDRSSF | Profilin-1 | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID7975 | VPTADLEDVLPLAEDITNILSK | Isoform 1 of Vitamin D-binding protein | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID7980 | VRGGCASGLYPDAFAPVAQFV | Neutrophil elastase | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID7984 | VRLLLPGELAKHAVSEGTKAV | Histone H2B type 1-C/E/F/G/I | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID7985 | VRLLLPGELAKHAVSEGTKAV | Histone H2B type 1-K | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID7986 | VRLLLPGELAKHAVSEGTKAV | Histone H2B type 1-L | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID7987 | VRLLLPGELAKHAVSEGTKAVTKY | Histone H2B type 1-C/E/F/G/I | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID7988 | VRLLLPGELAKHAVSEGTKAVTKY | Histone H2B type 1-K | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID7989 | VRLLLPGELAKHAVSEGTKAVTKY | Histone H2B type 1-L | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID7992 | VRVTASDPLDTLGSEGALSPGGVA | Putative uncharacterized protein C4A | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID7993 | VRVTASDPLDTLGSEGALSPGGVAS | Putative uncharacterized protein C4A | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID8000 | VSIEDPFDQDDWGAWQKFTASA | Isoform alpha-enolase of Alpha-enolase | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID8006 | VSNRVPIPWVSGTSASTPVFGGIL | "cDNA FLJ56402, highly similar to Tripeptidyl-peptidase 1" | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID8027 | VTRAAFNSGKVDIVAINDPFIDL | Glyceraldehyde-3-phosphate dehydrogenase | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID8028 | VTRAAFNSGKVDIVAINDPFIDLNY | Glyceraldehyde-3-phosphate dehydrogenase | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID8085 | VVGVFTAPGLHLKQPFVQGLAL | Angiotensinogen | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID8090 | VVLAGALLEEAEQLLDRGIHPI | T-complex protein 1 subunit epsilon | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID8092 | VVPWEKKIYPTVNCQPLGMIS | Isoform LMW of Kininogen-1 | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID8097 | VVSNRVPIPWVSGTSASTPVFGGIL | "cDNA FLJ56402, highly similar to Tripeptidyl-peptidase 1" | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID8104 | VYKVLKQVHPDTGISSKAMGI | Histone H2B type 1-C/E/F/G/I | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID8105 | VYKVLKQVHPDTGISSKAMGI | Histone H2B type 1-K | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID8106 | VYKVLKQVHPDTGISSKAMGI | Histone H2B type 1-L | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID8108 | VYPWTQRFFESFGDLSTPDAV | Hemoglobin subunit beta | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID8142 | WKVDNALQSGNSQESVTEQDSKDSTY | 26 kDa protein | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID8143 | WKVDNALQSGNSQESVTEQDSKDSTY | 26 kDa protein | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID8144 | WKVDNALQSGNSQESVTEQDSKDSTY | Anti-RhD monoclonal T125 kappa light chain | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID8145 | WKVDNALQSGNSQESVTEQDSKDSTY | Ig kappa chain C region | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID8146 | WKVDNALQSGNSQESVTEQDSKDSTY | Ig kappa chain C region | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID8147 | WKVDNALQSGNSQESVTEQDSKDSTY | IGKat protein | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID8148 | WKVDNALQSGNSQESVTEQDSKDSTY | IGKat protein | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID8149 | WKVDNALQSGNSQESVTEQDSKDSTY | Putative uncharacterized protein | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID8150 | WKVDNALQSGNSQESVTEQDSKDSTY | Putative uncharacterized protein IGKC | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID8152 | WLGNDNIHALTAQGTSELRVD | Isoform 1 of Ficolin-2 | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID8154 | WLNGGPGCSSLDGLLTEHGPF | Lysosomal protective protein | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID8160 | WLTFEGKPLEDQLPLGEYGLK | Interferon-induced 17 kDa protein | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID8161 | WLTFEGKPLEDQLPLGEYGLKPL | Interferon-induced 17 kDa protein | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID8173 | WQGVEVGEAGQGKDFISLGLQDGHL | Basement membrane-specific heparan sulfate proteoglycan core protein | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID8236 | YADKPETTKEQLGEFYEALDC | Alpha-1-acid glycoprotein 1 | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID8237 | YADKPETTKEQLGEFYEALDC | Alpha-1-acid glycoprotein 2 | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID8253 | YDQSATALHFLGRVANPLSTA | Angiotensinogen | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID8265 | YEIKEGDCPVQSGKTWQDCEY | Isoform LMW of Kininogen-1 | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID8286 | YIISCHPVGTDEEPLQFRVPGTSTS | Isoform 1 of Fibronectin | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID8288 | YIYTGLSKHVEDVPAFQALGSLNDL | Zinc-alpha-2-glycoprotein | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID8293 | YKQLVLKAPDKNVIFSPLSISTA | "cDNA FLJ35730 fis, clone TESTI2003131, highly similar to ALPHA-1-ANTICHYMOTRYPSIN" | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID8319 | YLWVGTGASEAEKTGAQELLRV | Isoform 1 of Gelsolin | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID8356 | YRPEAPDTALGIVSTKDTQFS | Isoform 1 of Immunoglobulin superfamily member 8 | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID8357 | YRPEAPDTALGIVSTKDTQFSY | Isoform 1 of Immunoglobulin superfamily member 8 | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID8364 | YSLPFLTAPGSQLPGFVPVAPI | Isoform 1 of Abhydrolase domain-containing protein 14B | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID8375 | YSRHPAENGKSNFLNCYVSGFHPSD | Beta-2-microglobulin | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID8384 | YTGLSKHVEDVPAFQALGSLNDLQF | Zinc-alpha-2-glycoprotein | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID8516 | SSSYSKQFTSSTSYNRGDSTFES | Fibrinogen alpha | Serum | 2552.09 | MALDI-TOF | "Breast cancer, Lung cancer, Rectal cancer" | NA | 23667664 |
| CancerPDF_ID8517 | SSSYSKQFTSSTSYNRGDSTFESKS | Fibrinogen alpha | Serum | 2767.22 | MALDI-TOF | "Breast cancer, Lung cancer, Rectal cancer" | NA | 23667664 |
| CancerPDF_ID8526 | SYKMADEAGSEADHEGTHSTKRGHA | Fibrinogen alpha | Serum | 2671.17 | MALDI-TOF | "Breast cancer, Lung cancer, Rectal cancer" | NA | 23667664 |
| CancerPDF_ID8527 | SYKMADEAGSEADHEGTHSTK | Fibrinogen alpha | Serum | 2249.95 | MALDI-TOF | "Breast cancer, Lung cancer, Rectal cancer" | NA | 23667664 |
| CancerPDF_ID8533 | MADEAGSEADHEGTHSTKRGHA | Fibrinogen alpha | Serum | 2292.98 | MALDI-TOF | "Breast cancer, Lung cancer, Rectal cancer" | NA | 23667664 |
| CancerPDF_ID8535 | ADEAGSEADHEGTHSTKRGHA | Fibrinogen alpha | Serum | 2161.94 | MALDI-TOF | "Breast cancer, Lung cancer, Rectal cancer" | NA | 23667664 |
| CancerPDF_ID8536 | DEAGSEADHEGTHSTKRGHAKSRPV | Fibrinogen alpha | Serum | 2658.25 | MALDI-TOF | "Breast cancer, Lung cancer, Rectal cancer" | NA | 23667664 |
| CancerPDF_ID8537 | DEAGSEADHEGTHSTKRGHAKSRP | Fibrinogen alpha | Serum | 2559.18 | MALDI-TOF | "Breast cancer, Lung cancer, Rectal cancer" | NA | 23667664 |
| CancerPDF_ID8541 | EAGSEADHEGTHSTKRGHAKSRPV | Fibrinogen alpha | Serum | 2543.22 | MALDI-TOF | "Breast cancer, Lung cancer, Rectal cancer" | NA | 23667664 |
| CancerPDF_ID8542 | GSEADHEGTHSTKRGHAKSRPV | Fibrinogen alpha | Serum | 2343.14 | MALDI-TOF | "Breast cancer, Lung cancer, Rectal cancer" | NA | 23667664 |
| CancerPDF_ID8562 | GLEEELQFSLGSKINVKVGGNS | Complement C3f | Serum | 2304.2 | MALDI-TOF | "Breast cancer, Lung cancer, Rectal cancer" | NA | 23667664 |
| CancerPDF_ID8563 | DDPDAPLQPVTPLQLFEGRRN | Complement C3f | Serum | 2377.2 | MALDI-TOF | "Breast cancer, Lung cancer, Rectal cancer" | NA | 23667664 |
| CancerPDF_ID8566 | GVLSSRQLGLPGPPDVPDHAAYHPF | Inter-alpha-trypsin inhibitor heavy chain H4 | Serum | 2626.33 | MALDI-TOF | "Breast cancer, Lung cancer, Rectal cancer" | NA | 23667664 |
| CancerPDF_ID8567 | SSRQLGLPGPPDVPDHAAYHPF | Inter-alpha-trypsin inhibitor heavy chain H4 | Serum | 2357.16 | MALDI-TOF | "Breast cancer, Lung cancer, Rectal cancer" | NA | 23667664 |
| CancerPDF_ID8581 | ISASAEELRQRLAPLAEDVRGNL | Aplipoprotein A-IV | Serum | 2507.35 | MALDI-TOF | "Breast cancer, Lung cancer, Rectal cancer" | NA | 23667664 |
| CancerPDF_ID8582 | GNTEGLQKSLAELGGHLDQQVEEFR | Aplipoprotein A-IV | Serum | 2754.36 | MALDI-TOF | "Breast cancer, Lung cancer, Rectal cancer" | NA | 23667664 |
| CancerPDF_ID8586 | ALGISPFHEHAEVVFTANDSGPR | Transthyretin | Serum | 2450.2 | MALDI-TOF | "Breast cancer, Lung cancer, Rectal cancer" | NA | 23667664 |
| CancerPDF_ID8594 | LMIIVPTDTQNIFFMSKVTNPKQA | Antichymotrypsin | Serum | 2735.44 | MALDI-TOF | "Breast cancer, Lung cancer, Rectal cancer" | NA | 23667664 |
| CancerPDF_ID8595 | IIVPTDTQNIFFMSKVTNPKQA | Antichymotrypsin | Serum | 2491.31 | MALDI-TOF | "Breast cancer, Lung cancer, Rectal cancer" | NA | 23667664 |
| CancerPDF_ID8598 | LMIDQNTKSPLFMGKVVNPTQK | Alpha-1 antitrypsin | Serum | 2488.32 | MALDI-TOF | "Breast cancer, Lung cancer, Rectal cancer" | NA | 23667664 |
| CancerPDF_ID8600 | SRSGGGGGGGLGSGGSIRSSY | Cytokeratin | Serum | 1811.85 | MALDI-TOF | "Breast cancer, Lung cancer, Rectal cancer" | NA | 23667664 |
| CancerPDF_ID8612 | DEAGSEADHEGTHSTKRGHAKSRPV | Isoform 2 of fibrinogen (FGA) chain precursor | Serum | 2660.11 | MALDI-TOF | Breast cancer | Upregulated in cancer as compare to normal control with fold change of 1.5 | 26705257 |
| CancerPDF_ID8649 | MKWVTFISLLFLFSSAYSRGVFRR | Albumin peptide (N terminal fragment of protein albumin) | Cerbrospinal fluid | NA | MALDI-TOF | Glioblastoma (Malignant brain tumor) | Downregulated in cancer as compare to normal control | 19674866 |
| CancerPDF_ID8652 | RTYAGGTASATKVSASSGATSKS | NA | Peripheral Blood mononuclear cells | NA | "HPLC (Biologic HR, BioRad, Hercules, CA), Mass spectrometry" | Breast cancer | NA | 22942358 |
| CancerPDF_ID8653 | SESAAAPAFASSSSEVNPAPKFHW | NA | Peripheral Blood mononuclear cells | NA | "HPLC (Biologic HR, BioRad, Hercules, CA), Mass spectrometry" | Breast cancer | NA | 22942358 |
| CancerPDF_ID8655 | GKFYLVIEELSQLFRSLVPIQL | NA | Peripheral Blood mononuclear cells | NA | "HPLC (Biologic HR, BioRad, Hercules, CA), Mass spectrometry" | Breast cancer | NA | 22942358 |
| CancerPDF_ID8710 | APHGPGLIYRQPNCDDPETEEA | Alpha-2-HS-glycoprotein | Ascites fluid | NA | LTQ-Orbitrap XL | Ovarian cancer | Uniquely expressed in ovarian cancer patient | 24694173 |
| CancerPDF_ID8717 | ARVQQPDCREPFLSCCQFAES | Complement C4-A | Ascites fluid | NA | LTQ-Orbitrap XL | Ovarian cancer | Uniquely expressed in ovarian cancer patient | 24694173 |
| CancerPDF_ID8724 | AVGDKLPECEADDGCPKPPEIAH | Haptoglobin | Ascites fluid | NA | LTQ-Orbitrap XL | Ovarian cancer | Uniquely expressed in ovarian cancer patient | 24694173 |
| CancerPDF_ID8793 | EITRGGSTSYGTGSETESPRNPSSA | Isoform 1 of Fibrinogen alpha chain | Ascites fluid | NA | LTQ-Orbitrap XL | Ovarian cancer | Uniquely expressed in ovarian cancer patient | 24694173 |
| CancerPDF_ID8821 | EVVTSEDGSDCPEAMDLGTLSG | Isoform 1 of Fibrinogen alpha chain | Ascites fluid | NA | LTQ-Orbitrap XL | Ovarian cancer | Uniquely expressed in ovarian cancer patient | 24694173 |
| CancerPDF_ID8844 | FQTVTDYGKDLMEKVKSPELQAEA | Apolipoprotein A-II | Ascites fluid | NA | LTQ-Orbitrap XL | Ovarian cancer | Uniquely expressed in ovarian cancer patient | 24694173 |
| CancerPDF_ID8870 | GHQQGPPPPPPGKPQGPPPQG | Salivary acidic proline-rich phosphoprotein 1/2 | Ascites fluid | NA | LTQ-Orbitrap XL | Ovarian cancer | Uniquely expressed in ovarian cancer patient | 24694173 |
| CancerPDF_ID8886 | GNKPQGPPPPGKPQGPPPQGDN | Basic salivary proline-rich protein 2 | Ascites fluid | NA | LTQ-Orbitrap XL | Ovarian cancer | Uniquely expressed in ovarian cancer patient | 24694173 |
| CancerPDF_ID8887 | GNKPQGPPPPGKPQGPPPQGGS | Basic salivary proline-rich protein 2 | Ascites fluid | NA | LTQ-Orbitrap XL | Ovarian cancer | Uniquely expressed in ovarian cancer patient | 24694173 |
| CancerPDF_ID8888 | GNPEQTPVLKPEEEAPAPEVGA | Vitronectin | Ascites fluid | NA | LTQ-Orbitrap XL | Ovarian cancer | Uniquely expressed in ovarian cancer patient | 24694173 |
| CancerPDF_ID8897 | GPPLPQGPPPLLPMSCSSCQH | Histidine-rich glycoprotein | Ascites fluid | NA | LTQ-Orbitrap XL | Ovarian cancer | Uniquely expressed in ovarian cancer patient | 24694173 |
| CancerPDF_ID8935 | HGSPVDICTAKPRDIPMNPMC | Antithrombin-III | Ascites fluid | NA | LTQ-Orbitrap XL | Ovarian cancer | Uniquely expressed in ovarian cancer patient | 24694173 |
| CancerPDF_ID8979 | IPPADLSDQVPDTESETRILL | Complement C3 (Fragment) | Ascites fluid | NA | LTQ-Orbitrap XL | Ovarian cancer | Uniquely expressed in ovarian cancer patient | 24694173 |
| CancerPDF_ID8980 | IPPADLSDQVPDTESETRILLQ | Complement C3 (Fragment) | Ascites fluid | NA | LTQ-Orbitrap XL | Ovarian cancer | Uniquely expressed in ovarian cancer patient | 24694173 |
| CancerPDF_ID8981 | IPPADLSDQVPDTESETRILLQG | Complement C3 (Fragment) | Ascites fluid | NA | LTQ-Orbitrap XL | Ovarian cancer | Uniquely expressed in ovarian cancer patient | 24694173 |
| CancerPDF_ID8990 | ITRGGSTSYGTGSETESPRNPSSA | Isoform 1 of Fibrinogen alpha chain | Ascites fluid | NA | LTQ-Orbitrap XL | Ovarian cancer | Uniquely expressed in ovarian cancer patient | 24694173 |
| CancerPDF_ID9063 | LVVDNGSGMCKAGFAGDDAPR | "Actin, cytoplasmic 1" | Ascites fluid | NA | LTQ-Orbitrap XL | Ovarian cancer | Uniquely expressed in ovarian cancer patient | 24694173 |
| CancerPDF_ID9078 | MRLRCNGDNDCGDFSDEDDCES | Complement component C9 | Ascites fluid | NA | LTQ-Orbitrap XL | Ovarian cancer | Uniquely expressed in ovarian cancer patient | 24694173 |
| CancerPDF_ID9123 | NVPSGTDTGDPQSKPLGDWAA | Isoform 2 of Apolipoprotein L1 | Ascites fluid | NA | LTQ-Orbitrap XL | Ovarian cancer | Uniquely expressed in ovarian cancer patient | 24694173 |
| CancerPDF_ID9140 | PPADLSDQVPDTESETRILLQG | Complement C3 (Fragment) | Ascites fluid | NA | LTQ-Orbitrap XL | Ovarian cancer | Uniquely expressed in ovarian cancer patient | 24694173 |
| CancerPDF_ID9227 | SEETKENEGFTVTAEGKGQGTLS | Complement C3 (Fragment) | Ascites fluid | NA | LTQ-Orbitrap XL | Ovarian cancer | Uniquely expressed in ovarian cancer patient | 24694173 |
| CancerPDF_ID9247 | SLTETIEGVDAEDGHGPGEQQ | "cDNA FLJ55673, highly similar to Complement factor B" | Ascites fluid | NA | LTQ-Orbitrap XL | Ovarian cancer | Uniquely expressed in ovarian cancer patient | 24694173 |
| CancerPDF_ID9322 | TPVLKPEEEAPAPEVGASKPEG | Vitronectin | Ascites fluid | NA | LTQ-Orbitrap XL | Ovarian cancer | Uniquely expressed in ovarian cancer patient | 24694173 |
| CancerPDF_ID9323 | TPVLKPEEEAPAPEVGASKPEGID | Vitronectin | Ascites fluid | NA | LTQ-Orbitrap XL | Ovarian cancer | Uniquely expressed in ovarian cancer patient | 24694173 |
| CancerPDF_ID9356 | VDSGNDVTDIADDGCPKPPEIAH | Haptoglobin | Ascites fluid | NA | LTQ-Orbitrap XL | Ovarian cancer | Uniquely expressed in ovarian cancer patient | 24694173 |
| CancerPDF_ID9481 | NGFKSHALQLNNRQIR(NH4) | Complement C4-A/Complement C4-B | Plasma | 1913.01 | MALDI-TOF | Colorectal cancer | "Similar median ion intensity between controls and liver metastasis, and higher median ion intensity for adenoma and CRC groups." | 26379225 |
| CancerPDF_ID9489 | KREEAPSLRPAPPPISGGGYR | Fibrinogen beta chain | Plasma | 2235.21 | MALDI-TOF | Colorectal cancer | "Similar median ion intensity between controls and liver metastasis, and higher median ion intensity for adenoma and CRC groups." | 26379225 |
| CancerPDF_ID9490 | QGVNDNEEGFFSARGHRPLDK | Fibrinogen beta chain | Plasma | 2356.13 | MALDI-TOF | Colorectal cancer | "Similar median ion intensity between controls and liver metastasis, and higher median ion intensity for adenoma and CRC groups." | 26379225 |
| CancerPDF_ID9492 | GLEEELQFSLGSKINVKVGGNSK | Complement C4-A/Complement C4-B | Plasma | 2433.3 | MALDI-TOF | Colorectal cancer | "Similar median ion intensity between controls and liver metastasis, and higher median ion intensity for adenoma and CRC groups." | 26379225 |
| CancerPDF_ID9493 | SSSYSKQFTSSTSYNRGDSTFESK | Fibrinogen alpha chain | Plasma | 2681.21 | MALDI-TOF | Colorectal cancer | "Similar median ion intensity between controls and liver metastasis, and higher median ion intensity for adenoma and CRC groups." | 26379225 |
| CancerPDF_ID9512 | AVHKAVLTIDEKGTEAAGAMF | Alpha-1-antitrypsin | Serum | 725.71 | LC-MS | Lung adenocarcinoma | "Differentially expressed between earlier-stage lung cancer group (stage-I, II, and IIIa) vs normal" | 21533267 |
| CancerPDF_ID9569 | GNTEGLQKSLAELGGHLDQQVEEF | Apolipoprotein A-IV | Serum | 867.1 | LC-MS | Lung adenocarcinoma | "Differentially expressed between earlier-stage lung cancer group (stage-I, II, and IIIa) vs normal" | 21533267 |
| CancerPDF_ID9570 | GNTEGLQKSLAELGGHLDQQVEEFR | Apolipoprotein A-IV | Serum | 689.6 | LC-MS | Lung adenocarcinoma | Differentially expressed between Lung cancer vs control | 21533267 |
| CancerPDF_ID9577 | HATKTAKDALSSVQESQVAQQA | Apolipoprotein C-III | Serum | 766.73 | LC-MS | Lung adenocarcinoma | "Differentially expressed between earlier-stage lung cancer group (stage-I, II, and IIIa) vs normal" | 21533267 |
| CancerPDF_ID9585 | TVGSLAGQPLQERAQAWGERL | Apolipoprotein E | Serum | 756.38 | LC-MS | Lung adenocarcinoma | Differentially expressed between Lung cancer vs control | 21533267 |
| CancerPDF_ID9586 | AATVGSLAGQPLQERAQAWGERL | Apolipoprotein E | Serum | 803.76 | LC-MS | Lung adenocarcinoma | "Differentially expressed between earlier-stage lung cancer group (stage-I, II, and IIIa) vs normal" | 21533267 |
| CancerPDF_ID9627 | GLEEELQFSLGSKINVKVGGNS | Complement C4-B | Serum | 769.05 | LC-MS | Lung adenocarcinoma | "Differentially expressed between earlier-stage lung cancer group (stage-I, II, and IIIa) vs normal" | 21533267 |
| CancerPDF_ID9642 | VPPNNSNAAEDDLPTVELQGVVPR | Coagulation factor XIII A chain | Serum | 844.41 | LC-MS | Lung adenocarcinoma | "Differentially expressed between earlier-stage lung cancer group (stage-I, II, and IIIa) vs normal" | 21533267 |
| CancerPDF_ID9643 | AVPPNNSNAAEDDLPTVELQGVVPR | Coagulation factor XIII A chain | Serum | 868.08 | LC-MS | Lung adenocarcinoma | "Differentially expressed between earlier-stage lung cancer group (stage-I, II, and IIIa) vs normal" | 21533267 |
| CancerPDF_ID9644 | RAVPPNNSNAAEDDLPTVELQGVVPR | Coagulation factor XIII A chain | Serum | 920.12 | LC-MS | Lung adenocarcinoma | "Differentially expressed between earlier-stage lung cancer group (stage-I, II, and IIIa) vs normal" | 21533267 |
| CancerPDF_ID9648 | HTFMGVVSLGSPSGEVSHPRKT | Alpha-2-HS-glycoprotein | Serum | 578.3 | LC-MS | Lung adenocarcinoma | "Differentially expressed between earlier-stage lung cancer group (stage-I, II, and IIIa) vs normal" | 21533267 |
| CancerPDF_ID9649 | HTFMGVVSLGSPSGEVSHPRKT | Alpha-2-HS-glycoprotein | Serum | 582.3 | LC-MS | Lung adenocarcinoma | "Differentially expressed between earlier-stage lung cancer group (stage-I, II, and IIIa) vs normal" | 21533267 |
| CancerPDF_ID9696 | ADEAGSEADHEGTHSTKRGHA | Fibrinogen alpha chain | Serum | 721.63 | LC-MS | Lung adenocarcinoma | "Differentially expressed between earlier-stage lung cancer group (stage-I, II, and IIIa) vs normal" | 21533267 |
| CancerPDF_ID9698 | MADEAGSEADHEGTHSTKRGHA | Fibrinogen alpha chain | Serum | 574.25 | LC-MS | Lung adenocarcinoma | "Differentially expressed between earlier-stage lung cancer group (stage-I, II, and IIIa) vs normal" | 21533267 |
| CancerPDF_ID9699 | MADEAGSEADHEGTHSTKRGHA | Fibrinogen alpha chain | Serum | 770.65 | LC-MS | Lung adenocarcinoma | "Differentially expressed between earlier-stage lung cancer group (stage-I, II, and IIIa) vs normal" | 21533267 |
| CancerPDF_ID9700 | SYKMADEAGSEADHEGTHSTKR | Fibrinogen alpha chain | Serum | 602.52 | LC-MS | Lung adenocarcinoma | "Differentially expressed between earlier-stage lung cancer group (stage-I, II, and IIIa) vs normal" | 21533267 |
| CancerPDF_ID9701 | KMADEAGSEADHEGTHSTKRGHA | Fibrinogen alpha chain | Serum | 606.26 | LC-MS | Lung adenocarcinoma | "Differentially expressed between earlier-stage lung cancer group (stage-I, II, and IIIa) vs normal" | 21533267 |
| CancerPDF_ID9702 | KMADEAGSEADHEGTHSTKRGHA | Fibrinogen alpha chain | Serum | 610.27 | LC-MS | Lung adenocarcinoma | "Differentially expressed between earlier-stage lung cancer group (stage-I, II, and IIIa) vs normal" | 21533267 |
| CancerPDF_ID9703 | SYKMADEAGSEADHEGTHSTKRG | Fibrinogen alpha chain | Serum | 616.77 | LC-MS | Lung adenocarcinoma | "Differentially expressed between earlier-stage lung cancer group (stage-I, II, and IIIa) vs normal" | 21533267 |
| CancerPDF_ID9704 | ESKSYKMADEAGSEADHEGTHST | Fibrinogen alpha chain | Serum | 617.51 | LC-MS | Lung adenocarcinoma | "Differentially expressed between earlier-stage lung cancer group (stage-I, II, and IIIa) vs normal" | 21533267 |
| CancerPDF_ID9705 | SYKMADEAGSEADHEGTHSTKRGHA | Fibrinogen alpha chain | Serum | 668.78 | LC-MS | Lung adenocarcinoma | "Differentially expressed between earlier-stage lung cancer group (stage-I, II, and IIIa) vs normal" | 21533267 |
| CancerPDF_ID9706 | SYKMADEAGSEADHEGTHSTKRGHA | Fibrinogen alpha chain | Serum | 672.78 | LC-MS | Lung adenocarcinoma | "Differentially expressed between earlier-stage lung cancer group (stage-I, II, and IIIa) vs normal" | 21533267 |
| CancerPDF_ID9725 | SSSYSKQFTSSTSYNRGDSTF | Fibrinogen alpha chain | Serum | 779.69 | LC-MS | Lung adenocarcinoma | "Differentially expressed between earlier-stage lung cancer group (stage-I, II, and IIIa) vs normal" | 21533267 |
| CancerPDF_ID9726 | FTSSTSYNRGDSTFESKSYKM | Fibrinogen alpha chain | Serum | 606.54 | LC-MS | Lung adenocarcinoma | "Differentially expressed between earlier-stage lung cancer group (stage-I, II, and IIIa) vs normal" | 21533267 |
| CancerPDF_ID9727 | YKMADEAGSEADHEGTHSTKRGHA | Fibrinogen alpha chain | Serum | 647.04 | LC-MS | Lung adenocarcinoma | "Differentially expressed between earlier-stage lung cancer group (stage-I, II, and IIIa) vs normal" | 21533267 |
| CancerPDF_ID9755 | SYKMADEAGSEADHEGTHSTK | Fibrinogen alpha chain | Serum | 563.5 | LC-MS | Lung adenocarcinoma | "Differentially expressed between earlier-stage lung cancer group (stage-I, II, and IIIa) vs normal" | 21533267 |
| CancerPDF_ID9756 | SYKMADEAGSEADHEGTHSTK | Fibrinogen alpha chain | Serum | 567.5 | LC-MS | Lung adenocarcinoma | "Differentially expressed between earlier-stage lung cancer group (stage-I, II, and IIIa) vs normal" | 21533267 |
| CancerPDF_ID9757 | SYKMADEAGSEADHEGTHSTKR | Fibrinogen alpha chain | Serum | 606.52 | LC-MS | Lung adenocarcinoma | "Differentially expressed between earlier-stage lung cancer group (stage-I, II, and IIIa) vs normal" | 21533267 |
| CancerPDF_ID9758 | SYKMADEAGSEADHEGTHSTKRG | Fibrinogen alpha chain | Serum | 620.77 | LC-MS | Lung adenocarcinoma | "Differentially expressed between earlier-stage lung cancer group (stage-I, II, and IIIa) vs normal" | 21533267 |
| CancerPDF_ID9769 | ATASRGASQAGAPQGRVPEARPN | Gelsolin | Serum | 563.04 | LC-MS | Lung adenocarcinoma | "Differentially expressed between earlier-stage lung cancer group (stage-I, II, and IIIa) vs normal" | 21533267 |
| CancerPDF_ID9814 | PGVLSSRQLGLPGPPDVPDHAA | Inter-alpha-trypsin inhibitor heavy chain H4 | Serum | 727.39 | LC-MS | Lung adenocarcinoma | "Differentially expressed between earlier-stage lung cancer group (stage-I, II, and IIIa) vs normal" | 21533267 |
| CancerPDF_ID9815 | PGVLSSRQLGLPGPPDVPDHAAYHP | Inter-alpha-trypsin inhibitor heavy chain H4 | Serum | 645.07 | LC-MS | Lung adenocarcinoma | "Differentially expressed between earlier-stage lung cancer group (stage-I, II, and IIIa) vs normal" | 21533267 |
| CancerPDF_ID9824 | SRSGGGGGGGLGSGGSIRSSY | "Keratin, type I cytoskeletal 9" | Serum | 604.96 | LC-MS | Lung adenocarcinoma | "Differentially expressed between earlier-stage lung cancer group (stage-I, II, and IIIa) vs normal" | 21533267 |
| CancerPDF_ID9840 | DIQMTQSPSSLSASVGNRVTIT | Ig kappa chain V-I region OU | Serum | 764.73 | LC-MS | Lung adenocarcinoma | "Differentially expressed between earlier-stage lung cancer group (stage-I, II, and IIIa) vs normal" | 21533267 |
| CancerPDF_ID9842 | DIVMTQSPDSLAVSLGERATIN | Ig kappa chain V-IV region (Fragment) | Serum | 773.08 | LC-MS | Lung adenocarcinoma | "Differentially expressed between earlier-stage lung cancer group (stage-I, II, and IIIa) vs normal" | 21533267 |
| CancerPDF_ID9853 | KGPGPGGPGGAGVARGGAGGGP | Neurogranin | Serum | 563.31 | LC-MS | Lung adenocarcinoma | "Differentially expressed between earlier-stage lung cancer group (stage-I, II, and IIIa) vs normal" | 21533267 |
| CancerPDF_ID9878 | SLDRNLPSDSQDLGQHGLEED | Serglycin | Serum | 775.68 | LC-MS | Lung adenocarcinoma | "Differentially expressed between earlier-stage lung cancer group (stage-I, II, and IIIa) vs normal" | 21533267 |
| CancerPDF_ID9879 | SLDRNLPSDSQDLGQHGLEEDFM | Serglycin | Serum | 873.71 | LC-MS | Lung adenocarcinoma | "Differentially expressed between earlier-stage lung cancer group (stage-I, II, and IIIa) vs normal" | 21533267 |
| CancerPDF_ID9880 | SLDRNLPSDSQDLGQHGLEEDFM | Serglycin | Serum | 868.4 | LC-MS | Lung adenocarcinoma | "Differentially expressed between earlier-stage lung cancer group (stage-I, II, and IIIa) vs normal" | 21533267 |
| CancerPDF_ID9886 | VLEEDEEVTEEAEMEPEDKGH | Tubulin beta-1 chain | Serum | 815.37 | LC-MS | Lung adenocarcinoma | "Differentially expressed between earlier-stage lung cancer group (stage-I, II, and IIIa) vs normal" | 21533267 |
| CancerPDF_ID9888 | SVVPSPKVSDTVVEPYNATLSVH | Tubulin beta-4 chain | Serum | 809.11 | LC-MS | Lung adenocarcinoma | "Differentially expressed between earlier-stage lung cancer group (stage-I, II, and IIIa) vs normal" | 21533267 |
| CancerPDF_ID9898 | KTETQEKNPLPSKETIEQEKQAGES | Thymosin beta-4-like protein 1 | Serum | 708.12 | LC-MS | Lung adenocarcinoma | "Differentially expressed between earlier-stage lung cancer group (stage-I, II, and IIIa) vs normal" | 21533267 |
| CancerPDF_ID9909 | YTIAALLSPYSYSTTAVVTNPKE | Transthyretin | Serum | 830.43 | LC-MS | Lung adenocarcinoma | "Differentially expressed between earlier-stage lung cancer group (stage-I, II, and IIIa) vs normal" | 21533267 |
| CancerPDF_ID9910 | RYTIAALLSPYSYSTTAVVTNPKE | Transthyretin | Serum | 882.46 | LC-MS | Lung adenocarcinoma | "Differentially expressed between earlier-stage lung cancer group (stage-I, II, and IIIa) vs normal" | 21533267 |
| CancerPDF_ID9914 | EKTPKDESANQEEPEARVPAQ | Vasodilator-stimulated phosphoprotein | Serum | 785.04 | LC-MS | Lung adenocarcinoma | "Differentially expressed between earlier-stage lung cancer group (stage-I, II, and IIIa) vs normal" | 21533267 |
| CancerPDF_ID9919 | KPQGPPPQGDKSQSPRSPPGK | Basic salivary proline-rich protein 1 | Saliva | 2220.07 | MALDI-TOF | Head and neck cancer | Differentially expressed between Head and neck cancer vs control groups | 20879038 |
| CancerPDF_ID9921 | GPPPQGDNKSQSARSPPGKPQ | Basic salivary proline-rich protein 2 | Saliva | 2333.15 | MALDI-TOF | Head and neck cancer | Differentially expressed between Head and neck cancer vs control groups | 20879038 |
| CancerPDF_ID9929 | QSQGPPPHPGKPEGPPPQEGNKS | Basic salivary proline-rich protein 4 | Saliva | 2330.09 | MALDI-TOF | Head and neck cancer | Differentially expressed between Head and neck cancer vs control groups | 20879038 |
| CancerPDF_ID9930 | QSQGPPPHPGKPEGPPPQEGNKSR | Basic salivary proline-rich protein 4 | Saliva | 2486.2 | MALDI-TOF | Head and neck cancer | Differentially expressed between Head and neck cancer vs control groups | 20879038 |
| CancerPDF_ID9933 | DEAGSEADHEGTHSTKRGHAKSRPV | Fibrinogen alpha chain | Serum | NA | LC-MS | Breast cancer | Differentially expressed between cancer vs control | 21124649 |
| CancerPDF_ID9938 | SRQLGLPGPPDVPDHAAYHPF | Inter-alpha-trypsin inhibitor heavy chain H4 | Serum | NA | LC-MS | Breast cancer | NA | 21124649 |
| CancerPDF_ID9939 | SSRQLGLPGPPDVPDHAAYHPF | Inter-alpha-trypsin inhibitor heavy chain H4 | Serum | NA | LC-MS | Breast cancer | Differentially expressed between cancer vs control | 21124649 |
| CancerPDF_ID9940 | GVLSSRQLGLPGPPDVPDHAAYHPF | Inter-alpha-trypsin inhibitor heavy chain H4 | Serum | NA | LC-MS | Breast cancer | Differentially expressed between cancer vs control | 21124649 |
| CancerPDF_ID9946 | SRQLGLPGPPDVPDHAAYHPF | Inter-alpha-trypsin inhibitor heavy chain H4 | Serum | NA | LC-MS | Breast cancer | Differentially expressed between cancer vs control | 21137033 |
| CancerPDF_ID9947 | SSRQLGLPGPPDVPDHAAYHPF | Inter-alpha-trypsin inhibitor heavy chain H4 | Serum | NA | LC-MS | Breast cancer | Differentially expressed between cancer vs control | 21137033 |
| CancerPDF_ID9948 | GVLSSRQLGLPGPPDVPDHAAYHPF | Inter-alpha-trypsin inhibitor heavy chain H4 | Serum | NA | LC-MS | Breast cancer | Differentially expressed between cancer vs control | 21137033 |
| CancerPDF_ID10302 | GGAGGPGGAGAGAAAGQLDAQVG | Regulator of nonsense transcripts 1 | Urine | 1766.8079 | MALDI-TOF | Muscle-invasive bladder cancer | Differentially expressed between cancer vs normal samples | 21805675 |
| CancerPDF_ID10341 | AELGGGAGAAAVTSVLGMYAA | Iroquois-class homeodomain protein IRX-1 | Urine | 1836.8531 | MALDI-TOF | Muscle-invasive bladder cancer | Differentially expressed between cancer vs normal samples | 21805675 |
| CancerPDF_ID10342 | AAELGGGAGAAAVTSVLGMYA | Iroquois-class homeodomain protein IRX-1 | Urine | 1836.8567 | MALDI-TOF | Muscle-invasive bladder cancer | Differentially expressed between cancer vs normal samples | 21805675 |
| CancerPDF_ID10407 | SGGEGKGGSDGGGSHRKEGEE | CD99 antigen | Urine | 1973.9468 | MALDI-TOF | Muscle-invasive bladder cancer | Differentially expressed between cancer vs normal samples | 21805675 |
| CancerPDF_ID10416 | DGVSGGEGKGGSDGGGSHRKEG | CD99 antigen | Urine | 1986.8795 | MALDI-TOF | Muscle-invasive bladder cancer | Differentially expressed between cancer vs normal samples | 21805675 |
| CancerPDF_ID10430 | TSGPGPVKCGGGGGGGGEGRGAPR | Putative histone-lysine N-methyltransferase PRDM6 | Urine | 2024.9347 | MALDI-TOF | Muscle-invasive bladder cancer | Differentially expressed between cancer vs normal samples | 21805675 |
| CancerPDF_ID10449 | VSGGEGKGGSDGGGSHRKEGEE | CD99 antigen | Urine | 2072.9208 | MALDI-TOF | Muscle-invasive bladder cancer | Differentially expressed between cancer vs normal samples | 21805675 |
| CancerPDF_ID10452 | QGQGQGQGQGQGQGRRPGLVS | Mesoderm posterior protein 2 | Urine | 2079.9366 | MALDI-TOF | Muscle-invasive bladder cancer | Differentially expressed between cancer vs normal samples | 21805675 |
| CancerPDF_ID10462 | DGQPGAKGEPGDAGAKGDAGPPGP | Collagen alpha-1(I) chain | Urine | 2102.93 | MALDI-TOF | Muscle-invasive bladder cancer | Differentially expressed between cancer vs normal samples | 21805675 |
| CancerPDF_ID10473 | PGAKGEDGKDGSPGEPGANGLPGA | Collagen alpha-1(III) chain | Urine | 2134.9569 | MALDI-TOF | Muscle-invasive bladder cancer | Differentially expressed between cancer vs normal samples | 21805675 |
| CancerPDF_ID10477 | TQFSDSTVQSGGSHTALGDRS | Protein HEG homolog 1 | Urine | 2137.9761 | MALDI-TOF | Muscle-invasive bladder cancer | Differentially expressed between cancer vs normal samples | 21805675 |
| CancerPDF_ID10478 | KQGGGGGGGSVPGIERMGPGIDR | Heterogeneous nuclear ribonucleoprotein M | Urine | 2139.0212 | MALDI-TOF | Muscle-invasive bladder cancer | Differentially expressed between cancer vs normal samples | 21805675 |
| CancerPDF_ID10490 | DKKREEAPSLRPAPPPISGGG | Fibrinogen beta chain | Urine | 2159.0898 | MALDI-TOF | Muscle-invasive bladder cancer | Differentially expressed between cancer vs normal samples | 21805675 |
| CancerPDF_ID10491 | ADEAGSEADHEGTHSTKRGHA | Fibrinogen alpha chain | Urine | 2162.9476 | MALDI-TOF | Muscle-invasive bladder cancer | Differentially expressed between cancer vs normal samples | 21805675 |
| CancerPDF_ID10506 | LDGAKGDAGPAGPKGEPGSPGENGA | Collagen alpha-1(I) chain | Urine | 2206.0017 | MALDI-TOF | Muscle-invasive bladder cancer | Differentially expressed between cancer vs normal samples | 21805675 |
| CancerPDF_ID10507 | AVETLQAGQDGPGSQVDTLLRG | FLYWCH-type zinc finger-containing protein 1 | Urine | 2212.0302 | MALDI-TOF | Muscle-invasive bladder cancer | Differentially expressed between cancer vs normal samples | 21805675 |
| CancerPDF_ID10509 | KPRLLLFSPSVVHLGVPLSVG | Complement C4-A | Urine | 2215.3122 | MALDI-TOF | Muscle-invasive bladder cancer | Differentially expressed between cancer vs normal samples | 21805675 |
| CancerPDF_ID10511 | DEAGSEADHEGTHSTKRGHAK | Fibrinogen alpha chain | Urine | 2219.9969 | MALDI-TOF | Muscle-invasive bladder cancer | Differentially expressed between cancer vs normal samples | 21805675 |
| CancerPDF_ID10512 | SKEQTSVSGAQKGRKQGGSQSS | Semenogelin-1 | Urine | 2222.1067 | MALDI-TOF | Muscle-invasive bladder cancer | Differentially expressed between cancer vs normal samples | 21805675 |
| CancerPDF_ID10517 | KREEAPSLRPAPPPISGGGYR | Fibrinogen beta chain | Urine | 2235.2016 | MALDI-TOF | Muscle-invasive bladder cancer | Differentially expressed between cancer vs normal samples | 21805675 |
| CancerPDF_ID10519 | LVRGSGEGGPQGNSSAGWAVASPC | G-protein coupled receptor family C group 5 member C | Urine | 2243.9954 | MALDI-TOF | Muscle-invasive bladder cancer | Differentially expressed between cancer vs normal samples | 21805675 |
| CancerPDF_ID10520 | DGVSGGEGKGGSDGGGSHRKEGEE | CD99 antigen | Urine | 2244.9891 | MALDI-TOF | Muscle-invasive bladder cancer | Differentially expressed between cancer vs normal samples | 21805675 |
| CancerPDF_ID10522 | AVTALWGKVNVDEVGGEALGRL | Hemoglobin subunit beta | Urine | 2254.2099 | MALDI-TOF | Muscle-invasive bladder cancer | Differentially expressed between cancer vs normal samples | 21805675 |
| CancerPDF_ID10524 | SSLTETIEGVDAEDGHGPGEQQ | Complement factor B | Urine | 2256.0136 | MALDI-TOF | Muscle-invasive bladder cancer | Differentially expressed between cancer vs normal samples | 21805675 |
| CancerPDF_ID10526 | QGQGQGQGQGQGQGQGRRPGLVS | Mesoderm posterior protein 2 | Urine | 2265.0274 | MALDI-TOF | Muscle-invasive bladder cancer | Differentially expressed between cancer vs normal samples | 21805675 |
| CancerPDF_ID10527 | ERRLNSGEKDVQKGVSKGSIS | Semenogelin-2 | Urine | 2274.2031 | MALDI-TOF | Muscle-invasive bladder cancer | Differentially expressed between cancer vs normal samples | 21805675 |
| CancerPDF_ID10530 | PEILFNPSDIGIQEMGIPEAI | Actin-related protein 6 | Urine | 2283.0701 | MALDI-TOF | Muscle-invasive bladder cancer | Differentially expressed between cancer vs normal samples | 21805675 |
| CancerPDF_ID10533 | GAVEDVISRNEIQGRSAEEAY | NF-kappa-B-repressing factor | Urine | 2293.0049 | MALDI-TOF | Muscle-invasive bladder cancer | Differentially expressed between cancer vs normal samples | 21805675 |
| CancerPDF_ID10534 | AAHLPAEFTPAVHASLDKFLAS | Hemoglobin subunit alpha | Urine | 2293.2203 | MALDI-TOF | Muscle-invasive bladder cancer | Differentially expressed between cancer vs normal samples | 21805675 |
| CancerPDF_ID10536 | VSGSTGQWHSESGSFRPDSPGSG | Fibrinogen alpha chain | Urine | 2305.9893 | MALDI-TOF | Muscle-invasive bladder cancer | Differentially expressed between cancer vs normal samples | 21805675 |
| CancerPDF_ID10537 | DEAGSEADHEGTHSTKRGHAKS | Fibrinogen alpha chain | Urine | 2307.0304 | MALDI-TOF | Muscle-invasive bladder cancer | Differentially expressed between cancer vs normal samples | 21805675 |
| CancerPDF_ID10539 | SEETKENEGFTVTAEGKGQGTL | Complement C3 | Urine | 2312.0743 | MALDI-TOF | Muscle-invasive bladder cancer | Differentially expressed between cancer vs normal samples | 21805675 |
| CancerPDF_ID10541 | VAGKSQIQAPNPKQEPWHGEN | Semenogelin-1 | Urine | 2315.1321 | MALDI-TOF | Muscle-invasive bladder cancer | Differentially expressed between cancer vs normal samples | 21805675 |
| CancerPDF_ID10543 | DKKREEAPSLRPAPPPISGGGY | Fibrinogen beta chain | Urine | 2322.2307 | MALDI-TOF | Muscle-invasive bladder cancer | Differentially expressed between cancer vs normal samples | 21805675 |
| CancerPDF_ID10547 | VTLAAHLPAEFTPAVHASLDKF | Hemoglobin subunit alpha | Urine | 2335.2281 | MALDI-TOF | Muscle-invasive bladder cancer | Differentially expressed between cancer vs normal samples | 21805675 |
| CancerPDF_ID10549 | PHGQKGQHYSGQKGKQQTESK | Semenogelin-1 | Urine | 2338.1706 | MALDI-TOF | Muscle-invasive bladder cancer | Differentially expressed between cancer vs normal samples | 21805675 |
| CancerPDF_ID10552 | LSDPEQGVEVTGQYEREKAGF | Inter-alpha-trypsin inhibitor heavy chain H4 | Urine | 2339.1062 | MALDI-TOF | Muscle-invasive bladder cancer | Differentially expressed between cancer vs normal samples | 21805675 |
| CancerPDF_ID10555 | DEELGGTPVQSRVVQGKEPAHL | Gelsolin | Urine | 2346.2069 | MALDI-TOF | Muscle-invasive bladder cancer | Differentially expressed between cancer vs normal samples | 21805675 |
| CancerPDF_ID10556 | VTLDGGFIYEAGLAPYKLRPVA | Lactotransferrin precursor | Urine | 2350.2693 | MALDI-TOF | Muscle-invasive bladder cancer | Differentially expressed between cancer vs normal samples | 21805675 |
| CancerPDF_ID10557 | GTLSGIGTLDGFRHRHPDEAAF | Fibrinogen alpha chain | Urine | 2354.154 | MALDI-TOF | Muscle-invasive bladder cancer | Upregulated in cancer vs normal | 21805675 |
| CancerPDF_ID10558 | INVHLRAGYIIPLQGPGLTTTE | Lysosomal alpha-glucosidase | Urine | 2363.2925 | MALDI-TOF | Muscle-invasive bladder cancer | Differentially expressed between cancer vs normal samples | 21805675 |
| CancerPDF_ID10559 | DIQGPTKADTEKWAEGGGHSRE | Secretogranin-1 | Urine | 2369.0907 | MALDI-TOF | Muscle-invasive bladder cancer | Differentially expressed between cancer vs normal samples | 21805675 |
| CancerPDF_ID10561 | DAGLVYDAYLAPNNLKPVVAEF | Serotransferrin precursor | Urine | 2379.2047 | MALDI-TOF | Muscle-invasive bladder cancer | Differentially expressed between cancer vs normal samples | 21805675 |
| CancerPDF_ID10564 | VDLFSPEKSKLPGIVAEGRDDL | Antithrombin-III | Urine | 2385.2626 | MALDI-TOF | Muscle-invasive bladder cancer | Differentially expressed between cancer vs normal samples | 21805675 |
| CancerPDF_ID10567 | MIEQNTKSPLFMGKVVNPTQK | Alpha-1-antitrypsin | Urine | 2390.2117 | MALDI-TOF | Muscle-invasive bladder cancer | Differentially expressed between cancer vs normal samples | 21805675 |
| CancerPDF_ID10568 | PHGQKGQHYSGQKGKQQTESKG | Semenogelin-1 | Urine | 2395.182 | MALDI-TOF | Muscle-invasive bladder cancer | Differentially expressed between cancer vs normal samples | 21805675 |
| CancerPDF_ID10570 | FSQFPHGQKGQHYSGQKGKQQ | Semenogelin-1 | Urine | 2402.1471 | MALDI-TOF | Muscle-invasive bladder cancer | Differentially expressed between cancer vs normal samples | 21805675 |
| CancerPDF_ID10571 | DDILASPPRLPEPQPYPGAPHH | Collagen alpha-1(XVIII) chain | Urine | 2404.1687 | MALDI-TOF | Muscle-invasive bladder cancer | Differentially expressed between cancer vs normal samples | 21805675 |
| CancerPDF_ID10573 | VSGSTGQWHSESGSFRPDSPGSGN | Fibrinogen alpha chain | Urine | 2420.0441 | MALDI-TOF | Muscle-invasive bladder cancer | Differentially expressed between cancer vs normal samples | 21805675 |
| CancerPDF_ID10574 | VSVQPNFQQDKFLGRWFSAGL | Prostaglandin-H2 D-isomerase | Urine | 2424.244 | MALDI-TOF | Muscle-invasive bladder cancer | Differentially expressed between cancer vs normal samples | 21805675 |
| CancerPDF_ID10575 | DAHKSEVAHRFKDLGEENFKA | Serum albumin precursor | Urine | 2428.2029 | MALDI-TOF | Muscle-invasive bladder cancer | Upregulated in cancer vs normal | 21805675 |
| CancerPDF_ID10577 | APEAQVSVQPNFQQDKFLGRW | Prostaglandin-H2 D-isomerase | Urine | 2445.2213 | MALDI-TOF | Muscle-invasive bladder cancer | Differentially expressed between cancer vs normal samples | 21805675 |
| CancerPDF_ID10578 | NGFKSHALQLNNRQIRGLEEE | Complement C4-A | Urine | 2453.2529 | MALDI-TOF | Muscle-invasive bladder cancer | Differentially expressed between cancer vs normal samples | 21805675 |
| CancerPDF_ID10579 | SALTSDNHGATYAFSGTHYWRL | Hemopexin | Urine | 2455.1245 | MALDI-TOF | Muscle-invasive bladder cancer | Differentially expressed between cancer vs normal samples | 21805675 |
| CancerPDF_ID10580 | EVDLLKNGERIEKVEHSDLSF | Beta-2-microglobulin | Urine | 2457.2621 | MALDI-TOF | Muscle-invasive bladder cancer | Differentially expressed between cancer vs normal samples | 21805675 |
| CancerPDF_ID10582 | VLSPADKTNVKAAWGKVGAHAGEY | Hemoglobin subunit alpha | Urine | 2469.2832 | MALDI-TOF | Muscle-invasive bladder cancer | Differentially expressed between cancer vs normal samples | 21805675 |
| CancerPDF_ID10583 | IYTGLSKHVEDVPAFQALGSLND | Zinc-alpha-2-glycoprotein | Urine | 2474.2609 | MALDI-TOF | Muscle-invasive bladder cancer | Differentially expressed between cancer vs normal samples | 21805675 |
| CancerPDF_ID10584 | AAHLPAEFTPAVHASLDKFLASVS | Hemoglobin subunit alpha | Urine | 2479.2756 | MALDI-TOF | Muscle-invasive bladder cancer | Upregulated in cancer vs normal | 21805675 |
| CancerPDF_ID10585 | PHGQKGQHYSGQKGKQQTESKGS | Semenogelin-1 | Urine | 2482.2283 | MALDI-TOF | Muscle-invasive bladder cancer | Differentially expressed between cancer vs normal samples | 21805675 |
| CancerPDF_ID10587 | IAVEWESNGQPENNYKTTPPVL | Ig gamma-1 chain C region | Urine | 2486.2068 | MALDI-TOF | Muscle-invasive bladder cancer | Differentially expressed between cancer vs normal samples | 21805675 |
| CancerPDF_ID10588 | AQYLQQCPFEDHVKLVNEVTE | Serum albumin precursor | Urine | 2490.1956 | MALDI-TOF | Muscle-invasive bladder cancer | Differentially expressed between cancer vs normal samples | 21805675 |
| CancerPDF_ID10589 | IAFAQYLQQCPFEDHVKLVNE | Serum albumin precursor | Urine | 2492.2137 | MALDI-TOF | Muscle-invasive bladder cancer | Differentially expressed between cancer vs normal samples | 21805675 |
| CancerPDF_ID10590 | VREDRGGRRVHRFQSPAGTEAL | Alpha-1B-glycoprotein | Urine | 2494.3016 | MALDI-TOF | Muscle-invasive bladder cancer | Differentially expressed between cancer vs normal samples | 21805675 |
| CancerPDF_ID10591 | LMIEQNTKSPLFMGKVVNPTQK | Alpha-1-antitrypsin | Urine | 2503.3475 | MALDI-TOF | Muscle-invasive bladder cancer | Differentially expressed between cancer vs normal samples | 21805675 |
| CancerPDF_ID10592 | LLRREGDHEFLEVPEAQEDVE | Alpha-1B-glycoprotein | Urine | 2510.2191 | MALDI-TOF | Muscle-invasive bladder cancer | Differentially expressed between cancer vs normal samples | 21805675 |
| CancerPDF_ID10593 | FLSSLTETIEGVDAEDGHGPGEQQ | Complement factor B | Urine | 2516.1478 | MALDI-TOF | Muscle-invasive bladder cancer | Differentially expressed between cancer vs normal samples | 21805675 |
| CancerPDF_ID10594 | YFAGGDAGDAFDGFDFGDDPSDKF | Fibrinogen gamma chain precursor | Urine | 2533.0019 | MALDI-TOF | Muscle-invasive bladder cancer | Differentially expressed between cancer vs normal samples | 21805675 |
| CancerPDF_ID10595 | DAHKSEVAHRFKDLGEENFKAL | Serum albumin precursor | Urine | 2541.2328 | MALDI-TOF | Muscle-invasive bladder cancer | Differentially expressed between cancer vs normal samples | 21805675 |
| CancerPDF_ID10597 | SELHCDKLHVDPENFRLLGNVL | Hemoglobin subunit beta | Urine | 2548.2929 | MALDI-TOF | Muscle-invasive bladder cancer | Differentially expressed between cancer vs normal samples | 21805675 |
| CancerPDF_ID10598 | FAVYDQSATALHFLGRVANPLSTA | Angiotensinogen | Urine | 2549.3048 | MALDI-TOF | Muscle-invasive bladder cancer | Differentially expressed between cancer vs normal samples | 21805675 |
| CancerPDF_ID10599 | DEAGSEADHEGTHSTKRGHAKSRP | Fibrinogen alpha chain | Urine | 2560.1784 | MALDI-TOF | Muscle-invasive bladder cancer | Differentially expressed between cancer vs normal samples | 21805675 |
| CancerPDF_ID10600 | HKSEVAHRFKDLGEENFKALVL | Serum albumin precursor | Urine | 2567.3749 | MALDI-TOF | Muscle-invasive bladder cancer | Differentially expressed between cancer vs normal samples | 21805675 |
| CancerPDF_ID10601 | FKKNWIQYKEGFGHLSPTGTTE | Fibrinogen gamma chain precursor | Urine | 2568.2859 | MALDI-TOF | Muscle-invasive bladder cancer | Differentially expressed between cancer vs normal samples | 21805675 |
| CancerPDF_ID10602 | IEVDLLKNGERIEKVEHSDLSF | Beta-2-microglobulin | Urine | 2570.3442 | MALDI-TOF | Muscle-invasive bladder cancer | Differentially expressed between cancer vs normal samples | 21805675 |
| CancerPDF_ID10603 | IQRTPKIQVYSRHPAENGKSNF | Beta-2-microglobulin | Urine | 2570.3511 | MALDI-TOF | Muscle-invasive bladder cancer | Differentially expressed between cancer vs normal samples | 21805675 |
| CancerPDF_ID10604 | SQFPHGQKGQHYSGQKGKQQTES | Semenogelin-1 | Urine | 2572.2139 | MALDI-TOF | Muscle-invasive bladder cancer | Differentially expressed between cancer vs normal samples | 21805675 |
| CancerPDF_ID10605 | EDPQGDAAQKTDTSHHDQDHPTF | Alpha-1-antitrypsin | Urine | 2577.0808 | MALDI-TOF | Muscle-invasive bladder cancer | Differentially expressed between cancer vs normal samples | 21805675 |
| CancerPDF_ID10606 | DVSSALDKLKEFGNTLEDKAREL | Apolipoprotein C-I | Urine | 2578.3322 | MALDI-TOF | Muscle-invasive bladder cancer | Differentially expressed between cancer vs normal samples | 21805675 |
| CancerPDF_ID10607 | LRSEETKENEGFTVTAEGKGQGTL | Complement C3 | Urine | 2581.2753 | MALDI-TOF | Muscle-invasive bladder cancer | Differentially expressed between cancer vs normal samples | 21805675 |
| CancerPDF_ID10609 | AFLSSLTETIEGVDAEDGHGPGEQQ | Complement factor B | Urine | 2587.1776 | MALDI-TOF | Muscle-invasive bladder cancer | Differentially expressed between cancer vs normal samples | 21805675 |
| CancerPDF_ID10610 | AYFAGGDAGDAFDGFDFGDDPSDKF | Fibrinogen gamma chain precursor | Urine | 2604.0364 | MALDI-TOF | Muscle-invasive bladder cancer | Differentially expressed between cancer vs normal samples | 21805675 |
| CancerPDF_ID10611 | LKNGERIEKVEHSDLSFSKDWS | Beta-2-microglobulin | Urine | 2604.2965 | MALDI-TOF | Muscle-invasive bladder cancer | Differentially expressed between cancer vs normal samples | 21805675 |
| CancerPDF_ID10612 | VTLAAHLPAEFTPAVHASLDKFLAS | Hemoglobin subunit alpha | Urine | 2606.3727 | MALDI-TOF | Muscle-invasive bladder cancer | Differentially expressed between cancer vs normal samples | 21805675 |
| CancerPDF_ID10613 | HEVAQDDHLTQQYNEDRNPIST | Semenogelin-2 | Urine | 2610.2222 | MALDI-TOF | Muscle-invasive bladder cancer | Differentially expressed between cancer vs normal samples | 21805675 |
| CancerPDF_ID10614 | AQVSVQPNFQQDKFLGRWFSAGL | Prostaglandin-H2 D-isomerase | Urine | 2623.3379 | MALDI-TOF | Muscle-invasive bladder cancer | Differentially expressed between cancer vs normal samples | 21805675 |
| CancerPDF_ID10615 | HTVHFHGHSFQYKHRGVYSSDV | Ceruloplasmin | Urine | 2625.2474 | MALDI-TOF | Muscle-invasive bladder cancer | Differentially expressed between cancer vs normal samples | 21805675 |
| CancerPDF_ID10616 | KDFLKKHNLNPARKYFPQWEA | Pepsin A | Urine | 2630.3959 | MALDI-TOF | Muscle-invasive bladder cancer | Differentially expressed between cancer vs normal samples | 21805675 |
| CancerPDF_ID10617 | FAQYLQQCPFEDHVKLVNEVTE | Serum albumin precursor | Urine | 2637.2685 | MALDI-TOF | Muscle-invasive bladder cancer | Differentially expressed between cancer vs normal samples | 21805675 |
| CancerPDF_ID10618 | AHKSEVAHRFKDLGEENFKALVL | Serum albumin precursor | Urine | 2638.407 | MALDI-TOF | Muscle-invasive bladder cancer | Differentially expressed between cancer vs normal samples | 21805675 |
| CancerPDF_ID10619 | IQTEEQIHGKSQNQVRIPSQAQE | Semenogelin-2 | Urine | 2648.3281 | MALDI-TOF | Muscle-invasive bladder cancer | Differentially expressed between cancer vs normal samples | 21805675 |
| CancerPDF_ID10620 | SDLHAHKLRVDPVNFKLLSHCLL | Hemoglobin subunit alpha | Urine | 2655.4468 | MALDI-TOF | Muscle-invasive bladder cancer | Differentially expressed between cancer vs normal samples | 21805675 |
| CancerPDF_ID10621 | VDLLKNGERIEKVEHSDLSFSKD | Beta-2-microglobulin | Urine | 2658.3742 | MALDI-TOF | Muscle-invasive bladder cancer | Differentially expressed between cancer vs normal samples | 21805675 |
| CancerPDF_ID10622 | AQLDEELGGTPVQSRVVQGKEPAHL | Gelsolin | Urine | 2658.381 | MALDI-TOF | Muscle-invasive bladder cancer | Differentially expressed between cancer vs normal samples | 21805675 |
| CancerPDF_ID10623 | DEAGSEADHEGTHSTKRGHAKSRPV | Fibrinogen alpha chain | Urine | 2659.2521 | MALDI-TOF | Muscle-invasive bladder cancer | Differentially expressed between cancer vs normal samples | 21805675 |
| CancerPDF_ID10624 | EAHDAQGDVPVTVTVHDFPGKKLVL | Complement C3 | Urine | 2672.4004 | MALDI-TOF | Muscle-invasive bladder cancer | Differentially expressed between cancer vs normal samples | 21805675 |
| CancerPDF_ID10625 | ALVREDRGGRRVHRFQSPAGTEAL | Alpha-1B-glycoprotein | Urine | 2678.4265 | MALDI-TOF | Muscle-invasive bladder cancer | Differentially expressed between cancer vs normal samples | 21805675 |
| CancerPDF_ID10626 | IWELLNQAQEHFGKDKSKEFQL | Serotransferrin precursor | Urine | 2688.382 | MALDI-TOF | Muscle-invasive bladder cancer | Differentially expressed between cancer vs normal samples | 21805675 |
| CancerPDF_ID10628 | LSHEQKGRYKQESSESHNIVITE | Semenogelin-2 | Urine | 2699.3305 | MALDI-TOF | Muscle-invasive bladder cancer | Differentially expressed between cancer vs normal samples | 21805675 |
| CancerPDF_ID10629 | EALKENGGARLAEYHAKATEHLSTL | Apolipoprotein A-I | Urine | 2709.3978 | MALDI-TOF | Muscle-invasive bladder cancer | Differentially expressed between cancer vs normal samples | 21805675 |
| CancerPDF_ID10630 | FKIDNVKKARVQVVAGKKYFIDF | Kininogen-1 | Urine | 2713.547 | MALDI-TOF | Muscle-invasive bladder cancer | Differentially expressed between cancer vs normal samples | 21805675 |
| CancerPDF_ID10634 | VVDPKSKEEDKHLKFRISHELDS | Osteopontin | Urine | 2736.4296 | MALDI-TOF | Muscle-invasive bladder cancer | Differentially expressed between cancer vs normal samples | 21805675 |
| CancerPDF_ID10635 | IPVKQADSGSSEEKQLYNKYPDAVA | Osteopontin | Urine | 2737.3666 | MALDI-TOF | Muscle-invasive bladder cancer | Differentially expressed between cancer vs normal samples | 21805675 |
| CancerPDF_ID10636 | LHTVHFHGHSFQYKHRGVYSSDV | Ceruloplasmin | Urine | 2738.3413 | MALDI-TOF | Muscle-invasive bladder cancer | Differentially expressed between cancer vs normal samples | 21805675 |
| CancerPDF_ID10637 | VAIDYINQNLPWGYKHTLNQIDE | Alpha-2-HS-glycoprotein | Urine | 2744.3252 | MALDI-TOF | Muscle-invasive bladder cancer | Differentially expressed between cancer vs normal samples | 21805675 |
| CancerPDF_ID10638 | LKNGERIEKVEHSDLSFSKDWSF | Beta-2-microglobulin | Urine | 2751.4089 | MALDI-TOF | Muscle-invasive bladder cancer | Differentially expressed between cancer vs normal samples | 21805675 |
| CancerPDF_ID10639 | DAHKSEVAHRFKDLGEENFKALVL | Serum albumin precursor | Urine | 2753.4445 | MALDI-TOF | Muscle-invasive bladder cancer | Upregulated in cancer vs normal | 21805675 |
| CancerPDF_ID10641 | LSDLHAHKLRVDPVNFKLLSHCLL | Hemoglobin subunit alpha | Urine | 2768.5407 | MALDI-TOF | Muscle-invasive bladder cancer | Differentially expressed between cancer vs normal samples | 21805675 |
| CancerPDF_ID10642 | IMYKVPLIRKKSLRRTLSERGLL | Pepsin A-3 | Urine | 2770.6958 | MALDI-TOF | Muscle-invasive bladder cancer | Differentially expressed between cancer vs normal samples | 21805675 |
| CancerPDF_ID10643 | TPDVSSALDKLKEFGNTLEDKAREL | Apolipoprotein C-I | Urine | 2776.4278 | MALDI-TOF | Muscle-invasive bladder cancer | Differentially expressed between cancer vs normal samples | 21805675 |
| CancerPDF_ID10645 | EVDLLKNGERIEKVEHSDLSFSKD | Beta-2-microglobulin | Urine | 2787.4383 | MALDI-TOF | Muscle-invasive bladder cancer | Differentially expressed between cancer vs normal samples | 21805675 |
| CancerPDF_ID10648 | FKDSAHGFLKVPPRMDAKMYLGYE | Serotransferrin precursor | Urine | 2800.401 | MALDI-TOF | Muscle-invasive bladder cancer | Differentially expressed between cancer vs normal samples | 21805675 |
| CancerPDF_ID10650 | IAFAQYLQQCPFEDHVKLVNEVTE | Serum albumin precursor | Urine | 2821.3731 | MALDI-TOF | Muscle-invasive bladder cancer | Differentially expressed between cancer vs normal samples | 21805675 |
| CancerPDF_ID10652 | DLLKNGERIEKVEHSDLSFSKDWS | Beta-2-microglobulin | Urine | 2832.4203 | MALDI-TOF | Muscle-invasive bladder cancer | Differentially expressed between cancer vs normal samples | 21805675 |
| CancerPDF_ID10653 | ATLSELHCDKLHVDPENFRLLGNVL | Hemoglobin subunit beta | Urine | 2833.4663 | MALDI-TOF | Muscle-invasive bladder cancer | Differentially expressed between cancer vs normal samples | 21805675 |
| CancerPDF_ID10655 | LVVDPKSKEEDKHLKFRISHELDS | Osteopontin | Urine | 2849.4889 | MALDI-TOF | Muscle-invasive bladder cancer | Differentially expressed between cancer vs normal samples | 21805675 |
| CancerPDF_ID10658 | LLKNGERIEKVEHSDLSFSKDWSF | Beta-2-microglobulin | Urine | 2864.4666 | MALDI-TOF | Muscle-invasive bladder cancer | Differentially expressed between cancer vs normal samples | 21805675 |
| CancerPDF_ID10660 | YLAPNNLKPVVAEFYGSKEDPQTFY | Serotransferrin precursor | Urine | 2890.4384 | MALDI-TOF | Muscle-invasive bladder cancer | Differentially expressed between cancer vs normal samples | 21805675 |
| CancerPDF_ID10662 | IEVDLLKNGERIEKVEHSDLSFSKD | Beta-2-microglobulin | Urine | 2900.512 | MALDI-TOF | Muscle-invasive bladder cancer | Differentially expressed between cancer vs normal samples | 21805675 |
| CancerPDF_ID10675 | LKNGERIEKVEHSDLSFSKDWSFYL | Beta-2-microglobulin | Urine | 3027.5298 | MALDI-TOF | Muscle-invasive bladder cancer | Differentially expressed between cancer vs normal samples | 21805675 |
| CancerPDF_ID10677 | LNNFYPREAKVQWKVDNALQSGNSQE | Ig kappa chain C region | Urine | 3035.4949 | MALDI-TOF | Muscle-invasive bladder cancer | Differentially expressed between cancer vs normal samples | 21805675 |
| CancerPDF_ID10833 | APGAPGGKGDAGAPGERGPPG | Collagen alpha-1(III) chain | Urine | 1836.85 | MALDI-TOF | Muscle-invasive bladder cancer | Differentially expressed between cancer vs normal samples | 21805675 |
| CancerPDF_ID10834 | APGGKGDAGAPGERGPPGLAG | Collagen alpha-1(III) chain | Urine | 1836.8793 | MALDI-TOF | Muscle-invasive bladder cancer | Differentially expressed between cancer vs normal samples | 21805675 |
| CancerPDF_ID10836 | DAGPAGPKGEPGSPGENGAPG | Collagen alpha-1(I) chain | Urine | 1866.8102 | MALDI-TOF | Muscle-invasive bladder cancer | Differentially expressed between cancer vs normal samples | 21805675 |
| CancerPDF_ID10839 | GAPGAPGGKGDAGAPGERGPPG | Collagen alpha-1(III) chain | Urine | 1893.8628 | MALDI-TOF | Muscle-invasive bladder cancer | Differentially expressed between cancer vs normal samples | 21805675 |
| CancerPDF_ID10844 | EEGKRGPNGEAGSAGPPGPPG | Collagen alpha-2(I) chain | Urine | 1949.8923 | MALDI-TOF | Muscle-invasive bladder cancer | Differentially expressed between cancer vs normal samples | 21805675 |
| CancerPDF_ID10848 | EPGGKGERGAPGEKGEGGPPG | Collagen alpha-1(III) chain | Urine | 1967.9029 | MALDI-TOF | Muscle-invasive bladder cancer | Differentially expressed between cancer vs normal samples | 21805675 |
| CancerPDF_ID10852 | EGSPGRDGSPGAKGDRGETGP | Collagen alpha-1(I) chain | Urine | 2015.9013 | MALDI-TOF | Muscle-invasive bladder cancer | Differentially expressed between cancer vs normal samples | 21805675 |
| CancerPDF_ID10853 | GIPGEKGPAGERGAPGPAGPRG | Collagen alpha-1(III) chain | Urine | 2017.0132 | MALDI-TOF | Muscle-invasive bladder cancer | Differentially expressed between cancer vs normal samples | 21805675 |
| CancerPDF_ID10854 | GEPGGKGERGAPGEKGEGGPPG | Collagen alpha-1(III) chain | Urine | 2024.9347 | MALDI-TOF | Muscle-invasive bladder cancer | Differentially expressed between cancer vs normal samples | 21805675 |
| CancerPDF_ID10855 | SEGSPGHPGQPGPPGPPGAPGP | Collagen alpha-1(III) chain | Urine | 2026.856 | MALDI-TOF | Muscle-invasive bladder cancer | Differentially expressed between cancer vs normal samples | 21805675 |
| CancerPDF_ID10856 | PPGEAGKPGEQGVPGDLGAPGP | Collagen alpha-1(I) chain | Urine | 2047.9459 | MALDI-TOF | Muscle-invasive bladder cancer | Differentially expressed between cancer vs normal samples | 21805675 |
| CancerPDF_ID10857 | NGDDGEAGKPGRPGERGPPGP | Collagen alpha-1(I) chain | Urine | 2048.9342 | MALDI-TOF | Muscle-invasive bladder cancer | Differentially expressed between cancer vs normal samples | 21805675 |
| CancerPDF_ID10858 | DAGAPGAPGGKGDAGAPGERGPPG | Collagen alpha-1(III) chain | Urine | 2063.9189 | MALDI-TOF | Muscle-invasive bladder cancer | Differentially expressed between cancer vs normal samples | 21805675 |
| CancerPDF_ID10859 | NGDDGEAGKPGRPGERGPPGP | Collagen alpha-1(I) chain | Urine | 2064.9331 | MALDI-TOF | Muscle-invasive bladder cancer | Differentially expressed between cancer vs normal samples | 21805675 |
| CancerPDF_ID10860 | DAGAPGAPGGKGDAGAPGERGPPG | Collagen alpha-1(III) chain | Urine | 2079.9266 | MALDI-TOF | Muscle-invasive bladder cancer | Differentially expressed between cancer vs normal samples | 21805675 |
| CancerPDF_ID10862 | EGSPGRDGSPGAKGDRGETGPA | Collagen alpha-1(I) chain | Urine | 2086.9368 | MALDI-TOF | Muscle-invasive bladder cancer | Differentially expressed between cancer vs normal samples | 21805675 |
| CancerPDF_ID10863 | GAPGNDGAKGDAGAPGAPGSQGAPG | Collagen alpha-1(I) chain | Urine | 2097.9094 | MALDI-TOF | Muscle-invasive bladder cancer | Differentially expressed between cancer vs normal samples | 21805675 |
| CancerPDF_ID10864 | PPGKAGEDGHPGKPGRPGERG | Collagen alpha-2(I) chain | Urine | 2101.0124 | MALDI-TOF | Muscle-invasive bladder cancer | Differentially expressed between cancer vs normal samples | 21805675 |
| CancerPDF_ID10865 | GPPGEAGKPGEQGVPGDLGAPGP | Collagen alpha-1(I) chain | Urine | 2104.972 | MALDI-TOF | Muscle-invasive bladder cancer | Differentially expressed between cancer vs normal samples | 21805675 |
| CancerPDF_ID10866 | PPGKAGEDGHPGKPGRPGERG | Collagen alpha-2(I) chain | Urine | 2117.0065 | MALDI-TOF | Muscle-invasive bladder cancer | Differentially expressed between cancer vs normal samples | 21805675 |
| CancerPDF_ID10867 | DGQPGAKGEPGDAGAKGDAGPPGP | Collagen alpha-1(I) chain | Urine | 2118.9623 | MALDI-TOF | Muscle-invasive bladder cancer | Differentially expressed between cancer vs normal samples | 21805675 |
| CancerPDF_ID10868 | DGKTGPPGPAGQDGRPGPPGPPG | Collagen alpha-1(I) chain | Urine | 2129.9647 | MALDI-TOF | Muscle-invasive bladder cancer | Differentially expressed between cancer vs normal samples | 21805675 |
| CancerPDF_ID10869 | NGIPGEKGPAGERGAPGPAGPRG | Collagen alpha-1(III) chain | Urine | 2131.0582 | MALDI-TOF | Muscle-invasive bladder cancer | Differentially expressed between cancer vs normal samples | 21805675 |
| CancerPDF_ID10870 | GRDGNPGNDGPPGRDGQPGHK | Collagen alpha-2(I) chain | Urine | 2132.9349 | MALDI-TOF | Muscle-invasive bladder cancer | Differentially expressed between cancer vs normal samples | 21805675 |
| CancerPDF_ID10871 | DGQPGAKGEPGDAGAKGDAGPPGP | Collagen alpha-1(I) chain | Urine | 2134.9677 | MALDI-TOF | Muscle-invasive bladder cancer | Differentially expressed between cancer vs normal samples | 21805675 |
| CancerPDF_ID10872 | GDAGAPGAPGGKGDAGAPGERGPPG | Collagen alpha-1(III) chain | Urine | 2136.9478 | MALDI-TOF | Muscle-invasive bladder cancer | Differentially expressed between cancer vs normal samples | 21805675 |
| CancerPDF_ID10873 | NGEPGGKGERGAPGEKGEGGPPG | Collagen alpha-1(III) chain | Urine | 2138.9753 | MALDI-TOF | Muscle-invasive bladder cancer | Differentially expressed between cancer vs normal samples | 21805675 |
| CancerPDF_ID10874 | NGIPGEKGPAGERGAPGPAGPRG | Collagen alpha-1(III) chain | Urine | 2147.0405 | MALDI-TOF | Muscle-invasive bladder cancer | Differentially expressed between cancer vs normal samples | 21805675 |
| CancerPDF_ID10875 | DGQPGAKGEPGDAGAKGDAGPPGP | Collagen alpha-1(I) chain | Urine | 2150.9347 | MALDI-TOF | Muscle-invasive bladder cancer | Differentially expressed between cancer vs normal samples | 21805675 |
| CancerPDF_ID10877 | NGEPGGKGERGAPGEKGEGGPPG | Collagen alpha-1(III) chain | Urine | 2154.9697 | MALDI-TOF | Muscle-invasive bladder cancer | Differentially expressed between cancer vs normal samples | 21805675 |
| CancerPDF_ID10878 | NSGEPGAPGSKGDTGAKGEPGPVG | Collagen alpha-1(I) chain | Urine | 2154.9723 | MALDI-TOF | Muscle-invasive bladder cancer | Differentially expressed between cancer vs normal samples | 21805675 |
| CancerPDF_ID10879 | AEGSPGRDGSPGAKGDRGETGPA | Collagen alpha-1(I) chain | Urine | 2157.9725 | MALDI-TOF | Muscle-invasive bladder cancer | Differentially expressed between cancer vs normal samples | 21805675 |
| CancerPDF_ID10880 | GPPGKAGEDGHPGKPGRPGERG | Collagen alpha-2(I) chain | Urine | 2158.0406 | MALDI-TOF | Muscle-invasive bladder cancer | Differentially expressed between cancer vs normal samples | 21805675 |
| CancerPDF_ID10881 | AGPPGEAGKPGEQGVPGDLGAPGP | Collagen alpha-1(I) chain | Urine | 2160.0021 | MALDI-TOF | Muscle-invasive bladder cancer | Differentially expressed between cancer vs normal samples | 21805675 |
| CancerPDF_ID10882 | SDGQPGPPGPPGTAGFPGSPGAKG | Collagen alpha-1(III) chain | Urine | 2169.9663 | MALDI-TOF | Muscle-invasive bladder cancer | Differentially expressed between cancer vs normal samples | 21805675 |
| CancerPDF_ID10883 | NSGEPGAPGSKGDTGAKGEPGPVG | Collagen alpha-1(I) chain | Urine | 2170.9735 | MALDI-TOF | Muscle-invasive bladder cancer | Differentially expressed between cancer vs normal samples | 21805675 |
| CancerPDF_ID10884 | PGAAEGGAARTAGGMAVAGTATGPR | Protein FAM71B | Urine | 2171.0578 | MALDI-TOF | Muscle-invasive bladder cancer | Differentially expressed between cancer vs normal samples | 21805675 |
| CancerPDF_ID10885 | GPPGKAGEDGHPGKPGRPGERG | Collagen alpha-2(I) chain | Urine | 2174.0264 | MALDI-TOF | Muscle-invasive bladder cancer | Differentially expressed between cancer vs normal samples | 21805675 |
| CancerPDF_ID10886 | AGPPGEAGKPGEQGVPGDLGAPGP | Collagen alpha-1(I) chain | Urine | 2176.0067 | MALDI-TOF | Muscle-invasive bladder cancer | Differentially expressed between cancer vs normal samples | 21805675 |
| CancerPDF_ID10887 | ADGQPGAKGEPGDAGAKGDAGPPGP | Collagen alpha-1(I) chain | Urine | 2189.9958 | MALDI-TOF | Muscle-invasive bladder cancer | Differentially expressed between cancer vs normal samples | 21805675 |
| CancerPDF_ID10888 | NDGAPGKNGERGGPGGPGPQGPPG | Collagen alpha-1(III) chain | Urine | 2190.9709 | MALDI-TOF | Muscle-invasive bladder cancer | Differentially expressed between cancer vs normal samples | 21805675 |
| CancerPDF_ID10889 | NGDDGEAGKPGRPGERGPPGPQ | Collagen alpha-1(I) chain | Urine | 2192.9891 | MALDI-TOF | Muscle-invasive bladder cancer | Differentially expressed between cancer vs normal samples | 21805675 |
| CancerPDF_ID10890 | NDGPPGRDGQPGHKGERGYPG | Collagen alpha-2(I) chain | Urine | 2195.9632 | MALDI-TOF | Muscle-invasive bladder cancer | Differentially expressed between cancer vs normal samples | 21805675 |
| CancerPDF_ID10891 | ADGQPGAKGEPGDAGAKGDAGPPGP | Collagen alpha-1(I) chain | Urine | 2206.0017 | MALDI-TOF | Muscle-invasive bladder cancer | Differentially expressed between cancer vs normal samples | 21805675 |
| CancerPDF_ID10894 | ADGQPGAKGEPGDAGAKGDAGPPGP | Collagen alpha-1(I) chain | Urine | 2221.9847 | MALDI-TOF | Muscle-invasive bladder cancer | Differentially expressed between cancer vs normal samples | 21805675 |
| CancerPDF_ID10895 | GNSGEPGAPGSKGDTGAKGEPGPVG | Collagen alpha-1(I) chain | Urine | 2227.9964 | MALDI-TOF | Muscle-invasive bladder cancer | Differentially expressed between cancer vs normal samples | 21805675 |
| CancerPDF_ID10896 | AGPPGKAGEDGHPGKPGRPGERG | Collagen alpha-2(I) chain | Urine | 2229.0674 | MALDI-TOF | Muscle-invasive bladder cancer | Differentially expressed between cancer vs normal samples | 21805675 |
| CancerPDF_ID10897 | NGDDGEAGKPGRPGERGPPGPQG | Collagen alpha-1(I) chain | Urine | 2234.0037 | MALDI-TOF | Muscle-invasive bladder cancer | Differentially expressed between cancer vs normal samples | 21805675 |
| CancerPDF_ID10898 | GRTGDAGPVGPPGPPGPPGPPGPPS | Collagen alpha-1(I) chain | Urine | 2236.054 | MALDI-TOF | Muscle-invasive bladder cancer | Differentially expressed between cancer vs normal samples | 21805675 |
| CancerPDF_ID10899 | AGPPGKAGEDGHPGKPGRPGERG | Collagen alpha-2(I) chain | Urine | 2245.0637 | MALDI-TOF | Muscle-invasive bladder cancer | Differentially expressed between cancer vs normal samples | 21805675 |
| CancerPDF_ID10901 | DGNPGNDGPPGRDGQPGHKGER | Collagen alpha-2(I) chain | Urine | 2261.9931 | MALDI-TOF | Muscle-invasive bladder cancer | Differentially expressed between cancer vs normal samples | 21805675 |
| CancerPDF_ID10904 | QNGEPGGKGERGAPGEKGEGGPPG | Collagen alpha-1(III) chain | Urine | 2267.0218 | MALDI-TOF | Muscle-invasive bladder cancer | Differentially expressed between cancer vs normal samples | 21805675 |
| CancerPDF_ID10908 | QNGEPGGKGERGAPGEKGEGGPPG | Collagen alpha-1(III) chain | Urine | 2283.0055 | MALDI-TOF | Muscle-invasive bladder cancer | Differentially expressed between cancer vs normal samples | 21805675 |
| CancerPDF_ID10911 | GRDGNPGNDGPPGRDGQPGHKGE | Collagen alpha-2(I) chain | Urine | 2319.0397 | MALDI-TOF | Muscle-invasive bladder cancer | Differentially expressed between cancer vs normal samples | 21805675 |
| CancerPDF_ID10914 | GQNGEPGGKGERGAPGEKGEGGPPG | Collagen alpha-1(III) chain | Urine | 2324.0398 | MALDI-TOF | Muscle-invasive bladder cancer | Differentially expressed between cancer vs normal samples | 21805675 |
| CancerPDF_ID10915 | EAGRDGNPGNDGPPGRDGQPGHK | Collagen alpha-2(I) chain | Urine | 2333.0224 | MALDI-TOF | Muscle-invasive bladder cancer | Differentially expressed between cancer vs normal samples | 21805675 |
| CancerPDF_ID10920 | KNGDDGEAGKPGRPGERGPPGPQG | Collagen alpha-1(I) chain | Urine | 2362.0988 | MALDI-TOF | Muscle-invasive bladder cancer | Differentially expressed between cancer vs normal samples | 21805675 |
| CancerPDF_ID10921 | ERGSEGSPGHPGQPGPPGPPGAPGP | Collagen alpha-1(III) chain | Urine | 2369.0258 | MALDI-TOF | Muscle-invasive bladder cancer | Differentially expressed between cancer vs normal samples | 21805675 |
| CancerPDF_ID10922 | GKNGDDGEAGKPGRPGERGPPGPQ | Collagen alpha-1(I) chain | Urine | 2378.0898 | MALDI-TOF | Muscle-invasive bladder cancer | Differentially expressed between cancer vs normal samples | 21805675 |
| CancerPDF_ID10923 | GPAGPPGKAGEDGHPGKPGRPGERG | Collagen alpha-2(I) chain | Urine | 2399.1292 | MALDI-TOF | Muscle-invasive bladder cancer | Differentially expressed between cancer vs normal samples | 21805675 |
| CancerPDF_ID10926 | GPAGPPGKAGEDGHPGKPGRPGERG | Collagen alpha-2(I) chain | Urine | 2415.1359 | MALDI-TOF | Muscle-invasive bladder cancer | Differentially expressed between cancer vs normal samples | 21805675 |
| CancerPDF_ID10929 | PPGKNGDDGEAGKPGRPGERGPPGP | Collagen alpha-1(I) chain | Urine | 2444.1487 | MALDI-TOF | Muscle-invasive bladder cancer | Differentially expressed between cancer vs normal samples | 21805675 |
| CancerPDF_ID10931 | GRDGNPGNDGPPGRDGQPGHKGER | Collagen alpha-2(I) chain | Urine | 2475.1004 | MALDI-TOF | Muscle-invasive bladder cancer | Differentially expressed between cancer vs normal samples | 21805675 |
| CancerPDF_ID10941 | EAGRDGNPGNDGPPGRDGQPGHKGE | Collagen alpha-2(I) chain | Urine | 2519.0939 | MALDI-TOF | Muscle-invasive bladder cancer | Differentially expressed between cancer vs normal samples | 21805675 |
| CancerPDF_ID10944 | GRDGNPGNDGPPGRDGQPGHKGERG | Collagen alpha-2(I) chain | Urine | 2532.1321 | MALDI-TOF | Muscle-invasive bladder cancer | Differentially expressed between cancer vs normal samples | 21805675 |
| CancerPDF_ID11058 | NVHSGSTFFKYYLQGAKIPKPEAS | ITIH4 | Serum | 2669.1 | MALDI-TOF | Esophageal squamous cell carcinoma (ESCC) | Upregulated in ESCC patients vs control with mean intensity in cancer 417.72 and mean intensity in normal 190.00 | 26993605 |
| CancerPDF_ID12677 | DDPDAPLQPVTPLQLFEGRRN | Complement C4 | Serum | NA | LC-MS | Renal cell carcinaoma | Upregulated in cancer v/s Normal | 25168216 |
| CancerPDF_ID12694 | HTFMGVVSLGSPSGEVSHPRKT | Alpha-2-HS-glycoprotein | Serum | 2326.204 | MALDI-TOF | Breast cancer | "Upregulated with the fold change of 0.58 in breast cancer vs Cancer free patients with brca mutation, Upregulated in breast cancer vs sporadic breast cancer with fold change of 1.25, Upregulated in BC vs healthy with 1.217 fold change" | 27058005 |
| CancerPDF_ID12719 | AVPPNNSNAAEDDLPTVELQGVVPR | Coagulation factor XIII A chain | Serum | 2602.306 | MALDI-TOF | Breast cancer | "Upregulated with the fold change of 0.47 in breast cancer vs Cancer free patients with brca mutation, Upregulated in breast cancer vs sporadic breast cancer with fold change of 1.04, Upregulated in BC vs healthy with 1.073 fold change" | 27058005 |
| CancerPDF_ID12723 | SSSYSKQFTSSTSYNRGDSTFES | Fibrinogen alpha chain | Serum | 2553.201 | MALDI-TOF | Breast cancer | "Upregulated with the fold change of 0.60 in breast cancer vs Cancer free patients with brca mutation, Upregulated in breast cancer vs sporadic breast cancer with fold change of 0.85, Upregulated in BC vs healthy with 0.992 fold change" | 27058005 |
| CancerPDF_ID12724 | DEAGSEADHEGTHSTKRGHAKSRPV | Fibrinogen alpha chain | Serum | 2659.323 | MALDI-TOF | Breast cancer | "Upregulated with the fold change of 0.73 in breast cancer vs Cancer free patients with brca mutation, Upregulated in breast cancer vs sporadic breast cancer with fold change of 0.88, Upregulated in BC vs healthy with 1.033 fold change" | 27058005 |
| CancerPDF_ID12725 | SSSYSKQFTSSTSYNRGDSTFESKS | Fibrinogen alpha chain | Serum | 2768.32 | MALDI-TOF | Breast cancer | "Upregulated with the fold change of 1.35 in breast cancer vs Cancer free patients with brca mutation, Upregulated in breast cancer vs sporadic breast cancer with fold change of 1.18, Upregulated in BC vs healthy with 1.074 fold change" | 27058005 |
| CancerPDF_ID12726 | SSYSKQFTSSTSYNRGDSTFESKSY | Fibrinogen alpha chain | Serum | 2931.376 | MALDI-TOF | Breast cancer | "Upregulated with the fold change of 0.79 in breast cancer vs Cancer free patients with brca mutation, Upregulated in breast cancer vs sporadic breast cancer with fold change of 1.00, Upregulated in BC vs healthy with 1.128 fold change" | 27058005 |
| CancerPDF_ID12734 | SRQLGLPGPPDVPDHAAYHPF | Inter-alpha-trypsin inhibitor heavy chain H5 | Serum | 2271.203 | MALDI-TOF | Breast cancer | "Upregulated with the fold change of 0.99 in breast cancer vs Cancer free patients with brca mutation, Upregulated in breast cancer vs sporadic breast cancer with fold change of 0.93, Upregulated in BC vs healthy with 1.221 fold change" | 27058005 |
| CancerPDF_ID12735 | NVHSGSTFFKYYLQGAKIPKPEA | Inter-alpha-trypsin inhibitor heavy chain H5 | Serum | 2582.393 | MALDI-TOF | Breast cancer | "Upregulated with the fold change of 0.38 in breast cancer vs Cancer free patients with brca mutation, Upregulated in breast cancer vs sporadic breast cancer with fold change of 0.62, Upregulated in BC vs healthy with 0.975 fold change" | 27058005 |
| CancerPDF_ID12736 | GVLSSRQLGLPGPPDVPDHAAYHPF | Inter-alpha-trypsin inhibitor heavy chain H5 | Serum | 2627.365 | MALDI-TOF | Breast cancer | "Upregulated with the fold change of 0.51 in breast cancer vs Cancer free patients with brca mutation, Upregulated in breast cancer vs sporadic breast cancer with fold change of 0.86, Upregulated in BC vs healthy with 0.931 fold change" | 27058005 |